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A hexanucleotide GGGGCC (G4C2) repeat expansion in the chromosome 9 open reading 
frame 72 (C9ORF72) gene is the most common cause of familial amyotrophic lateral sclerosis 
(ALS) and frontotemporal dementia (FTD). The expansion is transcribed from the sense and 
the antisense strands and accumulates in the nucleus of cells as RNA foci. Moreover, it is 
translated into five dipeptide repeat (DPR) proteins that accumulate in the brain and spinal 
cord and causes a decrease in C9ORF72 transcripts and protein levels. In the present study, 
we reported that there are very few DPR inclusions in the spinal cord of ALS-C9ORF72 cases 
and we have assessed the presence of sense and antisense RNA foci in the spinal cords of 
ten C9ORF72-ALS cases. We have shown that sense RNA foci are more common that 
antisense foci in the spinal cord, and significantly more common in spinal motor neurons of 
C9ORF72-ALS cases. This suggests that the presence of intranuclear sense RNA foci may be 
the main contributor to toxicity. We have designed non-degrading antisense 
phosphorodiamidate morpholino oligomers (PMOs) that bind, but not degrade G4C2 target 
transcripts as a potential therapeutic strategy. We tested the PMOs in HEK-293T cells 
expressing EGFP-72(G4C2) constructs showing that PMOs bind and reduce the number of 
pathological RNA foci. We have also shown that the use of PMOs reverse C9ORF72-specific 
phenotypes in neuronal progenitor cells (NPCs) and neurons from C9ORF72-ALS patient-
derived induced pluripotent stem cells (iPSC). All together our results suggest that sense RNA 
foci may be the main contributor to C9ORF72-associated toxicity and that its effect can be 
mitigated using non-degrading PMOs targeting the G4C2 repeats. Finally, our results 
highlight an alternative therapeutic approach which consists in blocking the G4C2 expanded 
RNA transcripts but not degrading them, which may be important given that 
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1.1 AMYOTROPHIC LATERAL SCLEROSIS 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease 
characterised by the loss of motor neurons in the brain and spinal cord, causing progressive 
paralysis of limb and bulbar muscles and death due to respiratory failure within an average 
of three years from symptom onset. Cytoplasmic inclusions containing the transactive 
response DNA-binding protein (TDP-43) are the neuropathological hallmark in ~95 % of ALS 
cases (Neumann et al., 2006).  
The clinical signs of lower motor neuron degeneration include fasciculations, muscle 
wasting and weakness, while signs of upper motor neuron degeneration include spasticity, 
hyper-reflexia and an extensor plantar response (Babinski sign). There is currently no cure, 
and the sole disease-modifying treatment, riluzole, has only a modest effect on survival; 
increasing life expectancy by only three months during an 18 month clinical trial (Cheah et 
al., 2010). The management of ALS is largely palliative and focussed on reducing the impact 
of symptoms arising from muscle weakness in the throat causing difficulty swallowing or 
limbs decreasing mobility and independence in the tasks of daily living. When respiratory 
weakness develops non-invasive or even invasive mechanical ventilation is instituted 
(Mitsumoto et al., 2014). The relentless progression of disabilities and loss of autonomy are 
reasons given as to why so many ALS patients seek euthanasia and in the Netherlands. 
Around 20% of ALS patients chose to die by “Physician assisted suicide” (Veldink et al., 2002). 
ALS is regarded as a rare condition with a prevalence of 3 to 6 per 100.000 people and an 
incidence of 3 per 100.000 people (Chio et al., 2013) however it appears as the cause of death 
in 1 in 300 UK death certificates (Johnston et al., 2006). Due to improvements in healthcare 
and increase in life expectancy this number is expected to rise significantly as the incidence 
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of ALS increases with age. ALS is mainly a late onset disease although juvenile onset (<25 
years) and early onset (<45 years) account for ~1 and ~20% of all ALS cases respectively 
(Turner et al., 2012).  
ALS and frontotemporal dementia (FTD) are strongly pathologically and genetically 
linked and are increasingly regarded as two ends of a phenotypic spectrum. TDP-43 
aggregates, common in ALS, are present in the frontal cortex of ~50% of FTD cases. Moreover 
the hexanucleotide repeat GGGGCC (G4C2) expansion in the chromosome 9 open reading 
frame 72 (C9ORF72) gene occurs in in 20-50% of familial (Snowden et al., 2012) and 10% of 
sporadic ALS and FTD cases (DeJesus-Hernandez et al., 2011). FTD is the second most 
common cause of dementia with an onset <65 years after Alzheimer’s disease. It is 
characterised by the loss of neurons in the frontal and temporal lobes leading to personality 
and behavioural changes and the loss of language skills. Frank dementia is rare in ALS but 
round 30-50% of ALS cases present with subtle cognitive and language deficits that are 
typical of FTD and it is estimated that 15% of FTD cases develop subtle signs of upper and 
lower motor neuron degeneration and the diagnostic criteria for ALS (Ling et al., 2013).  
1.2 DIAGNOSIS 
There are currently no disease specific biomarkers to diagnose ALS. Diagnosis 
according to El Escorial criteria is based on the history of progressive muscle dysfunction and 
signs of motor neuron degeneration in the absence of radiological evidence of a structural 
lesion and excluding other conditions that may mimic ALS (Brooks, 1999). These, although 
generally reliable to diagnose ALS, lack the ability to predict whether the disease will be slow 
or fast progressing in each case. Moreover, the lack of a reliable biomarker makes it hard to 
assess the efficacy of drugs tested in clinical trials in an objective manner. The diagnostic 
tests include magnetic resonance imaging, nerve conduction studies and blood tests for anti-
26 
 
ganglioside antibodies or a gene test for Kennedy’s disease. Diagnostic accuracy exceeds 95% 
in most experienced centres but post-mortem pathological examination may still be required 
to confirm a clinical ALS diagnosis in complex cases.  
1.3 GENETICS 
The majority of ALS cases (~90%) appear to be sporadic, with no known family history 
(sporadic ALS or sALS) (Chio et al., 2013). The remaining 10% of cases have a familial history 
of ALS or a dementia consistent with FTD (familial ALS or fALS) as shown in figure 1. In 1993 
mutations in the superoxide dismutase 1 (SOD1) gene were shown to cause ~20% of fALS 
cases (Rosen et al., 1993). It was not until recently, when with next generation gene 
sequencing techniques that the number of genes liked to ALS has increased dramatically. To 
date, mutations in over 30 different genes have been causally associated with ALS with 
variable degree of certainty (summarised in table 1.1) (White and Sreedharan, 2016). 
 
Figure 1.1: Diagram showing the prevalence of genetic mutations in sporadic and familiar 
ALS cases.  
(Special thanks to Micol Montessanti for generating the figure) 
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Gene ID Description Location Reference 
ALS2 Alsin Rho guanine nucleotide factor 2q33.2 (Yang et al., 2001) 
ALS3 Amyotrophic lateral sclerosis 3 18q21 (Hentati et al., 1994) 
ALS7 Amyotrophic lateral sclerosis 7 20p13 (Hoyer and Hecht, 
2000) 
ANG Angiogenin 14q11.1 (Greenway et al., 
2004) 
ATXN2 Ataxin 2 12q24.1 (Elden et al., 2010) 
C9ORF72 Chromosome 9 open reading frame 72 9p21.2 (DeJesus-Hernandez 
et al., 2011; Renton 
et al., 2011) 




22q11.23 (Bannwarth et al., 
2014) 
CHMPB2 Charged multivesicular body protein 2B 3p11.2 (Parkinson et al., 
2006) 
DAO d-amino-acid oxidase 12q24 (Mitchell et al., 
2010) 
DCTN1 Dynactin subunit 1 2p13 (Munch et al., 2005; 
Munch et al., 2004) 
ELP3 Elongator acetytransferase complex 
subunit 3 
8p21.1 (Simpson et al., 
2009) 
ERBB4 Erb-b2 receptor tyrosine kinase 2q33.3-
q34 




Gene ID Description Location Reference 
FIG4 FIG4 phosphoinositide 5-phosphatase 6q21 (Chow et al., 2009) 
FUS Fused in Sarcoma 16p11.2 (Kwiatkowski et al., 
2009; Vance et al., 
2009) 
GLE1 GLE1 RNA export mediator  9q34.11 (Kaneb et al., 2015) 
HNRNPA1 Heteronuclear ribonucleoprotein A1 12q13.1 (Kim et al., 2013) 
LMNB1 Laminin B1 5q23.2 (Johnson et al., 
2014) 
MATR3  Matrin 3 5q31.2 (Johnson et al., 
2014) 
NEFH Neurofilament heavy polypeptide 22q12.2 (Al-Chalabi et al., 
1999; Meyer and 
Potter, 1995) 
NEK1 NIMA related kinase 1 4q33 (Brenner et al., 2016; 
Cirulli et al., 2015; 
Kenna et al., 2016) 
OPTN Optieneurin 10p13 (Maruyama et al., 
2010) 
PFN1 Profilin 1 17p13.3 (Daoud et al., 2013) 
PRPH Peripherin 12q13.12 (Gros-Louis et al., 
2004; Leung et al., 
2004) 
SETX Senataxin 9q34.13 (Chen et al., 2004) 
SIGMR1 Sigma nonopioid intracellular receptor 1  9p13.3 (Al-Saif et al., 2011) 
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Gene ID Description Location Reference 
SOD1  Superoxide dismutase 1 21q22.11 (Rosen et al., 1993) 
SPAST Spastin 2p24-p21 (Meyer et al., 2005) 
SPG11 Spastic paraplegia 11 15q14 (Daoud et al., 2012) 
SQSTM1 Sequestosome 1 5q35 (Fecto et al., 2011) 
TAF15 TATA-box binding protein associated 
factor 15 
17q12 (Ticozzi et al., 2011) 
TARDBP Tar DNA protein binding  1p36.22 (Sreedharan et al., 
2008) 
TBK1 TANK binding kinase 1 12q14.1 (Cirulli et al., 2015; 
Freischmidt et al., 
2015) 
TUBA4A Tubulin alpha 4a 2q35 (Smith et al., 2014) 
UBQLN Ubiquilin 2 Xp11.21 (Deng et al., 2011) 
UNC13A Unc-13 homologue A 19p13.11 (van Es et al., 2009) 
VAPB VAMP associated protein B 20q13.33 (Nishimura et al., 
2004) 
VCP Valosin containing protein 9p13.3 (Johnson et al., 
2010) 
Table 1.1: List of genes causally associated with ALS (adapted and expanded from (White and 
Sreedharan, 2016)). It must be noted that the exact link between the reported mutations in 






1.4 MAIN ALS GENES 
1.4.1.1 SOD1 
SOD1 gene codes for superoxidase dismutase 1 protein which catalyses the 
dismutation of peroxide ions to free radicals with oxygen and hydrogen peroxide as 
substrates (Rosen et al., 1993). Mutations present in the SOD1 gene were the first to be 
identified in fALS cases. Initially, 11 missense mutations were discovered by linkage studies; 
since then over 180 disease-causing mutations have subsequently been reported (Rosen et 
al., 1993; Scarrott et al., 2015). Cases with SOD1 mutations do not show the typical TDP-43 
pathology identified in 90% of ALS cases. Instead, SOD1 cytoplasmic inclusions are present 
in the spinal cord of SOD1 mutation carriers (van Zundert and Brown, 2016). 
Pathogenic SOD1 mutations are predominantly single amino acid changes and 
account for 20% of fALS and 1% of sALS cases (White and Sreedharan, 2016). The mechanism 
of toxicity of SOD1-linked ALS is caused by misfolding and aggregation of SOD1 protein rather 
than by impairment of SOD1 activity (Williamson et al., 2000). Mice over-expressing G93A 
mutant SOD1 human protein develop progressive motor neuron loss and hind limb paralysis 
and are commonly used for preclinical studies. These mice however do not develop TDP-43 
pathology, which is observed in 90% of ALS cases (Picher-Martel et al., 2016). 
1.4.1.2 TARDBP (TDP-43) 
The TARDBP gene encodes for the RNA-binding protein TDP-43. Hyper-
phosphorylated, poly-ubiquitinated insoluble cytoplasmic TDP-43 inclusions are present in 
the spinal cord and frontal cortex of >90% of ALS cases. TDP-43 intracellular inclusions are 
present in the nucleus and cytoplasm of neurons and glia (Neumann et al., 2009; Neumann 
et al., 2006). TDP-43 pathology can be found in the majority of ALS patients with the 
exception of those with SOD1 and FUS mutations. TDP-43 pathology is indistinguishable 
between patients with and without mutations in the TARDBP gene. In 2008, the first 
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pathogenic mutations in the TARDBP were identified (Sreedharan et al., 2008), and since 
then, over 50 mutations have been reported accounting for 4% of all fALS and 1% of sALS 
cases. Most mutations are clustered in the low-complexity “prion like” glycine rich carboxyl 
(C)-terminus of the protein (Ling et al., 2013; Sreedharan et al., 2008). 
TDP-43 is a 414 amino acid protein containing two RNA recognition motifs (RRM) 
(Ling et al., 2013) that shuttles between the nucleus and the cytoplasm and it has been 
shown to bind ~5,500 different RNA transcripts, including TDP-43 mRNA, self-regulating its 
expression (Polymenidou et al., 2011; Tollervey et al., 2011). The presence of cytoplasmic 
aggregates and clearance of nuclear TDP-43 suggests that toxicity may arise though gain or 
loss-of-function mechanisms and it remains unclear which of the two is the main driver of 
toxicity (Diaper et al., 2013; Ratti and Buratti, 2016).  
Animal models have yielded conflicting results on whether TDP-43 toxicity is due to 
a loss-of-function or a gain-of-function mechanism. TDP-43 knockout (KO) mice are 
embryonically lethal, however heterozygous KO mice are viable and fertile with 
autoregulation maintaining nearly normal TDP-43 levels (Kraemer et al., 2010). Selective 
removal of TDP-43 from the motor neurons in mice causes weight loss, degeneration of the 
motor axons and loss of the neuromuscular junction (NMJ), however these mice did not have 
reduced survival rates and normal life spans (Iguchi et al., 2013b). Furthermore, homozygous 
KO of TDP-43 in zebrafish causes muscle degeneration and reduced motor neuron axon 
outgrowth (Schmid et al., 2013). Together this data suggests that loss of TDP-43 may play an 
important role in adult motor neuron degeneration, but it may not be sufficient to cause 
fatal motor neurone disease.  
Overexpression of TDP-43 in C. elegans causes cell death (Ash et al., 2010). This study 
showed that there was a correlation between endogenous TDP-43 levels and motor deficits. 
Moreover, the overexpression of wild type (WT) TDP-43 and M337V TDP-43 mutant causes 
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severe neurodegeneration and short life span in transgenic mice (Mitchell et al., 2015). These 
mice develop most of the observed pathology in post mortem tissue, including 
hyperphosphorylated, poly-ubiquitinated TDP-43 aggregates and loss of upper and lower 
motor neurons. These studies suggest that overexpression of TDP-43 is also capable of 
causing neurodegeneration and reducing life span. Finally KO and overexpression of the 
endogenous tardbp gene in zebrafish are both sufficient to cause motor phenotypes in 
zebrafish (Kabashi et al., 2010). These results indicate that motor neuron degeneration may 
be driven by both the loss of nuclear TDP-43 and the presence of cytoplasmic TDP-43 
aggregates. 
1.4.1.3 C9ORF72 
In 2011 a large intronic hexanucleotide expansion GGGGCC (G4C2) in the 
chromosome 9 open reading frame 72 (C9ORF72) gene was identified and accounts for 20-
50% of all fALS cases (DeJesus-Hernandez et al., 2011; Renton et al., 2011). In ALS cases the 
G4C2 repeat can be expanded up to 2000 times, this contrasts with the presence of 2-20 
repeats in healthy individuals (DeJesus-Hernandez et al., 2011; Renton et al., 2011).  
The TDP-43 pathology observed in C9ORF72 cases is indistinguishable from other ALS 
cases (Mackenzie et al., 2013a), however C9ORF72 cases also show abundant p62-positive 
and TDP-43-negative inclusions in non-motor regions such as the cerebellum (Al-Sarraj et al., 
2011). Additionally, expanded G4C2 RNA accumulates in the nucleus of neurons and glia as 
RNA foci in most regions of the brain and the spinal cord (Cooper-Knock et al., 2012; DeJesus-
Hernandez et al., 2017; DeJesus-Hernandez et al., 2011; Lee et al., 2013; Mizielinska et al., 
2013). Moreover, the repeats can be translated through unconventional repeat-associated 
non-ATG (RAN) translation of the sense and the antisense strands. Five dipeptide-repeat 
(DPR) proteins have been identified in post mortem tissues from C9ORF72 ALS and FTD cases; 
poly-Gly-Pro (GP), Gly-Ala (GA) and Gly-Arg (GR) from the sense strand (Ash et al., 2013; Mori 
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et al., 2013c) and poly-Gly-Pro (GP), Pro-Ala (PA) and Pro-Arg (PR) from the antisense strand 
(Gendron et al., 2013; Mori et al., 2013a). Aggregates of these five DPR proteins have been 
identified to varying degree in many different regions of the brain and spinal cord of C9ORF72 
expansion carriers (Ash et al., 2013; Mori et al., 2013a). 
The mechanisms by which the hexanucleotide repeats might exert toxicity are highly 
controversial. It was initially reported that the presence of the G4C2 repeats lead to a 
decrease in C9ORF72 transcripts and protein, therefore suggesting toxicity could be due to 
haploinsufficiency (DeJesus-Hernandez et al., 2011; Renton et al., 2011). This theory was 
subsequently not supported as C9orf72-KO mice do not develop any neurological defects or 
any ALS associated pathology and instead have immune deficiency and dysfunctional 
macrophages and microglia (O'Rourke et al., 2016) (Koppers et al., 2015). Furthermore, 
homozygous expansion carriers do not develop disease at an earlier age or a more rapidly 
progressive disease course compared to heterozygous carriers (Fratta et al., 2013), which 
would be expected if haploinsufficiency was the mechanism. 
Sense and antisense transcripts have been identified in the major sites of 
neurodegeneration in C9ORF72 expansion carriers as nuclear RNA foci and sequester RNA 
binding proteins (Lee et al., 2013; Mizielinska et al., 2013). We and others have shown that 
G4C2 RNA foci can sequester RNA binding proteins such as hnRNP-H, ADARB2 and nucleolin 
and increase nucleolar stress (Donnelly et al., 2013; Haeusler et al., 2014; Lee et al., 2013). 
Additionally, expanded transcripts can form secondary structures such as G-quadruplexes 
and R-loops (DNA-RNA hybrids) that bind proteins and possibly disrupt nucleocytoplasmic 
transport in the cell (Conlon et al., 2016b; Fratta et al., 2012; Haeusler et al., 2014; Jovicic et 
al., 2015; Zhang et al., 2015). Finally, the presence of antisense RNA foci has been reported 
to be correlated with the nuclear depletion of TDP-43 in the spinal motor neurons of a 
reduced number of C9ORF72 ALS cases. This study failed to observe any correlation between 
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the nuclear depletion of TDP-43 in motor neurons and the presence of sense RNA foci 
(Cooper-Knock et al., 2015).  
The expression of DPR proteins has also been strongly implicated in causing 
neurotoxicity. Although it is unclear which specific DPR is toxic; poly-GR and PR have been 
shown to be toxic in drosophila causing eye degeneration when overexpressed in the retina 
and reducing life span when expressed under an ELAV neuronal promoter (Mizielinska et al., 
2014). The arginine-rich DPRs Poly-GR and PR, may also exert toxicity though impairment of 
biogenesis of ribosomal RNA (Kwon et al., 2014). Additionally, poly-GA has been shown to be 
toxic in an aggregation-dependent manner when overexpressed in mice. Poly-GA may exert 
its toxicity though endoplasmic reticulum stress and caspase-3 activation (Schludi et al., 
2017; Zhang et al., 2016a). However, the extremely low presence of DPR inclusions in some 
areas of maximal neurodegeneration, such as the spinal cord, challenges the idea that DPRs 
are the main source of toxicity (Gomez-Deza et al., 2015; Mackenzie et al., 2015). It is also 
unclear whether any of the three mechanisms are sufficient to exert toxicity on their own. 
Based on the current evidence it is clear that a combination of all three processes may 
differentially contribute to neurodegeneration in different sites. The recent emergence of 
C9ORF72 bacterial artificial construct (BAC) mouse models and neurons derived from 
induced pluripotent stem cells (iPSCs) carrying the expansion opens the possibility of 
studying  disease mechanisms in a more physiological setting (Jiang et al., 2016; Liu et al., 
2016; O'Rourke et al., 2015; Peters et al., 2015) 
The main mechanisms though which the C9ORF72 expansion may be exerting 
toxicity will be reviewed in greater detail in a later section. 
1.4.1.4 FUS 
Mutations in the gene fused in sarcoma (FUS) gene were reported by two 
independent groups in 2009 having been previously linked to chromosome 16q (Abalkhail et 
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al., 2003; Kwiatkowski et al., 2009; Ruddy et al., 2003; Sapp et al., 2003; Vance et al., 2009). 
FUS is another DNA and RNA binding protein, like TDP-43. Most mutations reside in the 
extreme C-terminus of the protein and reduce its nuclear import leading to increased 
cytoplasmic accumulation and aggregation. Pathological studies revealed the presence of 
large FUS-immunoreactive inclusions in the spinal cord and motor neurons of a subset of ALS 
cases (Vance et al., 2006). FUS is a 526 amino acid nuclear protein that shuttles between the 
nucleus and the cytoplasm and can bind single- and double-stranded DNA as well as RNA. It 
has been shown to participate in multiple cellular processes such as DNA repair, axonal 
transport of mRNA, RNA splicing and transcriptional regulation (Lagier-Tourenne et al., 
2010). 
Structurally, FUS belong to a family of FET RNA binding proteins which include FUS, 
Ewing’s sarcoma RNA binding protein 1 (EWSR-1) and Tata-binding protein associated factor 
2N (TAF-15). The FET protein family interact with the C-terminal domain of RNA polymerase 
II (RNAP II) and general transcription factor TFIID (Shang and Huang, 2016).  
Interestingly, FUS cases are pathologically distinct as they lack TDP-43 pathology. Instead FUS 
immunoreactive inclusions of varying morphologies are present in the spinal cord of ALS 
cases with FUS mutations (King et al., 2015; Vance et al., 2009). Moreover, 35% of ALS cases 
with symptom onset <40 years old carry mutations in the FUS gene and more than 60% of 
cases with FUS mutations disease onset before 45 years of age, with many juvenile onset in 
late teens and early 20’s (Baumer et al., 2010; Shang and Huang, 2016). 
Several groups have used a wide range of animal models to study the effect on 
expressing FUS mutant proteins. In vitro studies have shown that mutations known to cause 
ALS increase the levels of cytoplasmic FUS by impairing nuclear import and cause it to 
aggregate and sequester WT-FUS into cytoplasmic stress granules (Dormann et al., 2010; 
Vance et al., 2013). FUS knockdown using antisense morpholinos in zebrafish cause motor 
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and behavioural defects and reductions in the branching and length of motor axons. 
Morpholino knockdown of zebrafish FUS followed by overexpression of mutant human FUS 
proteins also cause defects in the neuromuscular junction (NMJ) (Armstrong and Drapeau, 
2013). Finally, murine models of FUS show that WT-FUS as well as mutant FUS 
overexpression causes degeneration in mice. FUS-R521C and FUS-R525L cause more severe 
dendritic outgrowth deficits than WT-FUS (Mitchell et al., 2013). Interestingly, transgenic 
mice expressing higher levels of WT-FUS also displayed early onset motor neuron 
degeneration in a dose-dependent manner (Mitchell et al., 2013).  
1.4.2   Genes involved in protein homeostasis 
1.4.2.1  UBQLN2 (Ubiquilin 2) 
Ubiquilins are known to associate with ubiquitin ligases and proteasomes to mediate 
protein degradation. Ubiquilin 2 is a 66 kDa protein (Zhang et al., 2014a) is highly 
homologous to Ubiquilin 1, which has been shown to play a role in mediating the ubiquitin 
proteasome system (UPS) and as a regulator of autophagy (Zhang et al., 2014a). Additionally, 
UBQLN2 has been linked to cell cycle regulation, to modulate G-protein coupled receptors in 
endocytosis and it associates with cytoskeletal elements (Zhang et al., 2014a). Five mutations 
were initially described in the UBQLN2 gene to cause ALS (Deng et al., 2011). All mutations 
were shown to be present in the PXX motif of the protein. ALS patients carrying mutations 
in the UBQLN2 gene are associated with an early age of onset and survival of 6 months to 5 
years from symptom onset (Deng et al., 2011; Gellera et al., 2013). 
The pathology of fALS patients with UBQLN2 mutations and sALS patients is 
characterised by the presence of ubiquilin 2 and ubiquitin-positive inclusions which also 
contain TDP-43, Optineurin and FUS. Ubiquilin 2 inclusions have also been found to be 
present in the molecular layer of the hippocampus of ALS-C9ORF72 cases regardless of the 
presence of UBQLN2 mutations (Brettschneider et al., 2012; Scotter et al., 2016). In some 
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cases these inclusions colocalised with other important ALS proteins such as TDP-43 and FUS, 
however, inclusions in the molecular layer of the hippocampus have been shown to be 
uniquely present in ALS-C9ORF72 cases (Brettschneider et al., 2012).  
Mutations in UBQLN2 decrease the interaction with another ALS-linked protein, 
hnRNPA1 (Gilpin et al., 2015) and have been linked to optineurin defects (Osaka et al., 2015). 
Furthermore, overexpression of ubiquilin-2 causes neuronal death in transgenic rats (Huang 
et al., 2016). Finally, transgenic mice overexpressing ALS-linked mutant ubiquilin-2 have TDP-
43 pathology, loss of motor neurons and impaired memory. Interestingly, only mice 
expressing the mutant forms of ubiquilin-2 and not WT showed these symptoms (Le et al., 
2016).   
1.4.2.2 Sequestosome 1/ p62 
The SQSTM1 gene codes for the 440 amino acid protein commonly known as p62, 
which amongst other functions, plays a critical role in autophagy. P62 binds poly-
ubiquitinated proteins though it’s ubiquitin-associated (UBA) domain and directs them into 
lysosomes. Mutations known to cause ALS and FTD were first reported in 2011 (Fecto et al., 
2011), since then, over 40 mutations have been identified accounting for 1.5-3% of familial 
and sporadic ALS/FTD cases (White and Sreedharan, 2016). Most mutations thought to be 
causative of ALS are missense mutations but the pathogenic mechanism is unclear. SQSTM1 
patients have classical p62- and TDP-43-positive inclusions and increased p62 and TDP-43 
levels in the spinal cord (Teyssou et al., 2013). Knockdown of SQSTM1 in zebrafish causes 
motor deficits which can be rescued by human WT p62 overexpression, but not by 




1.4.2.3 Valosin-containing protein/P97 (VCP)  
The VCP protein is an AAA ATPase involved in an extensive range of ubiquitin-
dependent cellular processes that rely on protein degradation via the UPS or autophagy 
(Majcher et al., 2015). Mutations in the VCP gene account for 1-2% of fALS cases (Johnson et 
al., 2010; Miller et al., 2012) and are found throughout the protein, making predictions about 
effect on protein-protein interactions challenging (Majcher et al., 2015). Patients carrying 
VCP mutations showed rapid disease progression and cognitive impairment (Johnson et al., 
2010).  
Mutations in VCP have also been found in Paget disease of the bone and 
frontotemporal dementia (IBMPFD). A mouse model of the disease-associated VCP R155H 
mutation was found to be show with muscle weakness and brain pathology with increased 
TDP-43 and ubiquitin-positive cytoplasmic inclusions (Nalbandian et al., 2013). VCP also plays 
a role in stress granule formation and processing body (P-body) clearance, delivering them 
to autophagy for degradation. Disease-associated mutations delay this process, highlighting 
the interconnection between RNA processing and autophagy defects in ALS (Buchan, 2014). 
Moreover, cortical neurons derived from ALS patients carrying pathogenic mutations in the 
VCP gene show slower rate of ADP/ATP translocation across the mitochondrial and as a result 
have impaired cellular energy homeostasis (Ludtmann et al., 2017). 
1.4.2.4 Charged multivesicular body protein 2B / CHMPB2 
Mutations in the CHMPB2 gene were the first identified in familial form of FTD linked 
to Chromosome 3 (Skibinski et al., 2015). CHMP2B codes for CHMP2B, which belongs to the 
charged multivesicular body protein family. As a component of the endosomal sorting 
complex required for transport III (ESCRTIII) multi-protein complex, CHMP2B is involved in 
vesicular trafficking, autophagy, and dendritic spine formation and functionality (Urwin et 
al., 2010; Vernay et al., 2016). Subsequently CHMP2B mutations have been reported ALS and 
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may account for up to 1% of fALS cases (Parkinson et al., 2006) (Cox et al., 2010; White and 
Sreedharan, 2016) but their role in pathogenesis has not been fully determined. ALS patients 
carrying mutations in the CHMP2B gene have a variable age of onset and show the typical 
ALS neuropathology with p62-positive TDP-43 neuronal inclusions (Cox et al., 2010; 
Parkinson et al., 2006) but FTD cases contain p62-positive, TDP-43 negative inclusions (Holm 
et al., 2007). Mice expressing the disease-causing CHMP2Bintron5 show neuronal loss and 
lysosomal storage pathology in the form of autofluorescent aggregates in a progressive 
manner (Clayton et al., 2015). A later study showed that mutant mice expressing 
CHMP2Bintron5 in a neuronal specific manner show a dose dependent disease phenotype, and 
paralysis (Vernay et al., 2016). 
1.4.2.5 Phosphoinositide phosphatase (FIG4) 
Mutations in FIG4 were reported in about 2% of ALS and primary lateral sclerosis 
patients in a cohort with European ancestry (Chow et al., 2009). Mutations in FIG4 have also 
been previously identified in Charcot-Marie-Tooth (CMT) disease (Chow et al., 2007). 
Patients with mutations had predominantly dysfunction in their upper extremities and show 
a typical age of onset and disease duration (Chow et al., 2009). FIG4 is a phosphatase that 
regulates intracellular vesicle trafficking along the endosomal-lysosomal pathway (Kon et al., 
2014). Kon et al. (2014) reported that FIG4 does not colocalise with TDP-43 immunoreactive 
inclusions in ALS cases, however, FIG4-positive inclusions were reported in other 
neurodegenerative diseases such as Parkinson’s disease and dementia with Lewy bodies 
(Kon et al., 2014). 
1.4.2.6 VAPB 
In 2004, Nishimura and colleagues reported a novel missense mutation in the VAPB 
gene in a large white Brazilian family and caused severe ALS with rapid disease progression 
(Nishimura et al., 2004). Mutations in the VAPB protein disrupt the cellular distribution and 
40 
 
increase VAPB aggregation (Landers et al., 2008; Nishimura et al., 2004). VAPB interacts with 
the mitochondrial protein tyrosine phosphatase-interacting protein-51 (PTPIP51) to regulate 
Endoplasmic Reticulum-mitochondria association and autophagy (De Vos et al., 2012). 
Interestingly is has been shown that mutations in TDP-43 known to cause ALS, disrupt this 
contact and decrease the calcium transmission into the mitochondria, mediated by GSK3β 
activation (Stoica et al., 2014).  
1.4.2.7 TBK1 
TANK-binding kinase (TBK1) is a kinase involved in the regulation of many cellular 
pathways, including immune response, inflammation, autophagy, cell proliferation and 
insulin signalling (Helgason et al., 2013). Nonsense truncation mutations in the TBK1 gene 
were first identified in a large ALS kindred and in a large Exome sequencing study (Cirulli et 
al., 2015). To date, 77 non-synonymous TBK1 variants have been identified in patients 
diagnosed with ALS and/or FTD (Freischmidt et al., 2016; Freischmidt et al., 2015). It is 
thought that pathogenic mutations in TBK1 may lead to haploinsufficiency and might impair 
the regulation of autophagy and/or inflammation signalling pathways regulated by TBK1. 
Furthermore, mutations in genes encoding two other components of the autophagic 
pathway interact with and are activated by TBK1; OPTN and SQTM1/p62 are also associated 
with ALS. Interestingly, a single patient with FTD carrying TBK1 and OPTN mutations resulting 
in a haploinsufficiency of both proteins has been identified (Pottier et al., 2015). This patient 
showed late age of onset (68 years) but fast disease progression, suggesting that a more 
severe disease pattern may arise if this pathway is severely disrupted.  
1.4.2.8 Optineurin (OPTN) 
Optineurin is a ubiquitin-binding protein that interacts with LC3, regulates 
autophagy and also plays a role in the turnover of damaged mitochondria (Majcher et al., 
2015). Mutations in the OPTN gene that codes for Optineurin were first identified to cause 
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ALS in a small Japanese population (Maruyama et al., 2010) and are known to account for 1-
4% of fALS cases (Iguchi et al., 2013a) but are absent from FTD cases (Maruyama et al., 2010). 
Optineurin-positive immunoreactive inclusions have been reported in sALS and SOD1-ALS 
cases (Maruyama et al., 2010). Interestingly, TBK1 is known to regulate Optineurin activity 
by phosphorylating it. The crystal structure of the TBK1-Optneurin complex has been 
resolved predicting that the ALS linked E696K TBK1 mutation disrupts the TBK1-Optneurin 
complex but has little effect on the NAP1/TBK1 complex (Li et al., 2016a). 
1.4.3 Other Genes involved in RNA metabolism 
In this section we review some of the most important genes involved in RNA binding 
and processing that have been identified in ALS cases in addition to TDP-43 and FUS. 
1.4.3.1 ELP3 
The elongator protein 3 (ELP3) protein is involved in the RNA polymerase II complex 
and RNA processing (Winkler et al., 2001). Mutations in the ELP3 gene were identified in ALS 
by carrying out an association study in UK, USA and Belgian populations (Simpson et al., 
2009). This group carried out a mutagenesis screen, where they found out that drosophila 
carrying two loss-of-function mutations in the ELP3 protein displayed axonal targeting and 
synaptic transmission deficits. Furthermore they showed that zebrafish showed axonal 
motor abnormalities when ELP3 levels where decreased using a morpholino in a dose-
dependent manner (Simpson et al., 2009). Simpson et al. (2009) showed that the expression 
of ELP3 was decreased in ALS patients carrying risk-associated alleles. The mechanism 
through which ELP3 leads to motor neuron disease remains unknown but it appears that 
mutations in the ELP3 gene may modulate the susceptibility to ALS.  
1.4.3.2 SETX 
SETX encodes a DNA/RNA helicase involved In DNA repair and RNA production. 
Mutations in the SETX gene were found to cause juvenile onset, slowly progressive ALS, with 
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a disease onset at <25 years, distal muscle weakness and atrophy, preserved sensation and 
a normal life span (Chen et al., 2004). Homozygous and compound heterozygous mutations 
in the SETX gene were subsequently identified in people with ataxia with oculomotor apraxia 
type 2 (Moreira et al., 2004).  
1.4.3.3 ATXN2 (Ataxin-2) 
Ataxin-2 is an RNA-binding protein containing 15-32 CAG repeats in exon 1 that are 
translated into poly glutamine (poly-Q) repeats in healthy individuals. However it has been 
shown that the presence of 33-64 CAG repeats can cause spinocerebellar ataxia type 2 
(SCA2). Elden et al. (2010) found that intermediate-length expansions of 27-33 CAG repeats 
in Ataxin-2 confer a significant risk for ALS and are present in 4.7% of all ALS cases (Elden et 
al., 2010). This finding has been replicated by several other groups (Baumer et al., 2014; 
Borghero et al., 2015). 
ALS patients carrying intermediate Ataxin-2 expansions show immunoreactive 
Ataxin-2 cytoplasmic aggregates in the spinal cord and have a distinct TDP-43 pathology. The 
motor neurons of ALS cases with Ataxin-2 poly-Q expansions contained primarily skein-like 
or filamentous TDP-43 pathology and only rarely, if ever, contained large round inclusions, 
whereas the ALS cases without Ataxin-2 poly-Q expansions contained abundant round and 
skein-like TDP-43 pathology (Elden et al., 2010; Hart et al., 2012).  
Moreover, recent work has shown that the RNA-dependent interaction of Ataxin-2 
and TDP-43 is involved in disease pathogenicity (Hart et al., 2012). Furthermore, Ataxin-2 
interacts with FUS and enhances FUS-related pathology (Farg et al., 2013). Finally, it has been 
recently reported that the Ataxin-2 locus can be bi-directionally transcribed. Ataxin-2 
antisense transcripts (ATXN2-AS) with CUG repeats are neurotoxic and may also contribute 
to the disease pathogenicity (Li et al., 2016b). Interestingly, knockout of Ataxin-2 with 
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antisense oligonucleotides significantly improves survival in TDP-43 transgenic mice (Becker 
et al., 2017). 
1.4.3.4 hnRNP A2/B1 and hnRNP A1 
Mutations in hnRNP A2/B1 and hnRNP A1 were identified by Kim et al. (2013) in 
patients with inclusion body myopathy with Paget’s disease of the bone (IBMPFD) and ALS. 
Patients carrying mutations in these genes showed hnRNP A2/B1 /hnRNP A1-positive 
cytoplasmic inclusions and normal TDP-43 pathology. Mutations present in these two genes 
were centred within the prion-like domains of the proteins. Mutated proteins were shown 
to have enhanced fibrillisation and were recruited into stress granules, cytoplasmic 
aggregates and colocalised with TDP-43 inclusions (Kim et al., 2013).  
Patient motor neurons differentiated from induced pluripotent stem cells (iPSC-
MNs) carrying the ALS-associated hnRNP A2/B1 D290V mutation had abnormal splicing 
changes, likely due to increased nuclear-insoluble hnRNP A2/B1. Mutant iPSC-MNs also 
displayed decreased survival in long-term culture and exhibiting hnRNP A2/B1 localization to 
cytoplasmic granules (Martinez et al., 2016). 
1.4.3.5 MATR3 
MATR3 encodes a nuclear DNA/RNA-binding protein that interacts with TDP-43 and 
regulates the alternative splicing of a large amount of genes (Coelho et al., 2015). Mutations 
in MATR3 were identified by exon sequencing of a family of European ancestry with 
dominantly inherited ALS and dementia. MATR3 cases show heterogeneous phenotypes; 
one mutation is associated with slow progressing ALS while another presented with classical, 
rapidly progressing ALS (Johnson et al., 2014). Johnson et al. (2014) showed that MATR3 is 
localised in the nucleus of motor neurons in control individuals but it is occasionally found in 
the cytoplasm of ALS cases. They hypothesized that ALS-causing mutations in MATR3 
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increased its affinity with TDP-43 and aggregates were identified in a skeletal muscle biopsy 
from an ALS patient carrying a MATR3 S85C mutation (Johnson et al., 2014). 
1.4.3.6 GLE1 
Recent candidate screening of GLE1 in 173 fALS and 760 sALS cases identified novel 
nonsense and missense mutations in two sALS cases and a splice site mutation in a fALS case 
(Kaneb et al., 2015). These mutations failed to rescue motor neuron pathology in zebrafish 
lacking GLE1, indicating pathogenicity though a loss of function/ haploinsufficiency 
mechanism (Kaneb et al., 2015). GLE1 has important roles in translation initiation, 
termination and some isoforms have been shown to associate with stress granules. 
Interestingly, GLE1 localises to the nuclear pore complex and can shuttle between the 
nucleus and the cytoplasm (Kaneb et al., 2015; White and Sreedharan, 2016), an area of great 
interest currently in the field of ALS.  
1.4.4 Other genes involved in ALS 
1.4.4.1 ALS2 
Mutations in the ALS2 gene cause the autosomal recessive juvenile-onset form of 
ALS (ALS2). ALS2 is a rare form of ALS, characterised by symptom onset in the 20’s and slowly 
progressing disease (Hadano et al., 2001). ALS2 codes for a guanine nucleotide exchange 
factor, which activates GTPases to regulate endosomal trafficking. Deletion mutations 
identified result in a frame shift that generates premature stop codons (Hadano et al., 2001). 
These mutations are predicted to cause a loss of protein function. Interestingly, 
simultaneous deletion of SQSTM1 and ALS2 in SOD1 H46R mice resulted in accelerated 
disease onset (Hadano et al., 2016). 
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1.4.4.2  PFN1 
Exome sequencing of two large families suffering from ALS showed the presence of 
mutations within the profiling 1 (PFN1) gene. PFN1 is crucial for the conversion of monomeric 
(G)-actin to filamentous (F)-actin. Exome sequencing of two large ALS families showed 
different mutations within the PFN1 gene. Further sequence analysis identified 4 mutations 
in 7 out of 274 fALS cases. Cells expressing PFN1 mutants contain ubiquitinated, insoluble 
aggregates that in many cases contain the ALS-associated protein TDP-43 (Wu et al., 2012). 
Transgenic mice expressing ALS-linked C71G mutant PFN1 display progressive motor neuron 
loss, unlike those expressing WT PFN1. The authors of this study suggested the mutation in 
the PFN1 caused motor neuron degeneration through gain-of-function toxicity. Mutant, but 
not wild-type, PFN1 forms insoluble aggregates, disrupts cytoskeletal structure, and elevates 
ubiquitin and p62 levels in motor neurons in these mice (Yang et al., 2016a).  
1.4.4.3 TUBA4A  
Only recently, Smith and colleagues (2016) have identified the presence of five non-
synonymous pathogenic mutations in the gene encoding the Tubulin, Alpha 4A protein 
(TUBA4A). Mutations were identified by carrying exon-wide rare burden analysis in 363 fALS 
index cases. All patients carrying TUBA4A mutations presented with spinal onset ALS with 
upper and lower motor neuron signs and two cases showed cognitive decline consistent with 
a diagnosis of FTD (Smith et al., 2014). This study also demonstrates the power of collecting 
exon capture data from fALS index cases and collecting them together in order to discover 
new pathogenic mutations (Smith et al., 2014). Mutations identified in TUBA4A, together 
with those in PFN1, highlight the role of axonal transport and the cytoskeletal in ALS.  
1.4.4.4 NEK1 
NIMA-related kinase 1 (NEK1) is a ubiquitously expressed, multifunctional kinase 
involved in many cellular activities including DNA damage response, microtubule stability, 
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neuronal morphology and axon polarity (Kenna et al., 2016). Interestingly, NEK1 is also 
known to interact with two known ALS-related proteins; Alsin and VAPB (White and 
Sreedharan, 2016). Loss of function mutations in the NEK1 gene were first identified as a 
minor hit by Cirulli and colleagues (Cirulli et al., 2015) but have since been confirmed by two 
individual studies by exon sequencing that analysed 265 and 1022 index fALS cases (Brenner 
et al., 2016; Kenna et al., 2016). In total, Kenna and colleagues (2016) identified NEK1 
variants in almost 3% of ALS cases (Kenna et al., 2016).  
1.5 MECHANISMS OF PATHOGENESIS 
 
Figure 1.2: Summary of the main cellular mechanisms affected in ALS (adapted from (Taylor 
et al., 2016)) 
1.5.1 Failure of the proteasome degradation pathways 
As with most neurodegenerative conditions, a hallmark feature of ALS is the 
presence of pathological protein aggregates in affected tissues. In addition a large number 
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of ALS mutant genes play a vital role in protein quality control, trafficking and degradation 
maintaining protein homeostasis, (VCP, UBQLN2, OPTN and TBK1). This indicates that 
defective proteostasis is a key pathogenic mechanism (Blokhuis et al., 2013). 
The aggregation of mutant proteins in ALS is well-documented. Mutant SOD1 has 
been shown to misfold and adopt a conformation to prevent ubiquitin-mediated degradation 
(Niwa et al., 2007). Mutant SOD1 forms toxic oligomers (Urushitani et al., 2002), which 
further accumulates as aggregates to induce a stress response in cells (Atkin et al., 2006). 
The oxidation of WT SOD1 also leads to misfolding and aggregation of the protein in a similar 
fashion to mutant SOD1. Aggregation of SOD1 has toxic effects on two major protein 
degradation pathways, the UPS and autophagy. 
Similarly, TDP-43 and FUS form insoluble protein aggregates in ALS and FTD but are 
also present in other neurodegenerative disorders such as Alzheimer’s, Parkinson’s and 
Huntington’s disease (Neumann et al., 2006; Vance et al., 2009). Mutant TDP-43 and FUS are 
recruited into cytoplasmic stress granules upon stress. Stress granules are normally resolved 
by disaggregases and chaperones; however, it is thought that mutant TDP-43 and mutant 
FUS aggregate with stress granule components in an irreversible manner to give rise to 
pathological inclusions (Chen et al., 2016; Vance et al., 2013). This may be mediated by 
mislocalisation from the nucleus to the cytoplasm of the mutant protein and the prion-like 
domain within the protein structure of TDP-43 and FUS (Hock and Polymenidou, 2016). 
1.5.2 RNA metabolism 
The first link between alterations in RNA processing and motor neuron degeneration 
was described over a decade ago. The expression of a neurofilament transgene was found to 
affect binding of a ribonucleoprotein to the neurofilament mRNA and lead to the 
degeneration of enteric and motor neurons in transgenic mice (Canete-Soler et al., 1999). 
The discovery of disease-linked mutations in multiple RNA binding proteins has highlighted 
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dysfunctional RNA processing as a major pathogenic pathway in ALS (Kwiatkowski et al., 
2009; Sreedharan et al., 2008; Vance et al., 2009). Pathological, as well as in vitro and in vivo 
studies, have provided evidence of abnormalities in multiple steps of RNA processing, 
including transcription, splicing, translation and decay (Baloh, 2012). Mutations present in 
TARDBP, the gene encoding for TDP-43, and FUS, both coding for RNA binding proteins with 
hundreds of target transcripts highlight the importance of dysregulated RNA metabolism. 
Knock-down of TDP-43 and FUS affects the level of thousands of transcripts (Lagier-Tourenne 
et al., 2012).  
1.5.3 Axonal dysfunction 
Motor neurons are characterised by a unique morphology. These cells are highly 
polarised, typified by axonal projections that can reach a meter in length in adult humans. 
This morphology requires active axonal transport of organelles, cytoskeletal, synaptic 
components, and trophic factors to maintain normal cellular function. Axonal transport 
defects have been shown to occur in pre-symptomatic stages of disease in animal models of 
motor neuron disease, and the selective loss of neuromuscular synapse subtypes are 
believed to precede motor neuron degeneration (Frey et al., 2000). The accumulation of 
neurofilaments in the soma and axons of motor neurons in the spinal cord constitutes one 
of the pathological hallmarks in ALS (Hirano et al., 1984). Additionally, the loss of the 
neuromuscular junction is common in patients and mouse models of the disease (Mitchell et 
al., 2015) and ALS-causing mutations in TDP-43 also affect axonal transport in iPSC-derived 
neurons (iPSN) (Alami et al., 2014).  
1.5.4 Mitochondrial dysfunction 
Evidence for mitochondrial involvement in ALS was first identified when 
ultrastructural studies revealed an increase in the number of mitochondria in myelinated 
axons (Atsumi, 1981). Dysfunctional mitochondria have also been observed in transgenic 
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mice overexpressing the G93A SOD1 mutant. The presence of mutant SOD1 aggregates 
correlates with mitochondrial vacuolar degeneration in G93A SOD1 mice (Dal Canto and 
Gurney, 1995; Wong et al., 1995). Transgenic mice expressing TDP-43 also display 
mitochondrial abnormalities, such as mitochondrial aggregation, and develop impaired 
motor function (Xu et al., 2010). Mitochondrial dysfunction may lead to apoptosis through 
the release of cytochrome-C into the cytoplasm.  
1.5.5 Excitotoxicity 
Levels of glutamate, one of the main neurotransmitters in the central nervous 
system (CNS), have been shown to be elevated in the cerebrospinal fluid (CSF) of ALS patients 
(Shaw et al., 1995a). Moreover, knock down of metabolic glutamate receptor 1 in G93A SOD1 
mice extends survival and increase the number of motor neurons (Milanese et al., 2014). 
SOD1 fALS mutations inhibit the function of excitatory amino acid transporter-2 responsible 
for glutamate uptake (Trotti et al., 1999). Additionally, iPSN derived from C9ORF72 expansion 
carriers show an increased susceptibility to glutamate toxicity (Donnelly et al., 2013). Finally, 
Riluzole, the only licensed drug for ALS, reduces excitotoxicity through the inhibition of pre-
synaptic glutamate release (Cheah et al., 2010).  
1.5.6 Oxidative stress  
Oxidative stress arises from the imbalance in the production of reactive oxygen (ROS) 
and reactive nitrogen (RNS) species and their clearance by the cell. ROS are important 
signalling molecules necessary for a range of physiological processes. However, excess ive 
production of ROS causes damage of biomolecules interfering with their normal functions 
and leading ultimately to cellular dysfunction or even death. 
There is strong evidence showing that oxidative stress may be a contributing factor 
in the pathogenesis of ALS. Spinal cord samples from ALS patients contain higher levels of 
oxidative damage markers and free radicals (Ihara et al., 2005; Shaw et al., 1995b). 
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Most of in vivo studies assessing the effect of oxidative stress in ALS have been 
carried out in the G93A SOD1 mice. The same oxidative stress makers seen to be upregulated 
in ALS patients have been reported in the spinal cord and cortex of G93A SOD1 transgenic 
mice (Ferrante et al., 1997). Finally, a recent study has proposed that some DPRs translated 
from the G4C2 expansion may also induce oxidative stress in iPSC-MNs derived from 
C9ORF72 expansion carriers (Lopez-Gonzalez et al., 2016).   
1.5.7 Nucleocytoplasmic transport 
The efficacy of nucleocytoplasmic transport has been shown to deteriorate 
significantly during aging (D'Angelo et al., 2009) and studies using iNeurons show that it is 
particularly affected in neurons derived from old people compared to younger ones 
(Mertens et al., 2015a).  The presence of cytoplasmic aggregates of FUS and TDP-43 are the 
main pathological hallmark of 98% of ALS cases. Although TDP-43 and FUS are known to 
shuttle between the nucleus and the cytoplasm, they are mainly nuclear proteins. The 
existence of cytoplasmic aggregates therefore highlights the possibility of the 
nucleocytoplasmic transport of proteins may be dysregulated in ALS (Boeynaems et al., 
2016b; Dormann and Haass, 2011). 
Most pathogenic FUS mutations affect its nuclear localisation signal (NLS) and 
interfere with proper nuclear targeting (Dormann et al., 2010; Vance et al., 2013). 
Interestingly, the nuclear/cytoplasmic ratio of different FUS mutants inversely correlate with 
the age of onset in FUS-ALS patients (Dormann et al., 2010). Independently of the amino acid 
sequence, the methylation of the FUS NLS also perturbs its nuclear targeting and increases 
its affinity to transportin (Dormann et al., 2012; Suarez-Calvet et al., 2016). 
Moreover, a large group of proteins implicated in nucleocytoplasmic transport, the 
karyopherins, have been shown to be misregulated in ALS and FTD (Nishimura et al., 2010) 
and a recent study has shown that the presence of cytoplasmic protein aggregates may 
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interfere with the nucleocytoplasmic transport process (Woerner et al., 2016). Interestingly, 
DPRs translated from the G4C2 expansion, together with expanded RNA, have also been 
shown to affect the nucleocytoplasmic transport in several ways which will be reviewed in 
greater detail later (Boeynaems et al., 2016a; Jovicic et al., 2015; Zhang et al., 2015; Zhang 
et al., 2016b).  
Despite the importance of nucleocytoplasmic transport in aging and ALS pathology, 
genes regulating nucleocytoplasmic transport have not been strongly implicated in the 
genetics of the disease. The only exception is GLE1, where mutations have been linked to 
ALS cases and GLE1 knockdown in zebrafish causes motor neuron deficits that can be rescued 
by wildtype but not mutant Gle1 (Kaneb et al., 2015).   
1.5.8 Neuro-inflammation 
Another of the main pathological hallmarks of ALS is the presence of activated 
microglia and infiltrated lymphocytes in the main sites of neurodegeneration (Engelhardt 
and Appel, 1990). Research using positron emission tomography has provided direct 
evidence of microglial activation in the brains of living patients with ALS. The intensity of 
microglial activation was correlated with the severity of disease, suggesting an active 
involvement of microglial activation in ALS throughout the disease process (Turner et al., 
2004). Microgliosis and inflammation have been demonstrated in mutant G93A SOD1 mice 
and ALS cases. ALS patients contain elevated levels of proinflammatory molecules such as 
cytokines, reactive oxygen species, chemokines, and glutamate (Komine and Yamanaka, 
2015). However it still remains unclear whether the presence of M2, protective microglia and 
M1, neurotoxic microglia are a response to the loss of neurons of actively contribute to 
neurodegeneration (Henkel et al., 2009). 
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Finally, it has been shown that C9ORF72 KO mice show increased microglia activation, 
possibly indicating that the G4C2 expansion may be causing a decrease in the levels of 
C9ORF72 protein and increasing neuroinflamation (O'Rourke et al., 2016).  
1.6 MODELLING ALS AND FTD WITH IPSCS 
In 2006 a study published by the Yamanaka group showed that mouse fibroblasts 
could be reprogrammed to become induced embryonic stem cells (ESC) following the 
expression of only four transcription factors, OCT3/4, KLF4, c-MYC and SOX2, now known as 
the “Yamanaka factors” (Takahashi and Yamanaka, 2006). These cells were capable of 
differentiation into a wide range of tissues and contribute to chimeric mice. Soon after the 
same group reprogrammed human fibroblasts into induced pluripotent stem cells (iPSCs) 
(Takahashi et al., 2007). Pluripotent cells have the ability to be differentiated into any type 
of cell, including neurons and glia. This technology has facilitated the generation of iPSCs 
from ALS patients carrying mutations in the SOD1, TARDBP, C9ORF72, FUS and VCP genes. 
Studies in these lines have yielded valuable information about the disease patho-mechanism 
and raised the prospect of utilising these lines for drug discovery purposes. Interestingly, a 
study in iPSCs derived from Alzheimer’s disease (AD) patients are resistant to therapeutically 
relevant concentrations of NSAID-based GSMs that failed in clinical trials but had an effect 
on mouse models of the disease (Mertens et al., 2013). Moreover, iPSC-derived neurons 
from patients with bipolar disorder are responsive to therapeutically relevant lithium levels 
in the culture medium (Mertens et al., 2015b). These results highlight the potential use of 
iPSC-derived neurons in order to test potential therapeutic strategies.  
iPSCs derived from fibroblasts carrying mutations in the SOD1 gene were the first to 
be generated carrying an ALS-causing mutation showing that iPSCs from ALS patients could 
be differentiated into motor neurons (SOD1-iPSMN) (Dimos et al., 2008). Several studies 
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have followed showing that spinal motor neurons derived from ALS-SOD1 patients display 
neurofilament aggregation and neurite degeneration. These changes were reversed in one 
of the cell lines by genetic modification using transcription activator-like effector nuclease 
(TALEN) technology (Chen et al., 2014).  A recent study has shown that SOD1-iPSMNs show 
loss of excitability and increased ER stress. These deficits were reversed upon treatment of 
the FDA approved drug 4-aminopyridine (Naujock et al., 2016). Finally it has been shown that 
genetic correction of SOD1 mutant iPSCs using clustered regularly interspaced short 
palindromic repeats (CRSIPR)-Cas9 mediated gene editing revealed that ERK and JNK 
activated AP1 played an important role in ALS (Bhinge et al., 2017). This is one of the first 
studies that utilises CRISPR technology to remove a pathogenic mutation in ALS iPSCs. 
Several groups have derived iPSCs by reprograming fibroblasts from ALS patients 
carrying mutations in the TARDBP gene which encodes for TDP-43. iPSC-derived motor 
neurons (iPSC-MNs) generated from these lines show increased levels of detergent insoluble 
TDP-43 and decreased motor neuron survival, two key pathological features of ALS (Bilican 
et al., 2012). The increased levels of detergent insoluble TDP-43 were partially reversed by 
allele specific knockdown of the mutant allele in neuronal progenitor cells carrying the 
mutation (Nishimura et al., 2014). A separate study reported decreased levels of total TDP-
43, increased levels of cytoplasmic TDP-43 levels as well us downregulation of miRNA9 in 
iPSC-MNs carrying TDP-43 mutations (Zhang et al., 2013). Finally, iPSC-MNs carrying TDP-43 
mutations have also been reported to show cytoplasmic TDP-43 aggregates and increased 
levels of detergent insoluble TDP-43. The authors of this study showed that the phenotypes 
could be reversed with the histone acetyl transferase inhibitor anacardic acid (Egawa et al., 
2012). This is another example of the potential of iPSC-derived neurons for drug discovery. 
The hexanucleotide repeat G4C2 repeat present in the C9ORF72 gene is the most 
common cause of fALS and a number of iPSC lines have been generated and have made 
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important contributions to our understanding of disease mechanisms. All groups have 
reported the presence of intranuclear RNA foci which sequester a number of RNA binding 
proteins such as hnRNP-H or ADARB2 in iPSC-derived neurons from C9ORF72 expansion 
carriers, but the presence of DPR has not been consistent. These studies have reported 
several different additional phenotypes which include: elevated p62 levels and dysfunctional 
proteasome system (Almeida et al., 2013), increased toxicity to glutamate-induced stress 
(Donnelly et al., 2013), diminished capacity to fire continuous spikes upon depolarization 
(Sareen et al., 2013), hypermethylation of the C9ORF72 promoter (Esanov et al., 2016), 
decreased neurite (Burguete et al., 2015) and axonal outgrowth (Sivadasan et al., 2016), 
altered ER calcium homeostasis and increased cell death (Dafinca et al., 2016), mitochondrial 
stress and DNA damage (Lopez-Gonzalez et al., 2016), decreased levels of C9ORF72 transcript 
and protein levels (Aoki et al., 2017) and nucleocytoplasmic transport deficits (Zhang et al., 
2015). Interestingly one study has shown how iPSN carrying TDP-43 mutations or C9ORF72 
expansion show hyperexcitability followed by loss of action potential output and activity at 
the synapse (Devlin et al., 2015). Some of these deficits have been reversed with antisense 
oligonucleotides (Aoki et al., 2017; Donnelly et al., 2013; Sareen et al., 2013; Zhang et al., 
2015) and will be reviewed in greater detail in the following section. Once again, it highlights 
the potential of iPSC-derived neurons to be used as a drug screening tool.  
Finally iPSCs have also been derived from ALS patients carrying FUS and VCP mutations 
as well as from sALS patients. Several independent groups have shown that iPSN harbouring 
mutations in the FUS gene show increased levels of mislocalised cytoplasmic FUS that is 
localised into stress granules (Higelin et al., 2016; Ichiyanagi et al., 2016; Lenzi et al., 2015). 
These deficits were reversed by removal of the pathogenic mutations using TALEN (Lenzi et 
al., 2015) and CRISPR-Cas9 (Ichiyanagi et al., 2016) genome editing techniques. Moreover, 
cortical neurons carrying pathogenic mutations in the VCP gene show slower rate of ADP/ATP 
translocation across the mitochondrial membrane and as a result have impaired cellular 
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energy homeostasis (Ludtmann et al., 2017). Interestingly, astrocytes derived from sALS-
iPSCs transplanted into the spinal cord of mice induced motor neuron loss (Qian et al., 2017). 
Motor neurons differentiated from multiple sALS-iPSCs showed cytoplasmic TDP-43 
aggregates. These cell lines apparently carried no mutations known to be implicated in ALS. 
TDP-43 aggregation was subsequently identified in post-mortem tissue of one of the patients 
from which the iPSCs were derived (Burkhardt et al., 2013), highlighting that iPSC-derived 
neurons are an exciting tool by which to model disease. 
The use of iPSC-derived neurons to study FTD has also been explored by deriving iPSCs 
from sporadic FTD and FTD patients carrying pathogenic mutations in the PGRN gene 
encoding progranulin. Comparison between sporadic FTD and PRGN neurons showed varying 
levels of progranulin and contrasting sensitivity to cellular stressors such as kinase inhibitors. 
Consequently iPSN were used for the validation of small molecules with potential to reverse 
these deficits (Lee et al., 2014b). A separate study has shown that behavioural variant FTD 
patient derived neuronal cultures display altered levels of AMPA receptors and miRNA-124 
(Gascon et al., 2014).  
1.7 CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) 
In this section I will review the main cellular and pathogenic finding of how the expansion in 




Figure 1.3: Schematic representation of the C9ORF72 gene and transcript variants (adapted 
from Barker et al., 2017) 
 
1.7.1 Genetics of the expansion, methylation and genomic instability 
In 2011 two groups independently reported the discovery of an intronic 
hexanucleotide expanded repeat of GGGGCC repeat between the first alternative exons of 
the C9ORF72 gene (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Only 2-20 repeats 
are found in healthy individuals, in contrast between 50 and 3,000 repeats have been 
identified in ALS and FTD cases. The expansion which is known to cause 20-40% of all fALS 
cases of European ancestry was thought to have multiple origins that arose about 300-13,000 
years ago (Fratta et al., 2015; Smith et al., 2013) and has strikingly low presence is Asian 
populations (Majounie et al., 2012). 
The genomic region around the expanded repeat is unstable as the size of the 
expansion has been shown to vary widely in different tissues and even different brain regions 
on Southern blots. Expansion sizes are shorter in white blood samples and the cerebellum 
compared to the frontal cortex of ALS and FTD patients (van Blitterswijk et al., 2013). In some 
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cases, expansion size in white blood cells was up to 40 times shorter than in neuronal tissue 
in the same patient (Nordin et al., 2015). Some studies report  that the number of repeats 
detected in the frontal cortex of ALS and FTD patients correlates with age of onset (van 
Blitterswijk et al., 2013) and that there is an inverse correlation between the number of G4C2 
repeats and disease duration (Suh et al., 2015).  
G4C2 repeats can form secondary structures like G-quadruplexes, R-Loops from the sense 
strand (Fratta et al., 2012; Haeusler et al., 2014) and i-motifs and protonated hairpins from 
the antisense strand in vitro (Kovanda et al., 2015). The presence of G-quadruplexes has been 
also confirmed in G4C2 repeat-expressing cells and ALS post-mortem tissue (Conlon et al., 
2016a). Moreover, in vitro studies have shown that the processing of R-loops formed by the 
expansion increases cellular stress (Reddy et al., 2014). The formation of secondary 
structures is essential for the initiation of repeat associated non-ATG (RAN) translation and 
for the formation of RNA foci and sequestration of RNA-binding proteins (Zamiri et al., 2014; 
Zhang et al., 2015). G-quadruplexes can be disrupted with TMPYP4, reducing the ability of 
repeats to form intranuclear RNA foci and bind RNA-binding proteins (Zamiri et al., 2014; 
Zhang et al., 2015). Interestingly, TDP-43 has also been shown to have the ability to bind G-
quadruplexes (Ishiguro et al., 2016).  
Hypermethylation of the CpG islands 5’ of the expansion repeat has been extensively 
reported and is thought to play a neuroprotective counter mechanism in both ALS (Xi et al., 
2013) and FTD (Liu et al., 2014a; Xi et al., 2014) and the expansion itself is hypermethylated 
(Xi et al., 2015a). The G4C2-expansion was found to be generally methylated in unrelated 
carriers of alleles >50 repeats (97 %), while small (<22) and intermediate (22-90) repeats are 
unmethylated in ALS and FTD cases (Xi et al., 2015b). Methylation of the G4C2 repeats alters 
the secondary structure and influences the affinity of binding to RNA-binding proteins (Zamiri 
et al., 2015). Neuropathological studies have shown that C9ORF72 cases with higher 
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methylation of the C9ORF72 promoter have less RNA foci and DPR levels. Furthermore, 
demethylation of mutant C9ORF72 promoter with 5-aza-deoxycytidine resulted in increased 
vulnerability of mutant cells to oxidative and autophagic stress (Liu et al., 2014b).  
1.7.2 Role of the C9ORF72 protein 
At the time of discovery, little was known about the expression pattern and role of 
the C9ORF72 protein. Bioinformatics analysis revealed that there are two isoforms of the 
C9ORF72 protein; a short (S-C9ORF72) form including exons 2-5 and a long (L-C9ORF72) form 
including exons 2-11 (Figure 1.3). C9ORF72 has been linked to the regulation of autophagy 
by several independent studies. One of them showed that C9ORF72 interacts with Rab1 and 
the ULK1 complex to regulate autophagy. Furthermore, they showed that iNeurons derived 
from expansion carriers had low levels of autophagy (Webster et al., 2016). Moreover, two 
independent studies showed that the C9ORF72 protein interacts with a poorly characterised 
protein called SMCR8 and regulates autophagy through that pathway too (Amick et al., 2016; 
Yang et al., 2016b). In motor neurons the C9ORF72 protein has been shown to interact with 
cofilin and regulate actin dynamics (Sivadasan et al., 2016) and to regulate stress granule 
formation and its depletion results in increased sensitivity to cellular stress (Maharjan et al., 
2016). 
In mice, the C9orf72 protein can be observed in synaptic puncta in neurons (Atkinson 
et al., 2015), however depletion of the C9orf72 protein in KO mouse models does not cause 
neurodegeneration and instead splenomegaly and disturbed microglia and macrophage 
function is observed (Atanasio et al., 2016; O'Rourke et al., 2016). Interestingly, many of the 
pathways dysregulated in C9orf72 KO mice are also dysregulated in C9ORF72 patients 
(O'Rourke et al., 2016). Neuropathological studies have shown that the L-C9ORF72 shows 
diffuse cytoplasmic staining while S-C9ORF72 shows specific labelling around the nuclear 
envelope. Co-immunoprecipitation experiments revealed an interaction of the C9ORF72 
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isoforms with both Importin β1 and Ran-GTPase, components of the nuclear pore complex 
(Xiao et al., 2016). Thus, a reduction in levels of the C9orf72 protein due to the expanded 
allele may affect nucleocytoplasmic transport. 
1.7.3 Neuropathological features of ALS and FTD C9orf72 expansion carriers 
The TDP-43 pathology observed in C9ORF72 ALS, FTD and ALS/FTD is 
indistinguishable from sporadic cases (Murray et al., 2011). ALS and FTD cases carrying the 
C9ORF72 expansion have a highly distinct P62 (Al-Sarraj et al., 2012) and Ubiquilin-2 
pathology in the cerebellar granular layer and the hippocampal molecular layer. This 
pathological signature is enough to predict the presence of the expansion from port mortem 
tissue (Brettschneider et al., 2012). Additionally, neuroimaging studies of C9ORF72-FTD 
patients have revealed that these patients have altered connectivity networks (Lee et al., 
2014a). C9ORF72 protein levels are decreased in post mortem samples of the motor, frontal 
and temporal cortex but not in the cerebellum or the spinal cord of C9ORF72 expansion 
carriers compared to controls. The generation of isoform specific antibodies revealed that S-
C9ORF72 is enriched in the temporal and frontal cortex of C9ORF72 expansion carriers 
(Waite et al., 2014; Xiao et al., 2016). 
Furthermore, sense and antisense RNA foci are common in the brain and spinal cord 
of ALS and FTD cases (DeJesus-Hernandez et al., 2017; Mizielinska et al., 2013). Sense RNA 
foci colocalise with many RNA-binding proteins such as hnRNPA3, ALEYREF or hnRNP-H 
(Cooper-Knock et al., 2014a; Lee et al., 2013; Mori et al., 2013b). RNA foci are mostly present 
in the nucleus and cytoplasm of neuronal cells, although they have also been detected in 
oligodendrocytes, microglia and astrocytes (Mizielinska et al., 2013; Gendron et al., 2013). In 
the frontal cortex, hippocampus and cerebellum of FTD patients there are a greater number 
of cells containing sense than antisense RNA foci (Mizielinska et al., 2013). Moreover, sense 
RNA foci are also present in the spinal cord of ALS and FTD cases and there are a significantly 
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larger number of sense foci in the spinal motor neurons than hippocampal granular neurons 
(Cooper-Knock et al., 2014a). 
Antisense foci are also present in the frontal cortex, hippocampus, cerebellum and 
spinal cord of ALS and FTD cases and the number of antisense foci in the motor neurons of 
ALS patients has been reported to correlate with TDP-43 proteinopathy and bind similar RNA 
binding proteins than sense foci such as hnRNP-H or ALEYREF (Cooper-Knock et al., 2015). 
This report suggests that the number of antisense RNA foci in spinal motor neurons 
correlates with the nuclear depletion of TDP-43 (Cooper-Knock et al., 2015).  
The sense and the antisense strand of the G4C2 expansion can be can be translated though 
non-ATG repeat-associated (RAN) translation yielding five different DPR proteins (poly-GP, 
GA, GR, PA and PR) which accumulate in the brain and spinal cord of ALS and FTD patients 
and are largely absent from peripheral tissues (Ash et al., 2013; Gendron et al., 2013; Mori 
et al., 2013a; Mori et al., 2013c; Zu et al., 2013). It was initially reported that C9ORF72 ALS 
and FTD cases contained large numbers of p62 positive/ TDP-43 negative inclusions in the 
hippocampus and the cerebellum (Al-Sarraj et al., 2011), these inclusions where later 
identified as containing DPR protein aggregates as well as hnRNP A3 (Mori et al., 2013b; Mori 
et al., 2013c). 
The pattern of DPR pathology is highly consistent amongst cases regardless of their 
ALS or FTD clinical phenotype with a high DPR load in the cerebellum, the neocortical regions 
and the hippocampus while moderate in the subcortical regions (Mackenzie et al., 2013a). 
Interestingly soluble and inclusions from all DPRs are almost absent from the spinal cord of 
ALS cases (Gomez-Deza et al., 2015; Mackenzie et al., 2015) and the presence of DPR protein 
inclusions does not correlate with neurodegeneration (Davidson et al., 2016). DPR protein 
aggregates frequently colocalise with p62 (Mann et al., 2013) but rarely colocalise with TDP-
43 (Gomez-Deza et al., 2015) and never with pTDP-43 (Mori et al., 2013c). Different DPRs 
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occasionally colocalise together (Zu et al., 2013) and occasionally contain hnRNP A3 (Mori et 
al., 2013b) and drosha (Porta et al., 2015).  
1.8 C9ORF72 TOXIC MECHANISMS 
The toxic mechanisms of the C9ORF72 expansion are unknown but three hypotheses 
have been proposed: i) loss of C9ORF72 protein due to reduced expression and degradation 
of its mRNA (DeJesus-Hernandez et al., 2011), ii) neuronal toxicity caused by RNA 
accumulation from the sense and antisense strands into nuclear RNA foci (Lee et al., 2013) 
and iii) cellular toxicity by repeat-associated non-ATG (RAN) translation of dipeptide repeat 
(DPR) proteins (Mori et al., 2013c). In the following section I will review the evidence for and 
against each of the main hypotheses.  
1.8.1 Haploinsufficiency 
It was initially reported that the presence of the G4C2 hexanucleotide repeat 
expansion lead to a reduction of C9ORF72 transcript levels. The presence of the expansion 
leads to the hypermethylation of its promoter, the use of an alternative start codon and to 
nuclear transcript retention (Niblock et al., 2016). As a result, C9ORF72 protein levels are 
reduced in the frontal, temporal and motor cortex but not in the cerebellum of ALS and FTD 
patients (Waite et al., 2014; Xiao et al., 2016). Moreover it has been proposed that higher 
levels of C9ORF72 transcripts may be beneficial in ALS and FTD patient (Gijselinck et al., 
2016). 
In vitro studies have shown that the knockdown of C9ORF72 protein in neurons leads 
to increased levels of cytoplasmic TDP-43 and cleavage (Sellier et al., 2016) as well as an 
increased cellular sensitivity to stress (Maharjan et al., 2016). Knock down of the C. elegans 
C9ORF72 homologue shows that lack of C9ORF72 protein leads to motor neuron 
degeneration and increased sensitivity to cellular stress (Therrien et al., 2013). Zebrafish 
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lacking C9orf72 develop motor deficits (Ciura et al., 2013), however, although the C9orf72 
mouse orthologue is enriched in neurons (Suzuki et al., 2013), C9orf72 KO mice do not 
develop neurodegeneration, but immune dysregulation (Jiang et al., 2016; Koppers et al., 
2015). Interestingly, many of the dysregulated pathways in the brains of C9orf72 KO mice 
are also dysregulated in C9ORF72 expansion carriers who also have impaired microglia and 
macrophage function (O'Rourke et al., 2016). 
Arguing against the possibility that the loss of C9ORF72 protein is the main driver of 
toxicity is the absence of loss of function mutations in C9ORF72 (Harms et al., 2013) and that 
individuals homozygous for the expansion do not develop disease at an earlier onset or 
progress more rapidly (Cooper-Knock et al., 2013; Fratta et al., 2013). Furthermore, C9orf72 
KO mice do not develop neurodegeneration or motor deficits (Jiang et al., 2016; Koppers et 
al., 2015), whereas mice overexpressing 66x(G4C2) show TDP-43 and DPR pathology and 
motor deficits indicating that the G4C2 repeats are sufficient to cause neurodegeneration 
(Chew et al., 2015b). Although a possibility remains that haploinsufficiency may increase 
cellular sensitivity to stress, it is not a major contributor to neurodegeneration.  
1.8.2 RNA gain-of-function 
Toxicity driven by expanded G4C2 RNA transcripts in the nucleus and cytoplasm has 
attracted a lot of interest in the field. Several studies have demonstrated a length and dosage 
dependent toxicity of G4C2 repeats in vitro (Lee et al., 2013; Rossi et al., 2015; Stopford et 
al., 2017) and in vivo (Freibaum et al., 2015). G4C2 transcripts form secondary structures 
such as G-quadruplexes and R-loops in vitro (Fratta et al., 2012) and in vivo (Conlon et al., 
2016a). This conformational change promotes their accumulation in the nucleus as RNA foci 
that can sequester RNA binding proteins. Many RNA binding proteins have been shown to 
colocalise with intranuclear RNA foci in the brain and spinal cord of ALS and FTD cases, which 
include hnRNP-H (Cooper-Knock et al., 2014a; Lee et al., 2013), ADARB2 (Donnelly et al., 
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2013), hnRNPA3 (Mori et al., 2013b), RanGAP1 (Zhang et al., 2015) and nucleolin (Haeusler 
et al., 2014). Interestingly, many of the splicing changes observed in human C9ORF72 brains 
also correlate with the splicing targets of hnRNP-H (Prudencio et al., 2015). 
Studies using iPSCs derived from ALS patients carrying the C9ORF72 expansion have 
revealed that the binding of G4C2 RNA causes severe splicing dysregulation (Donnelly et al., 
2013), diminished capacity to fire continuous spikes upon depolarization (Sareen et al., 
2013), increased levels of abortive transcripts and nucleolar stress (Haeusler et al., 2014; 
Thys and Wang, 2015). The presence of expanded transcripts in the cytoplasm has also been 
shown to be toxic, induce neuronal branching deficits and impair vesicular transport 
(Burguete et al., 2015). 
In vivo models of the disease have shown that G4C2 repeats are neurotoxic in C. elegans 
(Kramer et al., 2016), drosophila (Freibaum et al., 2015; Xu et al., 2013) and zebrafish (Lee et 
al., 2013). Neuropathological studies have also revealed that sense RNA foci are primarily 
neuronal (Mizielinska et al., 2013) and that there are a significantly greater number of RNA 
foci in the motor neurons of ALS patients that in the granule layer of the cerebellum (Cooper-
Knock et al., 2014b). 
Two independent studies expressing G4C2 repeats in drosophila argue against the 
possibility that the expanded G4C2 RNA is the main driver of toxicity. Mizielinska et al. (2014) 
showed that drosophila expressing ~108 and ~288 G4C2 repeats in the drosophila eye that 
are not translated into DPR proteins (so called RNA-only repeats) are not neurotoxic. 
However, a similar number of repeats that are able to be translated into arginine rich DPR 
proteins (poly-GR and PR) are profoundly neurotoxic in the fly eye and shorten their life span 
when expressed under a pan-neuronal ELAV promoter (Mizielinska et al., 2014). Additionally, 
Tran et al. (2015) expressed 160 G4C2 repeats in an intronic construct. Flies expressing the 
repeats have RNA foci but no developmental deficits or toxicity was observed. When the 
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expression of these constructs was increased by elevating the temperature at which 
drosophila were grown, DPR proteins were expressed and toxicity was observed (Tran et al., 
2015). 
1.8.3 Toxicity driven by DPR proteins 
The C9ORF72 G4C2 expansion can be translated through unconventional repeat 
associated non-ATG (RAN) translation into five different dipeptide repeat proteins. Poly-GP, 
poly-GA and poly-GR are translated from the sense strand (Ash et al., 2013; Mori et al., 
2013c) and poly-PA, poly-PR and poly-GP (Gendron et al., 2013; Mori et al., 2013a; Zu et al., 
2013) from the antisense strand. All five DPRs are found to be aggregated in the central 
nervous system of C9ORF72 ALS and FTD post-mortem tissue and absent from peripheral 
tissue such as the heart, the kidney or the spleen (Ash et al., 2013) and DPR pathology 
precedes overt ALS/FTD symptoms by many years (Baborie et al., 2014; Proudfoot et al., 
2014) although none of these studies attempted to quantify the abundance and distribution 
of RNA foci. Much effort has been spent studying the effect of DPRs generated by ATG 
sequence of non-repetitive codons which do not form nuclear RNA foci. In this section I will 
review the main findings for each DPR protein. 
Poly-GP can be translated from the sense and the antisense strands. However, poly-
GP inclusions are not the most common DPR aggregate in the brain and spinal cord of 
C9ORF72 ALS and FTD cases (Gomez-Deza et al., 2015; Mackenzie et al., 2015). Two recent 
studies have demonstrated that the presence of poly-GP in the cerebrospinal fluid (CSF) and 
peripheral blood mononuclear cells from C9ORF72 ALS and FTD patients by immunoassay. 
The presence of poly-GP in human samples was highly stable and could also be detected in 
asymptomatic C9ORF72 carriers (Gendron et al., 2017; Lehmer et al., 2017). This highlights 




Poly-GA is translated from the sense strand and it is the most commonly aggregated 
DPR in the frontal cortex and spinal cord of ALS and FTD cases (Gomez-Deza et al., 2015; 
Mackenzie et al., 2015). Poly-GA aggregates colocalise with P62 (Mann et al., 2013) and other 
DPRs as wells as other proteins, such as drosha (Porta et al., 2015), UNC119 (May et al., 2014; 
Schludi et al., 2015), hnRNPA3 (Mori et al., 2016) or HR23 (Zhang et al., 2016b) in C9ORF72 
expansion carriers. Transient expression of poly-GA forms nuclear and cytoplasmic 
aggregates, modelling what is observed in the central nervous system (CNS) of ALS and FTD 
patients (Schludi et al., 2015). Several studies have revealed that in vitro expression of poly 
GA induces neuronal branching deficits (May et al., 2014), ER stress and UPS impairment 
(Zhang et al., 2014b) and impairment of nuclear import causing TDP-43 to mislocalise in the 
cytoplasm (Khosravi et al., 2016). 
Moreover, poly GA forms 13 nm filaments and induces cell death (Zhang et al., 
2014b). Poly-GA can also form cross β structures that can be transmitted from cell to cells 
(Chang et al., 2016; Zhou et al., 2017). The aggregation, seeding capacity and transmission of 
poly-GA can be mitigated with the use of poly-GA-specific antibodies, opening the possibility 
that these antibodies can be used as a possible immunotherapy in the future (Zhou et al., 
2017). In vivo models of poly-GA have revealed that the expression of poly-(GA)x80 causes 
motor neuron loss in zebrafish. Additionally, there have been two published mouse models 
of poly-GA toxicity to date. Zhang and colleagues (2014) use an AAV serotype 1 vectors to 
express GFP-(GA)x50 in the mouse CNS. This study shows that aggregated and not soluble 
poly-GA induces motor deficits and neuronal loss (Zhang et al., 2016b). Shuldi et al. (2017) 
demonstrated that transgenic mice expressing poly-(GA)x149  under a Thy1 promoter have 
motor deficits but no neuronal loss (Schludi et al., 2017).  
Poly-GR and poly-PR are both arginine rich peptides and are translated from the 
sense and the antisense strand respectively. Addition of arginine rich peptides to the cell 
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culture media has revealed that these peptides are internalised by cells and migrate into the 
nucleolus impairing RNA biogenesis and inducing nucleolar stress and cell death (Kwon et al., 
2014). Additionally poly-GR and poly-PR impair assembly dynamics and function of 
membrane less organelles such as the nucleolus or stress granules (Boeynaems et al., 2017; 
Lee et al., 2016) and bind proteins with low complexity sequences such as TDP-43 (Lin et al., 
2016). Similarly to poly-GA, poly-GR and poly-PR can be transmitted from cell to cell in an 
exosome-dependent manner (Westergard et al., 2016) and poly-PR induced toxicity is 
thought to be aggregation-dependent (Wen et al., 2014). 
Transient expression of poly-GR and poly-PR in cells induces nucleolar stress by 
colocalising with nucleolin (Tao et al., 2015; Wen et al., 2014), impaired stress granule 
formation (Tao et al., 2015), DNA damage (Lopez-Gonzalez et al., 2016) and 
nucleocytoplasmic transport deficits (Jovicic et al., 2016). In vivo, poly-GR and poly-PR are 
toxic when expressed in the drosophila eye and lead to decreased lifespan (Mizielinska et al., 
2014). Moreover, in vivo genetics screens have shown that poly-GR and poly-PR are toxic by 
impairing nucleocytoplasmic transport in yeast (Jovicic et al., 2016) and in drosophila 
(Boeynaems et al., 2016a).  
Although numerous studies have shown that the transient expression of poly-GA, 
poly-GR and poly-PR are toxic in vivo and in vitro the main argument against the fact that the 
main source of toxicity is driven by DPRs is that soluble DPRs and DPR inclusions are very rare 
in the spinal cord of ALS patients and almost absent from motor neurons (Gomez-Deza et al., 
2015; Mackenzie et al., 2015). Additionally neurodegeneration in ALS and FTD patients 
correlates with the presence of TDP-43 inclusions and not with DPR inclusions (Davidson et 
al., 2016). The fact that some studies have demonstrated the necessity for DPRs to aggregate 
to induce cell death (Wen et al., 2014; Zhang et al., 2016b) increases the significance of these 
pathological studies. Moreover, in vitro and in vivo studies studying DPR toxicity present 
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contradictory results in which different studies suggest that different DPRs are toxic and only 
what is observed in cells expressing poly-GA is representative of the human pathology 
(Schludi et al., 2015). 
1.9  APPROVED THERAPEUTIC TREATMENTS 
To date, riluzole is the only FDA approved therapeutic treatment for ALS. Although its 
mechanism of action is unknown, it is thought to reduce glutamate toxicity by inhibiting the 
levels presynaptic glutamate (Cheah et al., 2010). Riluzole received marketing authorization 
in 1995 in the USA and in 1996 in Europe. In the years that followed, over 60 molecules have 
been investigated as a possible treatment for ALS. Despite significant research efforts, the 
overwhelming majority of human clinical trials have failed to demonstrate clinical efficacy. 
Two clinical trials are in an advanced phase; oral masitinib and intravenous edaravone, and 
may soon be approved for clinical use (Petrov et al., 2017). 
1.10 GENE SILENCING STRATEGIES FOR ALS 
1.10.1 Gene knockdown through RNA interference (RNAi)  
RNA interference (RNAi) exploits one of the endogenous cell capabilities to regulate 
gene expression. The target RNA is cleaved into a 21-23 nucleotide long double stranded 
RNA that binds to the RNA-induced silencing complex (RISC) complex in the cell. Upon 
loading to the RISC complex one of the RNA stands is degraded and the guide strand remains 
loaded (Ku et al., 2016). In this way it is able to cleave target transcripts repeatedly. 
The complex is able to bind target RNA sequences through complementary Watson-
Crick base pairing and induces the cleavage and degradation of the target RNA molecule in a 
highly specific manner. The exclusive presence of the RISC complex in the cytoplasm makes 
RNAi a uniquely cytoplasmic event (Ku et al., 2016). 
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There are two ways of achieving targeted gene repression 1. Through the expression 
of hairpin structures that are then processed by the cell and loaded into the RISC complex in 
a similar way as endogenous micro RNAs (miRNAs) are. This is known as small hairpin RNA 
(shRNA) and it achieves robust and highly accurate gene silencing. 2. Therapeutic RNA 
duplexes can be delivered directly without the need of processing by the cell; this is known 
as small interfering RNA (siRNA) (Walton et al., 2010). 
1.10.1.1 SOD1 
The availability of a reliable mouse model of SOD1-linked disease made it possible to 
develop RNAi strategies. Initially, different studies were able to show the feasibility of using 
siRNA-mediated SOD1 knockdown in G93A mouse models. Raoul et al. (2015) showed a delay 
in the symptom onset and degrease in progression rate by administering a single injection of 
lentiviral delivered SOD1 shRNA. Additionally, Ralph at al. (2015) were able to obtain similar 
results by injecting pseudotyped lentivirus expressing SOD1 shRNA into various muscle 
groups (hind limb, diaphragm, intercostal, facial and tongue). A single dose of injection was 
performed into multiple sites of the muscle. These authors were able to show that lentiviral-
delivered SOD1 shRNA delayed the symptom onset by over 100%, increasing life span and 
rotarod performance. Both studies demonstrated the feasibility and safety of using lentivirus 
to deliver SOD1 siRNAs (Ralph et al., 2005; Raoul et al., 2005). 
Later in 2013 the feasibility of delivering SOD1 shRNA in an AAV9 vector was shown by Foust 
and colleagues (2013). AAV9 are advantageous as they achieve high expression in the CNS 
from a single intravenous injection of AAV9 containing SOD1 shRNA which was able to reduce 
mutant SOD1 protein levels by 40- 60%, delaying disease onset by 39% and disease 
progression in a G73R SOD1 mouse model. When the AAV9 SOD1 shRNA was administered 
at post-natal day 21 there was no improvement in rotarod performance but there was a 30% 
of increase life span. Finally, they showed that intravenous delivery of AAV9 SOD1 shRNA 
69 
 
achieved a high level of motor neuron transduction and demonstrated the safety of using 
this strategy in non-human primates (Foust et al., 2013).  
1.10.1.2 TDP-43 
TDP-43 homozygous knockout mice are not viable and die at 7.5 days of embryonic 
development (Kraemer et al., 2010). Additionally, there have been many identified 
mutations in the TARDBP gene linked to ALS. These two reasons make TDP-43 silencing a 
challenging strategy. Any gene silencing strategy would have to involve targeting the mutant 
allele while not degrading the wild type allele (Picher-Martel et al., 2016). Nishimura and 
colleagues (2014) performed a siRNA screen and identified two siRNAs that selectively 
reduced the levels of the M377V mutant transcript. They then tested the siRNA in neural 
stem cells derived from two individuals carrying the M377V mutation and were able to show 
that cytosolic TDP-43 was reduced by 30% compared to cells transfected with a scrambled 
siRNA. Further work should be carried out to assess the feasibility of this strategy in mice 
(Nishimura et al., 2014).  
1.10.1.3 C9ORF72 
Several groups have shown that knock out of C9ORF72 protein in mice does not 
cause any neurological defects; instead mice have enlarged spleens and immunological 
defects. This may rule out the possibility that haploinsufficiency contributes to the toxicity 
of C9ORF72 expansions (Koppers et al., 2015; Sudria-Lopez et al., 2016). The main focus of 
the field is now to elucidate whether the toxicity arises from the expanded RNA or the 
abnormally translated DPRs.  
The fact that the RISC complex is only present in the cytoplasm and that expanded 
G4C2 transcripts accumulate in the nucleus does not make the use of a siRNA against the 
C9ORF72 expansion a suitable therapeutic strategy. Nevertheless, Lagier-Tourenne and 
colleagues (2013) have shown that by using a pool of four different siRNAs targeting exons 2 
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and 4 of the C9ORF72 gene they were able to obtain a 30% reduction on the total C9ORF72 
transcripts. However, no decrease in the number of RNA foci was detected in fibroblasts from 
patients carrying the expansion; indicating that toxicity may be due to the presence of 
expanded transcripts in the nucleus (Lagier-Tourenne et al., 2013). 
1.10.1.4 SPT4 
SPT4 is a highly conserved transcription elongation factor that upon binding to SPT5 
regulates the activity of RNA polymerase II. It has been very recently shown that SPT4 
regulates the transcription of both sense and antisense expanded G4C2 transcripts (Kramer 
et al., 2016). Knockdown of SPT4 in yeast and C. elegans overexpression models of the 
C9ORF72 expansion repeats resulted in increased survival. Furthermore, siRNA mediated 
knockdown of SPT4 was able to partially reduce the observed toxicity in an overexpressing 
model of G4C2 repeats in drosophila eye. Finally, the authors of this study showed that the 
use of an siRNA against the human homologues of SUPT4H1 and SUPT5H are able to reduce 
DPR levels in neurons derived from stem cells carrying the C9ORF72 expansion (Kramer et 
al., 2016).  
1.10.2 Antisense oligonucleotides 
Antisense oligonucleotides (ASOs) are short strings of nucleic acids used to target an 
RNA transcript. ASOs are able to bind to a specific target by means of a standard Watson-
Crick base pairing and commonly have a length of 8-50 bases (DeVos and Miller, 2013). ASOs 
can be chemically modified in order to increase their resistance to nucleases thereby 
increasing their half-life. Irrespective of their chemical modifications, ASOs are broadly 
separated into two different categories, described by their mechanism of action; RNAse H 




RNAse H dependent ASOs have the ability to bind to target RNA in the nucleus and 
sequester RNAse H that cleaves the RNA strand in the RNA-DNA heteroduplexes, releasing 
the intact DNA strand. This allows for the ASO to exert its activity repeatedly, effectively 
having an enzymatic function (Cerritelli and Crouch, 2009). In order to retain the RNA-se H 
degrading capability and increase nuclease resistance synthetic chemists have developed 
“gapmers”. Gapmers are ASOs whereby the 2’-modifications together with backbone 
modifications are introduced at the flanking regions of the ASO, and the centre remains 
unmodified effectively creating a “gap”. In this way high nuclease resistance is achieved and 
the ability to degrade target transcripts is retained.  
Steric hindering ASOs exert their activity by steric blockage upon binding to the 
target transcript. Chemical modifications in the nucleic acid backbone and the 2’-sugar ring 
remove the chemical charge of the nucleic acid, thereby make it increasingly resistant to 
degradation by nucleases, but removing their ability to induce RNAse H activity (DeVos and 
Miller, 2013). High nuclease resistance and robust affinity to target RNA makes them ideal 
to target translation inhibition, prevention of accumulation, alter gene splicing and miRNA 
silencing (DeVos and Miller, 2013). 
1.10.2.1 ASO entry mechanism and viability for use in vivo 
ASO cellular uptake varies according to the chemical modifications, however it is 
generally understood that ASOs can bind to proteins in the extracellular medium. ASOs are 
then internalised through endosomes (Koller et al., 2011). Cellular uptake of uncharged ASOs 
can be facilitated by coupling to arginine-rich cell-penetrating peptides. Although the 
mechanism of exit of these vesicles is yet unknown, once internalised in the cell, ASOs can 
diffuse freely between the nucleus and the cytoplasm (Lorenz et al., 2000). ASOs may 
maintain their activity for 16 weeks in the case of gapmers or longer in the case of PMOs 
after cellular internalisation (DeVos and Miller, 2013). 
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Due to their uncharged nature, some ASOs scarcely cross the blood brain barrier 
(BBB) making intramuscular and intravenous injections unsuitable methods of delivery to the 
CNS in order to target neurological conditions. Alternatively, they can be delivered directly 
into the cerebral spinal fluid (CSF) by means of a single injection or constant diffusion. ASOs 
show a uniform distribution across the CNS upon direct delivery into the CSF in rodents and 
rhesus monkeys (Rigo et al., 2014). Additionally, once ASOs are administered into the CSF 
their tissue half-life is much greater than in peripheral tissues due to the lower presence of 
endonucleases in the CNS. ASOs were detected 71-206 days and 145-191 days in the brain 
and the spinal cord, respectively, after a single injection. This contrasts with the 10-65 day 
presence detected in peripheral tissue (Rigo et al., 2014). However, the fact that ASOs are 
eventually cleared from the CNS means that there is the possibility of terminating the 
therapy if necessary. Moreover, it has been shown that it is possible to reverse the beneficial 
effects of ASOs by injecting a fully complementary ASO, showing that a complementary ASO 
has the potential to act as an antidote in the case of side effects being detected (Rigo et al., 
2014). 
Tests in non-human primates have shown that bolus injection into the intrathecal 
(IT) space achieves a more uniform distribution in the CNS than intramuscular injections, 
although delivery of ASOs into deeper structures of the brain is harder to achieve 
(Kordasiewicz et al., 2012). This is a more invasive, costly, painful method but it is well 
tolerated, and it is a common procedure for delivery of anaesthetics. This method of delivery 
is relatively costly, meaning that ASO therapies are only being developed against life 
threatening conditions. For this reason, experts are studying the viability of the use of 
nanoparticles and coupling ASOs with arginine-rich cell penetrating peptides in order to help 
ASOs cross the BBB. If successful, it could mean that the cost of delivering ASOs into the CNS 
could be greatly decreased and making it viable to develop ASO-based therapies against 
other non-life threatening conditions.  
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1.10.2.2 Uses of ASOs in muscular and neurological conditions 
ASOs have been extensively tested as a possible therapy for many neuromuscular 
disorders. A main disadvantage of oligonucleotide-based therapies is achieving high 
concentrations of ASO in the target organ, however, in this case neurological conditions have 
the advantage that once in the CSF, ASOs escape the degradation by the liver and are rapidly 
taken by neurons (Butler et al., 2005). 
The use of ASOs has been pioneered in two muscular disorders; Myotonic dystrophy 
and Duchenne’s muscular dystrophy. In both cases steric hindering ASOs have been used but 
for very different purposes. Myotonic dystrophy, a hereditary degenerative disease, is 
caused by the presence of an expanded trinucleotide CTG repeat in the DM protein kinase 
(DMPK) gene. The expanded RNA causes the RNA to accumulate in the nucleus, sequestering 
the RNA-binding protein Mucleblind like 1 (MBNL1). Steric hindering ASOs have been used 
to prevent the sequestration of MBNL1 into RNA foci; mitigating the toxicity of the CUG 
repeats (Wheeler et al., 2012). In Duchenne’s muscular dystrophy, ASOs have been used to 
induce the exon skipping of a mutation carrying exon. The disease-causing mutation codes 
for a stop codon and leads to the translation of a short, inactive dystrophin protein. By 
targeting the intron boundary with steric hindering ASOs, incorporation of the mutation-
containing exon is prevented. In this way, exon skipping is induced and a shorter, but 
functional protein is translated that does not include the mutated exon. This approach has 
yielded very promising results showing a restoration of up to 97% of dystrophin protein and 
is currently in a phase III clinical trial (Goemans et al., 2011; Kinali et al., 2009; van Deutekom 
et al., 2007). 
In Alzheimer’s disease, gapmers have been used to decrease the amount of amyloid 
precursor protein (APP) showing a slight improvement in transgenic mice (Farr et al., 2014) 
and to reduce the levels of TAU protein encoded by the MAPT gene (Sud et al., 2014). 
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Gapmers have also been used in AD to specifically target mutated β-secretase, which is 
responsible for APP cleavage, showing a decrease in toxic amyloid beta (Aβ) levels (Chauhan 
and Siegel, 2007). 
Huntington’s disease is an autosomal dominant neurodegenerative disorder due to 
the expansion of a trinucleotide CAG repeat in the huntingtin gene. The CAG expansion is 
translated into a protein with an expanded poly-Q. Degrading ASOs could not be used to 
target the CAG expansion as poly-Q repeats are known to carry out many important cellular 
functions. Degrading ASOs have therefore been used to knock out both murine and human 
forms of huntingtin in transgenic mice showing a 75% reduction of transcript and a significant 
improvement in motor performance and survival (Kordasiewicz et al., 2012). The use of steric 
hindering ASOs has also been tested for Huntington’s showing an attenuation of 
neurotoxicity in vivo and in vitro (Sun et al., 2014). 
Additionally antisense oligonucleotides have been tested as a possible therapy for 
spinal muscular atrophy (SMA). SMA is an autosomal recessive condition that leads to the 
loss of motor neurons in the anterior horn of the spinal cord in a similar fashion to ALS. SMA 
is usually caused by the deletion of exon 7 in the SMN1 gene. The deletion is not usually 
embryonic lethal as humans uniquely express the almost identical SMN2 gene. However, the 
majority of SMN2 transcripts lack exon 7 due to a silent mutation that leads to the skipping 
of exon 7 and the translation of a shorter unstable SMN protein. Current strategies involve 
the use of steric hindering ASOs to modulate the splicing of exon 7 and increase its inclusion 
(Bogdanik et al., 2015; Lorson et al., 2010). Pre-clinical studies have shown that the use of 
ASOs targeting SMN2 are safe and are currently being taken into clinical trial. Children and 
adults suffering with SMA were treated with SMN2 targeting ASO showed a 5.9 fold increase 
in motor performance (n=84) compared to sham controls (n=42). 
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1.10.2.3 Uses of ASOs in ALS - SOD1 
RNAse H-dependent ASOs have been used to degrade SOD1 in G93A SOD1 rat model, 
showing that a 50% decrease in the total SOD1 protein can increase the lifespan by 8.8% (10 
days) compared to scrambled ASO although no effect was observed on disease onset (Smith 
et al., 2006). Intrathecal delivery of ASO was well tolerated in rats as well as non-human 
primates and a good ASO distribution throughout the CNS was achieved. This study also 
concluded that ASOs were safe to use as no adverse effects where reported with the highest 
doses (Smith et al., 2006). 
Following this study, a phase I clinical trial was carried out to test the safety, 
tolerability and pharmacokinetics of the therapeutic ASO – ISIS333611- which was completed 
in 2012 (Miller et al., 2013b). The study was carried out in a randomised, placebo-controlled 
way. The ASO was delivered by intrathecal infusion using an external pump over 11.5 h at 
increasing doses (0.15 mg, 0.50 mg, 1.50 mg, 3.00 mg) to four cohorts of eight patients with 
SOD1-positive amyotrophic lateral sclerosis. No dramatic decrease in SOD1 level in the CSF 
of treated cases was observed. The authors suggest, however, that this is because a low dose 
was administered in order to assess ASO safety (Miller et al., 2013b). 
The study concluded that, in order to achieve satisfactory SOD1 decrease a greater 
dose and longer infusion time would be necessary. The inability of the ASO to cross the blood 
brain barrier makes it an ideal candidate to treat CNS related conditions. ASOs may be 
administered intrathecally and not affect organs other than the CNS. Additionally, there were 
no reported adverse effect when using the ASO compared to placebo (Miller et al., 2013b). 
Overall this study constitutes a significant, but not conclusive advance in the implementation 
of ASOs as a possible therapy.  
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1.10.2.4 Uses of ASOs in ALS - C9ORF72 
There have been a number of in vitro studies exploring the used of mostly RNase-H 
dependent ASOs, although steric hindering ASOs have also been tested. Donnelly and 
colleagues (2013) have tested both RNAse-H dependent ASOs and steric hindering ASOs. 
Four degrading ASOs targeting the G4C2 repeat, the repeat-intron boundary and introns 1 
and 2 of the C9ORF72 gene were tested. All four ASOs showed a decrease in the number of 
detectable RNA foci but only the ASO targeting exon 2 showed a decrease in the total levels 
of C9ORF72 mRNA. All degrading ASOs as well as the steric hindering ASO were able to 
reduce the impact of glutamate susceptibility shown by iPSC-derived from expansion carriers 
(Donnelly et al., 2013). Another study generated iPSC-derived motor neurons from C9ORF72 
expansion carriers showing that they have diminished capacity to fire continuous spikes upon 
depolarization. These deficits were reversed upon treatment with antisense oligonucleotides 
which reduced both the number of RNA foci and C9ORF72 protein levels (Sareen et al., 2013). 
Lastly, ASOs targeting the C9ORF72 transcript were shown to reduce the number of 
detectable RNA foci in fibroblasts carrying the repeat expansion. Furthermore, ASOs were 
intrathecally administered to mice without any toxicity observed, thereby showing the 
potential safety of knocking down the C9ORF72 protein and arguing against the possibility 
haploinsufficiency contributes to the toxicity of C9ORF72 expansions (Lagier-Tourenne et al., 
2013).  
A single dose of degrading ASO was intraventricularly administered to 3 month old 
mice expressing a C9ORF72 bacterial artificial construct (BAC) with 450 G4C2 repeats. Tissues 
were collected 4 weeks after injection and the authors reported a decrease of 40% in repeat-
containing RNA in the cortex and the spinal cord. Administration of the ASO also resulted in 
over 50% decrease of RNA foci and almost complete depletion of poly-GP and poly-GR. A 
different ASO targeting the repeat-exon boundary was shown to improve age dependent 
behavioural deficits when tested 6 months post administration (Jiang et al., 2016).  
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1.10.2.5 Uses of ASOs in ALS - Other targets 
ALS cases have been shown to have increased acetylcholinesterase enzyme (AChE) 
serum levels, making it a potential therapeutic target (Gotkine et al., 2013; Rasool et al., 
1983; Rodriguez-Ithurralde et al., 1998). Moreover, the effects of a potential therapeutic 
strategy can be easily monitored. ASOs targeting AChE mRNA have been shown to lead to a 
10% increased life span in G93A SOD1 mice, as well as a decrease motor neuron loss (Gotkine 
et al., 2013). 
Additionally, it has been reported that the micro RNA, miRNA-155 is upregulated in 
sporadic and familial ALS. Although miRNA-155 is constitutively expressed, it is most highly 
expressed in T-cells and monocytes and have been shown to regulate pro-inflammatory 
pathways. Koval and colleagues (2013) used steric hindering ASOs to block the effect of 
miRNA155. G93A SOD1 mice were implanted with osmotic pumps at 60 days containing 20 
mg/day anti-miR-155. There was no significant change in the disease onset (measured by 
weight loss and neurological score), however, the anti-miR-155 ASO treated mice showed a 
7.4% (9.5 days) average increase in survival (Koval et al., 2013). 
Finally, degrading ASOs targeted at Ataxin-2 have been shown to significantly 
increase the median lifespan of mice expressing two copies of human TDP-43 by 34% (Becker 
et al., 2017). The use of this ASO achieved a 77% reduction of Ataxin 2 transcript levels by 
ICV injection Ataxin ASO at P1. No mice treated with control ASO lived past 32 days; in 
contrast 2/16 mice treated with Ataxin 2 ASO lived over 120 days. The authors of this study 
suggest that the improvement in survival and motor performance was due to preventing 
TDP-43 to be sequestered into stress granules which lead to its aggregation. This study opens 
an exciting new therapeutic avenue to treat the majority of ALS cases that have TDP-43 
inclusions (Becker et al., 2017). 
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1.10.3 Biological uses of steric hindering ASOs  
Steric hindering ASOs bind to the target with high affinity and do not induce 
degradation, for this reason there have a number of different biological applications. ASOs 
can be designed such that they bind to the 5’-cap formation site of specific genes in the 
nucleus in order to prevent polyadenylation and therefore reducing the transcript levels. 
Alternatively, protein levels can be decreased by using ASOs targeting the ribosomal entry 
site and inhibiting translation (Evers et al., 2015). Splicing modulation may also be achieved 
by designing ASOs that bind to the exon-intron boundary, splicing will be prevented 
achieving the removal of an intron containing a pathogenic mutation (Arechavala-Gomeza 
et al., 2007; Dominski and Kole, 1993). This has been shown in Duchenne’s muscular atrophy 
and is currently undergoing a phase III clinical trial (Goemans et al., 2011; Kinali et al., 2009; 
van Deutekom et al., 2007). Finally, ASOs have also been shown to reduce the effects of 




Table 1.2: Review of chemical ASO chemical modifications 




Phosphotioate (PS) oligomer 
+ Recruit RNAse H and 
degrade the target transcript 
+ Possess “enzymatic” 
activity 
- Have a short life due to 
degradation by nucleases 
- Off target effects 
 
Phosphorodiamidate 
Morpholino Oligomer (PMO) 
+ Good efficacy for 
translation inhibition 
+ Increased affinity to target 
+ High nuclease resistance 
- low cellular uptake 
- Do not degrade the target 
transcript 




+ Moderate cell uptake 
+ Low off target binding 
- Lower target affinity than 
PMO 
- Moderate nuclease 
resistance 
 
Locked nucleic acid (LNA) 
+ Robust binding to target 
+ High binding affinity 
- High cellular toxicity 
- Poor cellular uptake 
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1.11 PROJECT RATIONALE  
At the time that the present study was designed, the mechanisms of the C9ORF72 
expansion toxicity were relatively unexplored. Three main theories of toxicity; toxic gain-of-
function of RNA foci, DPR toxicity or haploinsufficiency, were equally plausible. In my project 
I tried to address this by quantifying the abundance and distribution of sense and antisense 
RNA foci, TDP-43 mislocalisation and inclusions from all five DPRs in spinal cord motor 
neurons of ten C9ORF72-ALS cases and compared them to five non-C9 ALS-TDP-43 cases. We 
have found that sense RNA foci are the most common species in the spinal cord of C9ORF72-
ALS cases. Moreover we observed that DPR protein inclusions are rare in the spinal cord and 
almost absent from the motor neurons of the ten C9ORF72-ALS cases analysed. 
We also explored the use of steric hindering ASOs, as they would not cause a decrease 
in the levels C9ORF72 transcript or protein. Additionally steric hindering ASOs had been 
shown to have the ability to decrease the number of RNA foci in an in vivo model of another 
repeat-expansion disorder and have been shown to be effective at translation inhibition 
(Mulders et al., 2009; Wheeler et al., 2009). Further publications have shown that the G4C2 
repeats are sufficient to cause cognitive deficits and TDP-43 mislocalisation in mice (Chew et 
al., 2015b). For this reason, targeting the repeats directly and no other flanking region may 
be sufficient to mitigate toxicity. Furthermore, C9orf72 knockout mice show microglia 
activation and macrophage dysfunction (O'Rourke et al., 2016). This may suggest that using 
gapmers as a therapeutic strategy may have toxic side effects. By using non-degrading ASOs 
that target the G4C2 expansion, we aim to mitigate the repeat expansion toxicity as well as 
reducing any possible side effects that may arise from decreasing the levels of C9ORF72 
mRNA and protein. 
A collaboration was initiated with Sarepta plc, a biotechnology company with great 
expertise in the use of phosphorodiamidate morpholino oligomers (PMOs) for other 
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neuromuscular conditions.  Having a commercial company collaborating in the project 
satisfied the ambition that the outcome of the project could be clinically explored if the 
results were satisfactory. Sarepta provided control and G4C2 targeting peptide-coupled 
PMOs (PPMOs) in order to increase the cellular uptake of PMOs. Additionally, PPMOs have 
been shown to show a wide distribution throughout the brain upon ICV injection and little 


















All reagents were purchased from Life Technologies unless otherwise stated 
2.1 HUMAN PATHOLOGICAL STUDY  
 
2.1.1 Human post-mortem tissue 
 
A total of thirty spinal cord sections were analysed for the presence of TDP-43 and 
all DPR inclusions and RNA foci by fluorescent in situ hybridisation and/or double 
immunofluorescence from each individual including ten ALS cases positive for the C9ORF72 
intronic expansion (C9ORF72-ALS). Thirteen sections were also analysed from five ALS cases 
negative for C9ORF72, FUS and SOD1 mutations (365 sections in total). Sections of frontal 
lobe and cerebellar cortex from a case of C9ORF72-FTD with abundant p62 pathology were 
chosen as a positive control for DPR staining. All cases were provided by the Medical 
Research Council London Neurodegenerative Diseases Brain Bank (Institute of Psychiatry, 
Psychology and Neuroscience, King’s College London). Samples were collected and 
distributed in accordance with local and national research ethics committee approvals. 
Expansion carriers were identified using repeat primed PCR (Smith et al., 2013) and all of the 
cases had previously been reported to show characteristic cerebellar p62 and TDP-43 
pathology (King et al., 2009; Troakes et al., 2012).  Details of the age, sex and post-mortem 
delay are recorded in the appropriate chapter. 
2.1.2 Motor neuron counting and double label immunofluorescence 
A total of 30 spinal cord sections were analysed from each C9ORF72-ALS case. 
Histological examination was performed on 7μm sections prepared from formalin-fixed, 
paraffin–embedded tissue from spinal cords of all ALS cases. Sections were stained with 
hematoxylin and eosin to perform motor neuron counts, and sequential sections were 
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processed for double label immunofluorescence for the DPRs, sense and antisense foci and 
TDP-43. Prior to double immunofluorescence staining, paraffin was removed with xylene and 
all sections were rehydrated in an ethanol series (100%, 95%, 70%) for 3 min per step. Slides 
were incubated in 0.3% Sudan black for 5 min to quench autofluorescence and washed with 
water. Antigen retrieval was carried out by microwaving for 6 min at maximum power and 
12 min at medium power in 100mM sodium citrate buffer (pH 6.0). Non-specific binding sites 
were then blocked for 20 min using 5% normal donkey serum in PBS.  
For double immunofluorescence staining, spinal cord sections were incubated with 
primary rabbit antibodies against the five different DPRs (poly-GA, GP, GR, PR and PA) at a 
dilution of 1:100 together with TDP-43 (rat monoclonal TDP-43 Sigma Scientific (SIG-39850) 
at a dilution of 1:100 antibody was carried out overnight in a humid chamber at 4oC. The DPR 
antibodies were obtained from Dr. Leonard Petrucelli and colleagues and were previously 
characterised (Gendron et al., 2013). After 3 washes with PBS, sections were incubated with 
anti-rabbit (Alexa Fluor 594) and anti-rat (Alexa Fluor 488) secondary antibodies for 1hr at 
room temperature. DAPI (Sigma) was used to counterstain nuclei. Sections were mounted in 
Fluorsave. Semi-quantitative and quantitative evaluation of DPR and TDP-43 pathology was 
performed using Zeiss Axiovert S100 microscope. Aggregates were also imaged using a Leica 
Confocal SP microscope. A “secondary antibody only” control was introduced in each staining 
procedure. 
2.1.3 Fluorescent in situ hybridisation for human sections 
Fluorescent in situ hybridisation (FISH) was performed in 20 lumbar spinal cord 
sections from each of ten C9+ve-ALS cases and 13 sections from 5 TDP-43-ALS cases. Human 
sections were provided as 10% formalin fixed and paraffin-embedded blocks. To perform 
FISH, paraffin was removed with two 3 minute washes in xylene and sections were 
rehydrated as described in Lee et al.(2013) Cy3-labelled sense ((C4G2)X4) and antisense 
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((G4C2)x4) LNA probes were used at a concentration of 200ng/μl (Exiqon). Hybridisation was 
carried out in a humid chamber at 60°C overnight. Sections were washed once in 2XSCC/ 
0.1% Tween 20 solution at room temperature and three times with 0.1X SCC solution at 60°C 
for 5 minutes. Sections were then incubated with 1.25ng/ml DAPI (Sigma) counterstain 
solution for 5 minutes and mounted in Fluorsave for quantification of RNA foci. 
If IHC was performed to assess the co-occurrence of TDP-43 and RNA foci, sections 
were blocked with 5% Donkey serum-PBS solution for 1 hour and incubated with TDP-43 
(mouse polyclonal TDP-43 10782-AP Proteintech) at a dilution of 1:100. Sections were 
washed three times with PBS and incubated with anti-rabbit AlexaFluor 488 secondary 
antibody for 1 hour. The sections were then treated with DAPI counterstain and mounted in 
Floursave.  
2.1.4 Semi quantitative and quantitative evaluation of pathology  
The presence of sense and antisense foci, DPRs and TDP-43 inclusions were scored in 
the spinal cord using a previously published semi-quantitative grading scale (Mackenzie et 
al., 2013b), in which the total number of immunoreactive inclusions, as well as the 
cytoplasmic inclusions (CI) and the intranuclear inclusions (NI), were rated as follows:  0 – 
Absent, 0.5 – one or two inclusions in the whole section, 1- very few, 2- occasional- easy to 
find and a few cells are affected, 3- moderate- many of the cells are affected, inclusions are 
easy to find, 4- numerous- nearly all of the cells are affected. Additionally, each section was 
re-analysed and the number of DPR and TDP-43 inclusions was counted manually in a 
systematic, blinded manner. The number of DPR aggregates was counted per section and 




2.2 CELL CULTURE 
2.2.1 Maintenance of Cell lines 
HEK-293T cells were grown in DMEM/GlutaMax media, 10% foetal bovine serum, 1% 
penicillin-streptomycin. Cells were grown T25 flask until 100% confluent and split by washing 
once with PBS and treating for 2-3minutes or until cells detached with 1ml of trypsin-EDTA 
reagent. Cells were then collected in 5ml of growth medium and spun at 1000g for 4 minutes. 
The supernatant was discarded and the pellet was then re-suspended in 6ml of growth 
medium. 2ml of re-suspended cells were put into a clean T25 flask together with 3ml of 
growth medium. The remaining re-suspended cells were counted and plated for 
experiments.  
2.2.2 Counting and Plating of Cell lines 
Cells were counted using a NucleoCounter NC-300 (Chemometech). Cells were 
counted following the cell count and viability protocol following the manufacturer’s 
instructions. The number of viable cells was used. Cells were then plated in 500μl of 
media/well for a 24-well plate and 1ml of media/well for a 12-well plate. Cells used for 
immunohistochemistry were plated in 13 mm coverslips. Prior to plating, coverslips were 
coated with poly-d-lysine hydrobromide (1:1000 in PBS) for 1 hour at 37°C and washed once 
with PBS. 
2.2.3 Maintenance of iPSC 
Cells were grown in Geltrex (Thermo Fisher Scientific) coated 6-well plates. Induced 
pluripotent stem cells (iPSC) were every other day with 2 ml of E8-FLEX (STEMCELL 
Technologies) medium and 5 ml of medium was used to feed iPSCs over the weekend. 
Cells were passaged when colonies were large, when the edges of the colonies were in 
contact with each other or when the centre of the colony changed colour, indicating that the 
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cells were differentiating. Prior to passaging 6-well plates were coated with 750 μl of Geltrex 
for one hour and washed once with PBS.  
For passaging, cells were incubated for at least one hour with 1X REVTACELL (Life 
technologies) prior to passaging. Cells were washed once with 500 μl of PBS and incubated 
for 3 minutes with Versene (Thermo Fisher Scientific). Versene was removed and 2 ml of E8-
FLEX medium was then added vigorously on the well in order to detach and break up the 
colonies. 1 ml was added to 3 wells of a 6-well plate. 
2.2.4 In vitro differentiation into smooth muscle actin (SMA) positive cells 
iPSCs were differentiated into smooth muscle cells (SMA positive) in order to show 
that they can be differentiated into mesodermal cells. iPSCs were spit as previously described 
and plated into a 24-well plate containing gelatine/fibronectin coated 5mm coverslips in E8-
FLEX (STEMCELL Technologies) culture medium. The next day the medium was removed and 
substituted for muscle differentiation medium (MDM) as described in table 2.1. The medium 
was replenished every other day for 10 days until cells were fixed from immunofluorescence. 
Component Final concentration 
DMEM:F12 1X 
Fetal bovine serum (FBS) 15%  
GlutaMax 1X  
Penicillin-streptomycin 1x 
MEM Non-essential amino acids  1x 
Monothioglycerol 1mM 
Retinoic acid 10 µM 
Table 2.1: Muscle differentiation medium (MDM) 
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2.2.5 In vitro differentiation into α-fetoprotein (AFP) positive cells 
iPSCs were differentiated into hepatocyte progenitors in order to show their ability 
to differentiate into endodermal cells as previously described by (Siller et al., 2015). iPSCs 
were split as previously described and plated into a 24-well plate containing Geltrex-coated 
5 mm coverslips in E8-FLEX (STEMCELL Technologies) medium. On Day 0 the medium was 
removed and replaced by AFP medium 1 (table 2.2). After one day, the medium was removed 
and replaced by AFP medium 2 (table 2.3). Cells were cultured for one day on AFP medium 
2, which was then removed and replaced AFP medium 3 (table 2.4). Cells were cultured for 
5 days in AFP medium 3 until fixed as previously described for immunofluorescence.  
Component Final concentration 
RMPI 1640 GlutaMax 1X 
B27 supplement 1X 
CHIR99021 4 µM 
Table 2.2: AFP medium 1 
 
Component Final concentration 
RMPI 1640 GlutaMax 1X 
B27 supplement 1X 








Component Final concentration 
Knockout DMEM 1X 
Knockout serum replacement (KOSR) 20% 
GlutaMax 1X 
2-Mercaptoethanol 100 µM 
MEM Non-essential amino acids  1x 
DMSO (Sigma-Aldrich) 1% 
Table 2.4: AFP medium 3 
2.2.6 In vitro differentiation of iPSCs into neuronal progenitor cells 
iPSCs were differentiated into neuronal progenitors cells (NPCs)  as described 
elsewhere (Devlin et al., 2015). Briefly, iPSCs were plated at 30–40% confluence in neural 
conversion media containing DMEM/F12,  1% L-glutamine, , 5 mg/mL BSA (Europa Bio-
products, Cambridge, UK), 1 x lipids (Life technologies), 450 µM monothioglycerol (Sigma), 7 
µg/ml insulin (Roche), 15 µg/ml transferrin (Roche) 10 µM of SB431542 (Tocris Biosciences, 
Bristol, UK) and 2 µM of dorsomorphin (Merck) for 7-10 days (CDM1 medium, table 2.5). 
Cells were cultured in suspension to form neurospheres in the same medium described 
above, withdrawing SB431542 and dorsomorphin and adding 1µM of Retinoic acid, 2.5 ng/ml 
of bFGF (Peprotech) and 2.5 ng/ml of heparin for 7-10 days (CDM2 medium, table 2.6). 
Neurospheres were dissociated with Stem Pro Accutase (Life technologies) and plated on 
matrigel in NPCs expansion medium containing Advance DMEM:F12, 1% 
Penicillin/streptomycin (P/S), 1% L-glutamine, 1% N2, 0.001% B27 and 10ng/ml of bFGF until 






Component Final concentration 
DMEM:F12 1X 
L-glutamine (10X) 1x 
BSA 5mg/ml (filter sterilize)  
Lipid 100x 1x 
Monothioglycerol 450 μM 
Insulin 7 μg/ml 
Transferrin 15 μg/ml 
Penicillin-streptomycin 1x 
Activin inhibitor 10 µM 
Dorsomorphin 2 µM 
Table 2.5:  Chemically defined medium 1 (CDM1) composition 
Component Final concentration 
DMEM:F12 up to 250 ml 
L-glutamine (10X) 1x 
BSA 5mg/ml (filter sterilize)  
Lipid 100x 1x 
Monothioglycerol 450 μM 
Insulin 7 μg/ml 
Transferrin 15 μg/ml 
Penicillin-streptomycin 1x 
Retinoic Acid 0.1 µM 
bFGF 2.5 ng/ml 
Heparin 2.5 ng/ml 




2.2.7 Maintenance of neuronal progenitor cells 
T25 Flasks were coated 1:50 with matrigel at least one day before. Prior to use flasks 
were placed for one hour at 37°C and washed once with PBS. Neuronal progenitor cells were 
grown in matrigel coated T25 flasks. Cells were maintained with bFGF-containing expansion 
media (table 2.7) and changed every two days. Cells were kept at 37°C in a hypoxia incubator 
to preserve the neuronal identity. Cells were grown until fully confluent and split 1:2. Cells 
were split by washing once with PBS and adding 1ml of Accutase (Life Technologies) until the 
cells detached. Cells were then collected in expansion media and pelleted by gentle 
centrifugation (1000g for 4 min). Cells were then resuspended in 500 μl of expansion media 
and half of the cells were placed into a fresh matrigel coated T25 flask containing 3 ml of 
expansion media. The remaining cells were plated for neuronal differentiation. 
Component Concentration 
Advanced DMEM/F12 1x 
L-glutamine 1x 
Penicillin-streptomycin 1x 
Heparin 2 μg/ml 
N2 0.5X 
B27 0.1X 
bFGF 20 ng/µl 
Table 2.7: Neuronal progenitor cell expansion medium 
 
2.2.8 In vitro differentiation of neuronal progenitor cells into mature neurons  
Neuronal progenitor cells were counted as previously described. Differentiation of 
neuronal progenitor cells into cortical neurons was driven by removal of bFGF (Preprotech) 
from the culture medium. Plates were coated with matrigel 1:50 the previous day. Prior to 
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plating, plates were placed at 37°C for one hour and washed once with PBS. Cells were plated 
in differentiation medium (table 2.8) at a confluency of 2.5x105 cells/well in a 24-well plate 
and double that for a 12-well plate. Cells were allowed to differentiate for 7 days in 
differentiation media. The medium was topped every 3-4 days. The differentiation medium 
removed 7 days after initiation of neuronal differentiation and replaced by GDNF and BDNF-
containing maturation medium (table 2.9). Maturation medium was added every 3-4 days 
for 5 weeks until the neurons were analysed. 
 
Component Concentration 
Advanced DMEM/F12 1x 
L-glutamine 1x 
Penicillin-streptomycin 1x 
Heparin 2 μg/ml 
N2 0.5X 
B27 0.1X 











Advanced DMEM/F12 1x 
L-glutamine 1x 
Penicillin-streptomycin 1x 
Heparin 2 μg/ml 
N2 0.5X 
B27 0.1X 
GDNF 5 ng/ml 
BDNF 5 ng/ml 
Table 2.9: Neuronal maturation medium 
2.2.9 Plasmid maxiprep 
Bacteria containing the plasmid of choice was grown over night at 37°C in a shaker 
in 500 ml Luria-Bertani (LB) media with 1X Ampicillin. Plasmids were isolated using a Plasmid 
Maxiprep Kit (Quiagen) following the manufacturer’s instructions. Plasmid was resuspended 
in 500μl of DNAse-free water (Ambion) and the concentration of DNA was measured using a 
microvolume spectrophotometer (Nanodrop, Thermoscientific). DNAse-free water was then 
added to make up a final concentration of 1μg/μl. 
2.2.10 Transfection of cells 
300 ng/well in a 24-well plate of plasmid DNA was used to transfect all cells unless 
otherwise stated. 200 μl of media was removed from each well. 300ng of DNA was mixed 
with 1 μl of Lipofectamine 2000 and 50μl of OPTIMEM in a sterile 1.5ml tube. The 
transfection mixture was shaken briefly, spun down and allowed to mix for 20 minutes. 50μl 
of transfection mixture was added dropwise into the 24-wellplate. Transfection was carried 
out for 24 hours.  
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2.2.11 Mycoplasma testing 
All cells were tested monthly for mycoplasma infection. 2ml of media was collected 
and analysed using MycoAlert Mycoplasma Detection Kit (Lonza) following the 
manufacturer’s instructions.  
2.2.12 Peptide-coupled PMO information 
PPMOs were provided by Sarepta Therapeutics (Cambridge MA). To increase the PMO 
cellular uptake capability, PMOs were coupled to a CP06062 cell penetrating peptide 
(PPMO). Peptide-coupled PMOs (PPMOs) and 5’ fluorescently labelled protein-coupled 
PMOs (5FL-PPMOs) where synthesized and by Sarepta Therapeutics (Cambridge, MA) and 
supplied as a lyophilised powder. PPMOs were resuspended in RNAse-free water to form a 
stock concentration of 2mM as suggested by the company. PPMOs and 5FL-PPMOs were 
diluted to the required concentration in cell culture media. A Control-PPMO with a scrambled 
sequence with no known target and a G4C2-PPMO directly targeting the G4C2 expansion 
(CCCCGG CCCCGG CCCCGG CCCCGG) were used for all experiments.  
2.3 ANALYSES 
2.3.1 RNA extraction  
Total RNA was isolated from cultures of cell lines with the RNeasy kit (Qiagen) 
according to manufacturer’s instructions. Cells were manually scraped and collected into 
RNAse-free polypropylene tubes. Cells were centrifuged for 1 minute at 12 000g and cell 
pellets were kept on ice and washed in PBS three times prior to RNA extraction. RNA was 




2.3.2 RT PCR 
cDNA was synthesized by using 1 μg of total RNA with the SuperScript® III First-Strand 
Synthesis System in a 20 μl volume following the manufacturer’s instructions. cDNA was 
diluted to 5ng/μl and standard polymerase chain reactions (PCR) were performed using 
Thermophilus aquaticus (Taq DNA polymerase). 25 ng of cDNA of each sample was amplified 
in a 25μl reaction containing 0.2mM dNTP, PCR primers, 1.5 mM MgCl2, 10x PCR buffer and 
0.1 μl Taq DNA polymerase. Amplification was performed at 95°C for 30 seconds, 35 cycles 
of 58°C or 61°C for 30 seconds and 72°C for 30 seconds, followed by extension at 72°C for 10 
minutes. PCR products were electrophoresed in 1% agarose gels.  
2.3.3 Quantitative PCR (qPCR) 
Total RNA from the appropriate cell type was isolated and cDNA was synthesized as 
previously described. For quantitative expression analysis, 20µl cDNA samples from 
SuperScript III reactions were diluted with a further 100 µl of nuclease-free H2O. Reactions 
were carried out in a total volume of 12µl, containing diluted cDNA, 1× HOT FIREPol® 
EvaGreen® q-PCR Mix (Solis Biodyne, Tartu, Estonia) and primers at 200nM, using an MJ 
Research Chromo 4 (Bio-Rad) and MJ Opticon Monitor analytic software (BioRad). Triplicate 
qPCR reactions were performed and averaged to measure each gene in each cDNA sample. 
The mean measures of target genes were normalized against a geometric mean determined 
from three internal control genes (GAPDH, RPL13A and SDHA) for each cDNA sample to yield 











Exon 2 For-GCAGAGAGTGGTGCTATAGATG 30 s, 60°C 40 s, 72°C 
 Exon 5 Rev-GCCTTCATGACAGCTGTCACC 
SOX2 Exon 1 For-TTCACATGTCCCAGCACTACCAGA 30 s, 60°C 20 s, 72°C 
 Exon 1 Rev-TCACATGTGTGAGAGGGGCAGTGTGC 
OCT4 Exon 1 For-ACTTCACTTTCCCTCCAACC 30 s, 60°C 40 s, 72°C 
 Exon 3 Rev-AGTTTGTGCCAGGGTTTTTG 
GAPDH Exon 7 For-GTGGACCTGACCTGCCGTCTAG 30 s, 61°C 30 s, 72°C 
Exon 8 Rev-CCTGTTGCTGTAGCCAAATTCGTTG 
RPLA13A Exon 1 For-CCTGGAGGAGAAGAGGAAAAG 30 s, 60°C 40 s, 72°C 
 Exon 1 Rev-TTGAGGACCTCTGTGTAATTGTC 
SDHA Exon 1 For-TGGGAACAAGAGGGGCTCTG 30 s, 60°C 40 s, 72°C 
 Exon 2 Rev-CAACAACTGCATCAAATTCAT 
Table 2.10: Details of primers used 
2.3.4 Gel electrophoresis 
Agarose was dissolved in TAE buffer by microwaving until the sample was boiling. 
1μl of ethidium bromide was added to 25ml of gel before it set in order to visualise the DNA 
and the gel was then poured into a casting tray. Samples were mixed with 5X loading buffer 
and loaded into the gel was allowed to settle for 30 minutes prior to running the samples. 
Samples were run for 30min – 1hour at 120V on a 1% w/v agarose gel in TAE buffer together 
with 5μl of 1Kb DNA ladder (New England BioLabs). Gels were removed and placed into the 
BioDOC-IT Imaging system, an UV transilluminator (UVP Inc., San Gabriel, U.S.A.), and 
photographed digitally under UV transillumination. The size of the DNA was determined by 
a 100 base pair (bp) DNA ladder (New England BioLabs). 
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2.3.5 Cell fixing 
Cells were grown in 5mm coverslips. Cells were washed twice with 500μl of PBS and 
then fixed with 4% paraformaldehyde solution for 20 minutes at room temperature. Cells 
were then washed twice with 500μl of PBS and stored in PBS until analysis was performed. 
2.3.6 Quantitative image analysis 
MetaMorph Image System 7.5 (v. 7.7, Molecular Devices) and ImageJ (version 1.45e, 
NIH, Bethesda, USA, http://rsb.info.nih.gov/ij/) software programs were used for 
quantitative image analysis. For each analysis, 7-12 images were taken with the same 
exposure times. Images were then converted into 16-bit images from each biological 
replicate. Three biological replicates were performed for each experiment. A detailed 
description of different analyses has been included in the corresponding chapters. 
2.3.7 Cell harvesting 
In order to harvest cells, cells were washed twice with PBS. Plates were then placed 
on ice and ice cold 300µl RIPA buffer (table 2.11) containing 1X Complete mini protease 
(Roche) inhibitors was added. Cells were rigorously pipetted and placed into a sterile 1.5ml 
tube. Cells were then sonicated 3 times for 10 seconds prior to protein quantification.  
Component Concentration 
TRIS-HCL pH7.4 50 mM 
NaCl 150 mM 
Triton X-100 1% 
Sodium Deoxycholate 1% 
SDS 0.5% 
Table 2.11: RIPA buffer composition 
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2.3.8 Protein assay 
Protein concentrations were determined using the DC Protein Assay Kit II (BioRad) 
according to the manufacturer’s instructions. 1μl of bovine serum albumin (BSA) standards 
(0 – 2μg/μl) and samples were used in duplicates and pipetted onto a microtiter plate 
(Corning). 25 μl of a mixture containing 1ml of Reagent A and 20 μl of Reagent S were added 
to each well. 200 μl of Reagent B was then added to each well. After 15 minutes at room 
temperature, absorbance was read with a microplate reader set to 750nm. Protein 
concentrations were calculated based on the mean absorbance of sample duplicates. 
2.3.9 Western blotting  
10-20μg of lysates were denatured by boiling with 2X SDS sample buffer for 10 
minutes at 100°C. Biological replicates, along with 2μl of Precision Plus Protein Dual Color 
Standard (BioRad), were run on separate NuPAGE Novex 10% Bis-Tris Midi gels in 
Morpholinepropanesulfonic acid (MOPS) buffer at 150 V until the samples run completely. 
The gels were incubated in transfer buffer for 5 minutes and transferred to nitrocellulose 
membranes using iBlot Transfer Stack and the iBlot Gel Transfer Device for 7.5 minutes. 
Membranes were washed with phosphate-buffered saline with 0.1% Tween 20 (PBST) 
(Sigma). Membranes were then blocked with 5% non-fat milk solution in PBS for 1 hour and 
then probed with primary antibodies diluted in a 2.5% milk solution in PBS rolling at 4°C 
overnight. Membranes were then washed three times with 5ml of PBST and probed with the 
relevant IRDye secondary antibodies (Li-Cor) diluted 1:5000 in 2.5% milk solution in TBST for 
1 hour at room temperature rolling in the dark. Membranes were washed three times with 
PBST and the fluorescent signal was detected with the Odyssey Infrared Imaging System (Li-




2.3.10 Filter trap assay 
An Acetate membrane was washed twice with 100µl of RIPA buffer. An appropriate 
amount of protein lysate was diluted into 100µl of RIPA buffer and added into each well and 
made to flow though the membrane by aspirating. The membrane was washed three more 
times with 100 μl of RIPA buffer per well. Membranes were then blocked with 5% non-fat 
milk solution in PBS for 1 hour and then probed with primary antibodies diluted in a 2.5% 
milk solution in PBS at rolling at 4°C overnight. Membranes were then washed three times 
with 5ml of PBST solution and probed with the relevant secondary antibodies (Li-Cor) diluted 
1:5000 in 2.5% milk solution in TBST for 1 hour at room temperature rolling in the dark. 
Membranes were washed three times with PBST and the fluorescent signal was detected 
with the Odyssey Infrared Imaging System (Li-Cor Biosciences). 
2.3.11 Fluorescent in situ hybridisation for RNA probes of cell lines 
PBS was removed and cells were permeabilised for 5 minutes with 0.1% Triton-X 
solution. Cells were then incubated for 15 minutes in pre-hybridisation solution (table 2.12). 
Probe was diluted to its final concentration (see table 2.14 of FISH probes) in hybridisation 
solution (table 2.13). Pre-hybridisation solution was discarded and 10μl of diluted probe was 
added dropwise at the top of the cells. Cells were then covered with circular pieces of 
parafilm to prevent evaporation. Cells were incubated in a hybridisation oven for the 
selected period of time at the indicated hybridisation temperature shown in table 2.14. Cells 
were then washed twice 2X SCC for 15 minutes followed by two washes with PBS at room 
temperature. Cells were then treated with 0.01% RNAse/PBS solution for 5 minutes in order 
to reduce background staining. Immunohistochemistry was then performed or cells were 
incubated with DAPI counterstain (1.25μg/ml) for 5 minutes and mounted on microscope 
slides (SuperFrost, VWR) using Fluorsave reagent and dried over night at 4°C. Samples were 
then imaged with a Zeiss inverted phase contrast fluorescent microscope or a Leica laser 






Table 2.12: Prehybridisation solution 
Table 2.13: Hybridisation solution 
 
2.3.12 Fluorescent in situ hybridisation for LNA probes 
After fixing, the PBS was removed and cells were permeabilised for 5 minutes with 
0.1% Triton-PBS solution. Cells were incubated for 15 minutes in pre-hybridisation solution 
(table 2.12). Probe was diluted to its final concentration (see table 2.14 of FISH probes) in 
hybridisation solution (table 2.13). Pre-hybridisation solution was discarded and 10μl of 
diluted probe was added dropwise at the top of the cells. Cells were then covered with 
circular pieces of parafilm to prevent evaporation. Cells were incubated in a hybridisation 
oven for the selected period of time at the indicated hybridisation temperature shown in 
table 2.14. Cells were then washed twice 2X SCC, 0.1% TWEEN solution for 15 minutes 
followed by two washes with 0.1X SCC solution at 60°C. Immunofluorescence was then 
performed or cells were incubated with DAPI counterstain (1.25 μg/ml) for 5 minutes and 





tRNA 10 mg/ml 
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2.3.13 Double fluorescent in situ hybridisation 
Hybridisation with an EGFP LNA targeting probe (5’TYE–563–
ATGATTGTGGCGGATCTTGAAGT) was performed at 66°C in a humid chamber overnight at a 
concentration of 20nM. Cells were washed 3 times with 2X SCC. A second hybridisation was 
carried out with an Cy5-(C4G2)x8 RNA probe over night as previously described. When FISH 
was followed by ICC, cells were kept PBS in the dark at 4°C. ICC was performed as previously 








C4G2 (CCC CGG)x8 – Cy3 48 5 ng/µl RNA 
C4G2 (CCC CGG)x8 – Cy5 48 5 ng/µl RNA 
C4G2 (CCC CGG)x4 – Cy3 60 2 ng/µl  LNA 
G4C2 (GGG GCC)x4-Cy3 60 2 ng/µl LNA 
EGFP LNA (ATGTTGTGGCGGATCT
TGAAGT) – Cy3 
60 20 ng/µl LNA 
Table 2.14: Details of FISH probes 
 
2.3.14 Immunofluorescence  
Cells were fixed as previously described, permeabilised in 0.1% Triton-X in PBS at 
room temperature for 5 minutes and blocked in 5% donkey serum (Sigma) in PBS at room 
temperature for 20 minutes. Cells were probed with the selected primary antibodies diluted 
in 2.5% donkey serum overnight at 4°C. Details of the antibodies used are provided in each 
chapter. AlexaFluor-488, AlexaFluor-550 and AlexaFluor-650-labelled secondary antibodies 
raised in the appropriate species (Thermo Scientific) were diluted 1:500 in PBS and applied 
for 1 hour at room temperature in the dark. DAPI (Sigma) counterstaining (1.25μg/ml) was 
101 
 
then applied for 5 minutes at room temperature in the dark. Coverslips were mounted on 
microscope slides (SuperFrost, VWR) with Fluorsave mounting medium and dried at 4°C 
overnight before imaging with a Zeiss Axiovert S100 (HB0100) (Carl Zeiss Ltd.) inverted phase 
contrast fluorescent microscope or a Leica laser scanning confocal microscope (TCS-SP5). 
2.3.15 Neurite outgrowth assay 
Neuronal progenitor cells were counted using a NucleoCounter (Chemometech). 
Approximately 1500 cells were plated per well per cell line in triplicate for each condition (no 
PPMO, control PPMO and G4C2 PPMO) on a 96-well optic plate (Falcon) coated with matrigel 
in neuronal differentiation medium. PMOs were added to each well shortly after plating. 
Cells were allowed to differentiate for 7 days in the absence of FGF and fixed in 4% PFA for 
15 minutes. Cells were stained with rabbit MAP2 antibody (ab5392) at a dilution of 1:500 at 
4°C overnight. Cells were washed twice with PBS and incubated with anti-rabbit AlexaFluor 
488 secondary for 1 hour at room temperature. Cells were washed three times with PBS and 
incubated for 5 minutes with DAPI counterstain solution.  
Images were taken by looking at the DAPI counterstain channel for all conditions in 
all 3 wells until 30-60 MAP2 positive cells were imaged where the neurites did not cross the 
image boundary using a Zeiss Axiovert S100 microscope at a magnification of X20. The 
average neurite length per cell was quantified in a blinded manner using Image J simple 
neurite tracer plugin.  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑡𝑜𝑡𝑎𝑙 𝑛𝑒𝑢𝑟𝑖𝑡𝑒 𝑙𝑒𝑛𝑔𝑡ℎ =
𝑡𝑜𝑡𝑎𝑙 𝑛𝑒𝑢𝑟𝑖𝑡𝑒 𝑙𝑒𝑛𝑔𝑡ℎ 
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 
2.3.16 Alamar Blue assay 
Alamar blue assay was performed in 96-well plated. Growth media was removed and 
an equal volume of medium containing Alamar blue reagent (Thermo Fischer) was added 
into each well following the manufacturer’s instructions. After 3 hours of incubation the 
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media was collected and analysed using a microplate reader following the manufacturer’s 
indications. 
2.3.17 Fluorescent activated cell sorting (FACS) – Cell survival assay 
Cell survival of iPSC-derived neurons was measured with FACS soring using the cell 
death marker Annexin V and the mitochondrial depolarisation marker DICL.  iPSC-derived 
neurons were grown in 12-well plates. The culture media was collected into a 15 ml falcon 
tube. Cells were washed once with PBS, which was collected and added in the same tube. 
Cells were dissociated by incubating with 300 µl of Accutase (Life Technologies) dissociation 
reagent for 7 minutes at 37°C. Accutase was inactivated by adding 700µl of plain culture 
media and all the cells were collected into the corresponding falcon tube. The cells were 
pelleted by centrifugation at 1000g for 4 minutes. Cells were dissociated into a single cell 
suspension in PBS by pipetting gently with a P1000 pipette. Cells were then centrifuged and 
resuspended in 500µl of warm PBS buffer containing DICL and Annexin V450 at 1:1000 and 
1:500 concentrations following the manufacturer’s instructions.  
FACS was carried out in a Canto II flow cytometer (BD Biosciences). 10 000 cells were 
sorted for each condition in each experiment. Three biological replicates were performed. 










3 PATHOLOGICAL STUDIES IN THE SPINAL CORD OF C9ORF72 
ALS MUTANT CASES 
3.1 INTRODUCTION 
The neurotoxic mechanisms of the C9ORF72 expansion are unknown but three 
mechanisms have been proposed: loss of C9ORF72 protein function, toxicity due to RNA 
aggregation, and toxicity due to repeat associated non-ATG (RAN) translation of dipeptide 
repeat (DPR) proteins. Although the G4C2 expansion does cause a decrease in C9ORF72 
mRNA no null alleles or missense mutations in C9ORF72 have been identified in ALS or FTD 
cases (Harms et al., 2013) and homozygous carriers do not have an earlier onset or rapidly 
progressive form of ALS or FTD to support the loss of C9ORF72 protein function hypothesis 
(Cooper-Knock et al., 2013; Fratta et al., 2013). We, and others have previously reported that 
G4C2 repeats generate length-dependent, RNase-resistant, intranuclear RNA foci, which can 
sequester RNA binding proteins potentially leading to defective RNA processing (Cooper-
Knock et al., 2014a; Lee et al., 2013; Mori et al., 2013b). Finally, the G4C2 repeat RNA form 
stable G-quadruplex secondary structures that can recruit the translation machinery (Zu et 
al., 2011) and generate five different DPRs; poly-GP, poly-GA and poly-GR from the sense 
G4C2 repeat and poly-PR, poly-PA and poly-GP from the antisense G4C2 repeat strand (Ash 
et al., 2013; Gendron et al., 2013; Mori et al., 2013a; Mori et al., 2013c).  
Antibodies to specific DPR proteins detect cytoplasmic aggregates of poly-GP, poly-GA 
and poly-PA and intranuclear aggregates of poly-PR and poly-GR in the cerebellum and 
frontal cortex of ALS and FTD patients (Mackenzie et al., 2013a; Mann et al., 2013). DPR 
protein aggregates colocalise with p62 but not with TDP-43 (Mackenzie et al., 2013a; Mann 
et al., 2013) and the connection between the C9ORF72 mutation, DPR protein deposition 
and TDP-43 mislocalisation is unknown. In the present study, we conducted a detailed 
comparison of the abundance and cellular location of inclusions immuno-reactive for the five 
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DPR proteins and TDP-43 in the spinal cord of ten C9ORF72-ALS cases. Using double 
immunofluorescence staining, we show that DPR protein aggregates are uncommon in the 
spinal cord of C9ORF72-ALS cases, rarely co-localise with TDP-43, and are almost absent from 
motor neurons. The abundance of TDP-43 inclusions in ALS cases with or without a C9ORF72 
repeat expansion was broadly similar. Given that TDP-43 mislocalisation is a recognised 
cause of lower motor neuron neurodegeneration, and given the lack of DPRs in motor 
neurons, it is difficult to implicate DPRs in this process. 
Moreover, there have been few pathological studies assessing the presence of sense 
and antisense RNA foci in ALS-C9ORF72 cases. Most of the studies have assessed the 
presence of sense and antisense foci in the frontal cortex, cerebellum and hippocampus of 
C9ORF72 ALS/FTD cases (DeJesus-Hernandez et al., 2017; Gendron et al., 2013; Mizielinska 
et al., 2013). Only one study has comprehensively quantified the number of sense and 
antisense RNA foci in the spinal cord of ALS cases (Cooper-Knock et al., 2015). Cooper-Knock 
et al. (2015) reported a strong correlation between the presence of antisense, but not sense, 
RNA foci and TDP-43 nuclear depletion in spinal motor neurons. Their study however only 
analysed 54 motor neurons from seven C9ORF72 ALS cases. In the present study we have 
assessed the presence of sense and antisense RNA foci in the spinal cord of ten C9ORF72 ALS 
cases using a semi quantitative scale. Additionally we have quantified the number of motor 
neurons containing sense and antisense foci and TDP-43 nuclear depletion. We show that 
sense and antisense RNA foci are common in the spinal cord of C9ORF72 ALS cases and that 





In the present study we aim to study the presence of all five DPR protein inclusions, as 
well as sense and antisense RNA foci, in the spinal cord of ten C9ORF72 ALS cases and five 
C9-ve ALS cases. Moreover, we have quantified the presence of each species and assessed 
whether their presence correlates with TDP-43 aggregation and nuclear depletion in spinal 
motor neurons. 
3.3 MATERIALS AND METHODS 
3.3.1 Cases 
Spinal cord sections were analysed for the presence of TDP-43 and all DPR inclusions 
by double immunofluorescence and TDP-43 and sense and antisense RNA foci from ten ALS 
cases positive for C9ORF72 intronic expansion (C9+ve-ALS) and sections from five ALS cases 
negative for C9ORF72, FUS and SOD1 mutations (365 sections in total). Sections of frontal 
lobe and cerebellar cortex from a case of C9ORF72 FTD with abundant p62 pathology were 
chosen as a positive control for DPR staining. Expansion carriers were identified using repeat 
primed PCR (Smith et al., 2013) and all of the cases had previously been reported to show 
characteristic cerebellar p62 and TDP-43 pathology (Troakes et al., 2012) (Al-Sarraj et al., 
2011). Details of the age, sex and post-mortem delay are recorded in table 3.1 and show little 




Table 3.1 Clinical data of cases studied  
(PMD) = post mortem delay (hours). 
 
3.3.2 Motor neuron counting and double label immunofluorescence 
A total of 30 spinal cord sections from C9+ve-ALS cases were analysed. Histological 
examination was performed on 7 μm sections prepared from formalin-fixed, paraffin–
embedded tissue from the spinal cord of all ALS cases. Sections were stained with 
hematoxylin and eosin to perform motor neuron counts, and sequential sections were 
processed for double label immunofluorescence for the DPRs, sense and antisense foci and 
TDP-43. Immunofluorescence was performed as described in the methods section. 
Semi-quantitative and quantitative evaluation of DPR and TDP-43 pathology was 
performed using Zeiss Axiovert S100 microscope.  Aggregates were also imaged using a Leica 




3.3.3 Semi quantitative and quantitative evaluation of pathology  
The presence of sense and antisense foci and DPR and TDP-43 inclusions were scored 
in the spinal cord using a previously published semi-quantitative grading scale (Mackenzie et 
al., 2013a), in which the total number of immuno-reactive inclusions/RNA foci, as well as the 
cytoplasmic inclusions (CI) and the intranuclear inclusions (NI), were rated as follows:  0 – 
Absent, 0.5 – one or two inclusions in the whole section, 1- very few, 2- occasional- easy to 
find and a few cells are affected, 3- moderate- many of the cells are affected, inclusions are 
easy to find, 4- numerous- nearly all of the cells are affected. Additionally, each section was 
re-analysed and the number of DPR and TDP-43 inclusions was counted manually in a 
systematic, blinded manner. The number of DPR aggregates was counted per section and 
averaged per case.  
3.3.4 Fluorescent in situ hybridisation for spinal cord sections 
Fluorescent in situ hybridisation (FISH) was performed in 20 lumbar spinal cord 
sections from ten C9+ve-ALS cases and 13 sections from five ALS-TDP-43 cases as described 
in the methods section.  
If IHC was performed to assess the co-occurrence of TDP-43 and RNA foci, sections 
were blocked with 5% Donkey serum-PBS solution for 1 hour and incubated with TDP-43 
(mouse polyclonal TDP-43 10782-AP Proteintech) at a dilution of 1:100. Sections were 
washed three times with PBS and incubated with anti-rabbit (AlexaFluor 488) secondary 





3.4.1 Appearance of DPR proteins in ALS spinal cords 
The appearance and subcellular location of each type of DPR inclusion within the 
spinal cord was recorded (Table 3.2 and Fig 3.1A-H). There were very few DPR inclusions with 
poly-GA aggregates being the most abundant DPR detected with a rating of only 0-1.0. 
Cytoplasmic immuno-reactive inclusions more common than intranuclear inclusions, which 
is consistent with previous studies in FTD and ALS (Mackenzie et al., 2013a). Cytoplasmic 
inclusions were characteristically large, irregular and perinuclear whilst nuclear inclusions 
were much smaller and round. Poly-GP inclusions, the second most common DPR inclusion, 
were all cytoplasmic and in a perinuclear position (Fig 3.1B). We observed very few 
cytoplasmic poly-GR inclusions and only one small intra-nuclear aggregate. Poly-PR 
cytoplasmic aggregates were also rare in the nucleus and cytoplasm (Fig 3.1E, 3.1G). 
Similarly, we were only able to identify a total of only seven poly-PA inclusions (six 
cytoplasmic and one nuclear; Fig 3.1D, 2.1H) and four poly-PR inclusions (two cytoplasmic 
and two nuclear; Fig 3.1E, 3.1G) inclusions in all the analysed cases (Fig 3.1D, 3.1H). No 
immuno-reactive DPR aggregates were identified in any C9-ve TDP-43 cases confirming the 
mutation-specificity of these inclusions and validating the antibodies. In a small number of 
cells that contained DPR aggregates granular TDP-43 staining was seen in the cytoplasm or 









Poly-GP  Poly-GA  Poly-GR  Poly-PR  Poly-PA  Diagnosis 
case Cyt.  Nuc.  Tot.  Cyt.  Nuc.  Tot.  Cyt.  Nuc.  Tot.  Cyt.  Nuc.  Tot.  Cyt.  Nuc.  Tot.     
1 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ALS-TDP 
2 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ALS-TDP 
3 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ALS-TDP 
4 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ALS-TDP 
5 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ALS-TDP 
MEAN±SEM 2.8±0.2 
               
ALS-TDP 
6 3 0.5 0 0.5 0 0 0 0.5 0 0.5 0 0 0 0.5 0 0.5 C9+ve-ALS 
7 3 0.5 0 0.5 1 0.5 1.5 0 0 0 0 0 0 0 0 0 C9+ve-ALS 
8 2 1 0 1 0.5 0 0.5 0.5 0 0.5 0 0 0 0.5 0 0.5 C9+ve-ALS 
9 3 1 0 1 1 0.5 1.5 0 0 0 0 0 0 0.5 0.5 1 C9+ve-ALS 
10 3 0.5 0 0.5 0.5 0.5 1 0.5 0 0.5 0 0 0 0 0 0 C9+ve-ALS 
11 3 1 0 1 1 0.5 1.5 0 0.5 0.5 0.5 0 0.5 0.5 0 0.5 C9+ve-ALS 
12 3 0.5 0 0.5 0.5 0 0.5 0.5 0 0.5 0.5 0.5 1 0 0 0 C9+ve-ALS 
13 3 1 0 1 1 0.5 1.5 0.5 0 0.5 0 0.5 0.5 0.5 0 0.5 C9+ve-ALS 
14 3 1 0 1 0.5 0 0.5 0 
 
 
0 0 0 0 0 0 0 0 C9+ve-ALS 
15 3 0.5 0 0.5 1 0 1 0 0 0 0 0 0 0 0 0 C9+ve-ALS 
MEAN±SEM 2.9±0.1 0.7±0.1 0.0 0.7±0.1 0.7±0.1 0.2±0.1 0.9±0.1 0.3±0.1 0.0±0.1 0.3±0.1 0.1±0.1 0.0±0.1 0.2±0.1 0.2±0.1 0.0±.01 0.3±0.1 
 
 
Table 3.2: Scoring of immunoreactive inclusions of TDP-43 and five DPRs in the spinal cord of 5 ALS-TDP-43 and 10 C9+ve-ALS cases. 
Results show that there are very few DPR aggregates in the spinal cord of C9+ve-ALS cases and are absent in ALS-TDP-43 cases. However we observe large 
numbers of TDP-43 aggregates in all 15 cases analysed. Cyt- cytoplasmic inclusion. Nuc.- Nuclear inclusion.  Scoring criteria:  0 – Absent 0.5 – one or two 
inclusions in the whole section 1- very few  2- occasional- easy to find and a few cells are affected 3- moderate- many of the cells are affected, inclusions are 





Figure 3.1: Appearance of DPR protein inclusions in the spinal cord of C9+ve-ALS cases 
(A-H) Representative immunofluorescence confocal images of DPR (red) and TDP-43 (green) 
(scale bar=20μm). (A-E) Cytoplasmic DPR inclusions, which are often perinuclear. (F-H) 
nuclear DPR inclusions. DPR inclusion (red), TDP-43 (green), Nuclei (blue). Scale bar= 20 μm. 
 
3.4.2 All DPRs are rare and some very rare, but TDP-43 pathology was abundant and 
consistent 
The frequency of each DPR inclusion was initially scored using a semi-quantitative 
system for each case (table 3.2). DPRs translated from the sense strand (poly-GP, poly-GA 
and poly-GR) were more abundant than those translated solely from the antisense strand 
(poly-PR, poly-PA). Although poly-GA and poly-GP were the most abundant immuno-reactive 
inclusions (scoring of 0.9 and 0.7, respectively) all DPRs were scored as either rare or very 
rare and there was not a single case that scored above 1.0 (rare) and no more than twelve 
inclusions of any DPR was observed in any of the cases analysed. No case scored above 0.5 
(very rare) for poly-GR, poly-PA and poly-PR inclusions and poly-GR and poly-PR inclusions 
were absent from several cases. The scoring of DPR aggregates within cases was highly 
consistent (poly-GA=0.9±0.1, poly-GP=0.7±0.1, poly-GR=0.8±0.21, poly-PA=0.4±0.20 and 
111 
 
poly-PR=0.3±0.1). Of note, there was no significant difference in the scoring of TDP-43 
inclusions for ALS cases lacking the C9ORF72 mutation (2.8±0.2) when compared to those 
carrying the C9ORF72 mutation (2.9±0.1). Thus, the presence of DPR inclusions in the spinal 
cord does not appear to be correlated with the abundance of TDP-43 inclusions. 
In order to provide greater detail the number of TDP-43 aggregates in the anterior horn of 
the spinal cord in each case was quantified in representative sections to explore any 
correlation between the abundance of DPR and TDP-43 inclusions. An average of 122±8 TDP-
43 aggregates was identified per case, which is between 45- and 750- fold greater than the 
number of any DPRs inclusions These results, graphically depicted in Figure 3.2, demonstrate 
that the abundance of TDP-43 cytoplasmic inclusions vastly outnumbers the number of DPR 
inclusions, singly or collectively (note that the Y axis scale is a logarithmic scale). reversing 
the formatting error.  
Figure 3.2: Frequency of TDP-43 and DPR inclusion per case. 
The number of TDP-43 and DPR immunoreactive inclusions was counted for each case. The 
graph shows the number of TDP-43 and the five different aggregates in order of abundance. 
There are many more TDP-43 aggregates than any DPR. Note: The Y axis scale is logarithmic 
scale.  Horizontal bars show mean ±SEM 
 
3.4.3 DPR and TDP-43 inclusions occasionally colocalise 
Although all DPRs were rare or very rare, we did see TDP-43 colocalise with 4 of the 
12 poly-GR inclusions and 2 of the 7 poly-PA inclusions (Fig 3.3 A-B). Interestingly, the poly-
GR immuno-reactive aggregates that did not colocalise were often surrounded by TDP-43 
(Fig 3.1B). None of the nuclear poly-GR and poly-PA intranuclear inclusions colocalised with 
TDP-43. We did not observe any poly-GP, poly-GA or poly-PR immuno-reactive inclusions 




Figure 3.3: DPR and TDP-43 protein inclusions occasionally colocalise 
(A-B) Evidence of poly-GR and poly-PA DPR inclusions colocalising with TDP-43. TDP-43 
inclusions. DPR inclusion (red), TDP-43 (green), Nuclei (blue). Scale bar= 20 μm. 
 
3.4.4 DPRs are almost absent from motor neurons 
ALS is characterised by the loss of lower motor neurons in the anterior horn of the 
spinal cord. Motor neurons are readily identified as they have large cell bodies and large pale 
nuclei by H&E staining and by DAPI for immunofluorescence.  The total number of motor 
neurons was counted in order to assess the relative preservation of motor neurons between 
cases and identify any that contained TDP-43 and DPR immuno-reactive inclusions. In total, 
of the 786 motor neurons analysed 268 (34%) contained cytoplasmic TDP-43 inclusions (Fig 
3.4), which is consistent with classical ALS pathology. In contrast, only one motor neuron 
contained a DPR inclusion, specifically a cytoplasmic poly-GP aggregate (0.1%) (Fig 3.4B). 





Figure 3.4: DPR inclusions are rare in the spinal cord of C9+ve-ALS cases 
(A-B) lower power images of the anterior horn showing the relative abundance of DPR and 
TDP-43 inclusions. (A) poly-GA inclusion, which is not in the motor neurons (dotted lines) 
that show extensive cytoplasmic TDP deposition. (B) poly-GP inclusion within a motor neuron 
(identified by its large pale nucleus), which does not show cytoplasmic TDP-43 inclusions. 
DPR inclusion (red), TDP-43 (green), Nuclei (blue) Scale bar= 50 μm. 
3.4.5 Sense and antisense RNA foci are common in the spinal cord and motor neurons in 
ALS cases 
We sought to investigate the same cohort of ALS cases and assess the presence of 
sense and antisense RNA foci. Fluorescent in situ hybridisation (FISH) was performed on 
spinal cord sections in the lumbar region from five TDP-ALS (C9-ve) and ten C9+ve-ALS cases 
and the presence of sense and antisense RNA foci was quantified using a semi-quantitative 
scale in a blinded manner. As expected, no RNA foci were observed in any of the ALS-TDP-43 
(C9-ve) cases and were therefore used as negative controls. In contrast, all C9+ve-ALS cases 
had occasional or moderate sense and antisense RNA foci in the anterior horn of the spinal 
cord and sense foci were more common than antisense foci (Fig 3.5 A and B sense foci score 
= 2.3 ± 0.3; antisense foci score = 1.8± 0.4). We conclude that sense RNA foci are more 
common than antisense RNA foci and both species are a consistent pathological hallmark of 




Figure 3.5: Sense and antisense RNA foci are common in the spinal cord of C9+ve-ALS cases 
(A) Representative images sense and antisense fluorescent in situ hybridisation in C9+ve-ALS 
cases and ALS-TDP. Asterisks (*) indicate the presence of sense and antisense RNA foci. RNA 
foci (red) and nuclei (blue). Scale bar = 20 µm (B) Sense and antisense RNA foci scoring in the 
spinal cord of C9ORF72 mutation negative (1-5) and positive ALS cases (6-15). Scoring 
criteria: 0 – Absent 0.5 – one or two inclusions in whole section, 1- very few, 2- occasional- 
easy to find and a few cells are affected, 3- moderate- many of the cells are affected, 





3.4.6 Sense RNA foci are significantly more common than antisense RNA foci in spinal 
motor neurons but do not correlate with TDP-43 proteinopathy 
ALS is characterised by the loss of motor neurons in the anterior horn of the spinal 
cord accompanied by nuclear TDP-43 depletion in the spinal cord motor neurons. We 
investigated the presence of sense and antisense RNA foci in the motor neurons of all ten 
C9+ve-ALS cases. Our results show that there are a significantly more spinal motor neurons 
containing sense than antisense RNA foci in the nucleus (Fig 3.6 B: sense foci = 33.8% ± 2.8 
vs. antisense 20.7% ± 1.6 over 200 motor neurons; Two-tail t-test, p<0.001 **).  
Next we sought to investigate whether there is a correlation between the presence 
of RNA foci (sense and antisense) and TDP-43 nuclear depletion in motor neurons of C9+ve-
ALS cases. A FISH analysis followed by immunohistochemistry (IHC) was performed on the 
same spinal cord samples aforementioned.  
TDP-43 nuclear depletion was observed in 38% of motor neurons and sense RNA foci 
in 33% of all motor neurons identified. Interestingly, 15% of all motor neurons contained 
both intranuclear RNA foci and showed TDP-43 nuclear depletion (Fig 3.6 A and C-D). This 
result shows that the burden of sense RNA foci was similar to TDP-43 nuclear depletion in 
the spinal cord of our C9+ve-ALS cohort. However we did not observe a correlation between 
the presence of sense RNA foci and loss of nuclear TDP-43 depletion (Χ2 = 3.72, d.f=1, 
p=0.073) (Fig 3.6 C).  
A previous study has reported the correlation between TDP-43 nuclear loss and the 
presence of antisense RNA foci in spinal motor neurons of C9+ve-ALS cases (Cooper-Knock 
et al., 2015). We therefore assessed the co-occurrence of antisense RNA foci and TDP-43 
nuclear depletion. Only 7% of the analysed motor neurons showed both loss of nuclear TDP-
43 and antisense RNA foci. In contrast, 14% of the motor neurons analysed showed the 
presence of antisense RNA foci but no apparent TDP-43 nuclear loss (Fig 3.6 D) (Χ2 = 0.26, 
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d.f=1, p=0.61). Thus we were unable to replicate the previous report correlating antisense 






Figure 3.6: Motor neurons containing sense foci are more common than those containing 
antisense foci 
(A) Representative images of sense and antisense fluorescent in situ hybridisation and 
immunohistochemistry on ALS-TDP-43 and C9+ve-ALS spinal cord motor neurons showing 
the presence of intranuclear sense RNA foci and TDP-43 nuclear clearing. G4C2 foci (red), 
TDP-43 (green) and nuclei (blue). Scale bar = 50 μm (B) The percentage of motor neurons 
containing sense RNA foci is significantly greater than antisense foci. n=10 over 200 motor 
neurons. Two-tailed t-test (p<0.001 **) (C) Results of the quantification of 213 spinal motor 
neurons of 10 C9+ve-ALS cases for the coincidence of sense RNA foci and TDP-43 nuclear 
clearing. Total number and percentage of motor neurons containing sense foci and TDP-43 
(D) Results of the quantification of 294 spinal motor neurons of 10 C9+ve-ALS cases for the 
coincidence of antisense RNA foci and TDP-43 nuclear clearing. Total number and percentage 
of motor neurons containing antisense foci and TDP-43. (E) Representative images of 
neurons containing large numbers of sense and antisense foci. Scale bar = 20 μm 
3.5 DISCUSSION 
The G4C2 repeat mutation in the C9ORF72 gene is the most common cause of ALS and 
FTLD known to date. Three mechanisms of toxicity have been proposed, i) loss of C9ORF72 
protein due to silencing and degradation of its transcript ii) toxicity though toxic RNA species 
and iii) toxicity though unconventional translation of G4C2 repeats from the sense and the 
antisense strand yielding toxic di-peptide repeat proteins (DPRs). In this study we analysed 
and quantified the presence of sense and antisense foci, all five DPRs known to translate 
from the sense and the antisense G4C2 strands and TDP-43 in the spinal cord five ALS-TDP-
43 (C9-ve) and ten C9+ve-ALS cases.  
We have shown that sense RNA foci are more common than antisense foci and are 
present throughout the spinal cord of C9+ve-ALS cases. We detected very low levels of all 
DPR protein inclusions in the spinal cords of C9+ve-ALS cases, with poly-GA being the most 
common followed by poly-GP, poly-GR, poly-PA and poly-PR. The frequency of TDP-43 
cytoplasmic inclusions was three to four orders of magnitude higher than DPR inclusions, 
providing much stronger circumstantial evidence that the accumulation of TDP-43 and not 
DPRs is the dominant pathogenic process in ALS. 
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Inclusions for all five DPRs were detected in the spinal cord of C9+ve-ALS cases but 
they were rare or very rare and it was very uncommon to see DPR and TDP-43 inclusions in 
the same cell. Poly-GA inclusions, present in the cytoplasm and occasionally the nucleus, 
were the most common. Poly-GP inclusions were purely cytoplasmic, which is consistent with 
published reports (Ash et al., 2013; Davidson et al., 2014; Mackenzie et al., 2013a; Mackenzie 
et al., 2014; Mann et al., 2013; Mori et al., 2013a; Mori et al., 2013c). Of the five DPRs, only 
poly-GR and poly-PA physically colocalised with TDP-43 inclusions, but this was a very rare 
event. The total number of TDP-43 inclusions in the spinal cord was between 45- and 750-
fold higher than the number of DPR inclusions. We detected only one motor neuron that 
contained a poly-GP inclusion, whereas on average 34% of motor neurons had cytoplasmic 
TDP-43 inclusions. Our results are consistent with those published  using single staining 
techniques but were the first to use double labelling with TDP-43 and all five DPRs in the 
spinal cord of ALS cases (Mackenzie et al., 2013a; Mackenzie et al., 2015). We acknowledge 
that detection of DPRs by immunofluorescence imaging may be less sensitive than horse 
radish peroxidase (HRP) but these were abundant in the frontal cortex of our C9ORF72 
mutation positive cases used as a positive control. This study was the first to analyse the 
presence of all five DPRs in the spinal cord of C9+ve-ALS cases. A separate study also 
demonstrated the absence of soluble DPRs in the spinal cord of C9+ve-ALS cases (Mackenzie 
et al., 2015) and the absence of correlation between DPR aggregation and 
neurodegeneration (Davidson et al., 2016).  
Several groups have studied DPR protein toxicity in various cellular models but these 
have generated conflicting results (May et al., 2014; Tao et al., 2015; Wen et al., 2014; 
Yamakawa et al., 2015; Zhang et al., 2014b). Some reports describe the greatest toxicity from 
poly-GR and poly-PR expression in cells (Wen et al., 2014; Yamakawa et al., 2015) and the 
Drosophila (Mizielinska et al., 2014). Several other studies have suggested that poly-GA is 
the most toxic DPR in vitro (Chang et al., 2016; Schludi et al., 2015; Zhang et al., 2014b) and 
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in vivo (Schludi et al., 2017; Zhang et al., 2016b). However, these models involve the 
overexpression of DPRs and no comparison was made with the burden of DPR deposition in 
human tissues. A landmark study, in which 66 G4C2 repeats were expressed in the central 
nervous system of mice, has shown that nuclear RNA foci, DPR inclusions and TDP-43 
pathology were present in the cortex and hippocampus of mice, suggesting that the repeat 
itself, possibly through foci formation, RAN translation or another mechanisms entirely, 
caused aberrant TDP-43 deposition (Chew et al., 2015a). We have demonstrated that DPR 
inclusions are very rare in C9+ve-ALS spinal cords, are infrequently associated with TDP-43 
inclusions and almost absent from motor neurons. On this basis we find no pathological 
evidence that DPR aggregation contributes to lower motor neuron degeneration in C9ORF72 
ALS. 
While we cannot entirely exclude the possibility that DPR aggregation and toxicity 
occurs at the sub-microscopic level, perhaps through toxic DPR oligomers, or that all of the 
motor neurons containing DPR inclusions rapidly degenerated, this explanation seems 
unlikely as neurotoxic protein aggregates are detected in the affected neurons for all other 
neurodegenerative diseases. Additionally a separate pathological study has shown the 
absence of soluble DPRs in the spinal cords of C9+ve-ALS cases (Mackenzie et al., 2015). 
Moreover some in vivo and in vitro these studies have shown that DPR aggregation is 
necessary to induce toxicity (Wen et al., 2014; Zhang et al., 2016b; Zhang et al., 2014b). As 
the number of TDP-43 inclusions in ALS cases, with and without the C9ORF72 mutation are 
nearly identical we can find no evidence that dipeptide repeat proteins are playing a 
pathogenic role in C9ORF72 ALS.  
We next sought to assess the presence of sense and antisense foci in the spinal cord 
of C9+ve-ALS cases. There have been few studies investigating their presence in the spinal 
cord, the main site of degeneration of ALS. The majority of studies have focused on screening 
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RNA foci on different regions of the brain such as the frontal cortex, the cerebellum or the 
hippocampus, showing that sense and antisense foci are primarily nuclear and in neurons 
(DeJesus-Hernandez et al., 2017; Mizielinska et al., 2013).  
Subsequent FISH analysis revealed a greater abundance of sense than antisense foci 
in the spinal cord of C9+ve-ALS cases (Fig 3.5 A-B). Moreover, we found that there were a 
significantly greater number of spinal motor neurons containing sense than antisense foci 
(Fig 3.6 B). We report that 33.8% of motor neurons investigated contained sense RNA foci 
contrasting with 20.7% antisense foci and almost no DPR inclusion.  
Cooper-Knock et al. (2015) reported a correlation between the number of antisense 
RNA foci and loss of nuclear TDP-43 in the motor neurons of ALS cases (Cooper-Knock et al., 
2015). The authors reported that 77% of motor neurons displayed antisense RNA foci 
combined with loss of nuclear TDP-43. Contrary to their findings we detected no correlation 
between the number of sense or antisense RNA foci and loss of nuclear TDP-43 in motor 
neurons. In fact, 15% of motor neurons contained sense RNA foci and loss of nuclear TDP-
43. Similarly, 7% of motor neurons contained antisense RNA foci and TDP-43 nuclear 
depletion. The difference in the number of motor neurons containing both antisense RNA 
foci and loss of nuclear TDP-43 in motor neurons may be due to the localization of the 
biopsies from each patient and the number of motor neurons counted for each C9ORF72 
patient. The authors also investigated hippocampal CA4 regions and they did not identify a 
significant correlation between the antisense RNA foci and loss of nuclear TDP-43. 
Furthermore, we were able to detect neurons with large numbers of intranuclear sense and 
antisense foci in all cases (Fig 3.6 E). This indicates that our FISH protocol is able to detect 
the presence of large numbers of RNA foci, but none of these cells were motor neurons.  
We have shown that there are a significantly greater number of motor neurons 
containing sense than antisense RNA foci and that the percentage of motor neurons with 
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sense RNA foci was similar to the percentage of neurons with nuclear TDP-43 depletion. In 
contrast we found that DPR inclusions were almost absent from spinal motor neurons in 
C9+ve-ALS cases.  We conclude that the evidence from our pathological studies implicates 
RNA foci and TDP-43 deposition rather than DPRs as the main contributor to the 
degeneration of motor neurons in C9ORF72-ALS cases. Other studies have reported the loss 
of C9ORF72 protein in spinal motor neurons in C9ORF72-ALS (Xiao et al., 2015). The knock 
down of C9ORF72 levels in cells results in TDP-43 insolubility and cleavage (Sellier et al., 
2016), suggesting that haploinsufficiency may also play an important role in the patho-
mechanism of C9ORF72 ALS. Lastly, we and others have reported that all five DPR protein 
inclusions and soluble DPR are very rare in the spinal cord of ALS cases, and that 
degeneration in the spinal cord correlates with TDP-43 proteinopathy and not with DPR 





4 MECHANISM OF ACTION OF PPMOS IN EGFP-72(G4C2) 
EXPRESSING HEK-293T CELLS 
4.1 INTRODUCTION  
In the previous chapter, we have shown that motor neurons containing sense RNA foci 
are significantly more common than those containing antisense RNA foci, and that DPRs are 
almost absent from motor neurons in the spinal cord of C9ORF72 ALS cases. Additionally we 
have shown that G4C2 repeats form RNA foci in a length dependent manner that sequester 
RNA binding proteins and are neurotoxic (Lee et al., 2013). For this reason, we hypothesize 
that the presence of expanded G4C2 RNA transcripts is the main source of toxicity of the 
C9ORF72 expansion. 
In order to develop a possible therapeutic strategy to mitigate the toxic effect of G4C2 
RNA, we designed non-degrading antisense oligonucleotides, which bind to, but do not 
degrade the target RNA. Antisense oligonucleotides have been used in other repeat 
expansion disorders such as myotonic dystrophy, a hereditary degenerative disease, is cause 
by the presence of an expanded trinucleotide CTG repeat in the DM protein kinase (DMPK) 
gene. The expanded RNA causes the RNA to accumulate in the nucleus, sequestering the 
RNA-binding protein Mucleblind like 1 (MBNL1). ASOs have been used to prevent the 
sequestration of MBNL1 into RNA foci; mitigating the toxicity of the CUG repeats (Wheeler 
et al., 2012).  
The use of degrading ASOs (gapmers) has been explored in in vitro and in vivo models 
of the C9ORF72 expansion (Donnelly et al., 2013; Jiang et al., 2016). iPSC-derived neurons 
from C9ORF72 expansion carriers show intranuclear RNA foci, increased glutamate toxicity 
(Donnelly et al., 2013) and diminished capacity to fire continuous spikes upon depolarization 
(Sareen et al., 2013). The number of RNA foci was reduced and the glutamate toxicity and 
123 
 
diminished firing capability of iPSC-derived neurons was reversed upon treatment with ASOs 
targeting C9ORF72 transcripts (Donnelly et al., 2013; Sareen et al., 2013). Gapmers have also 
been tested in an in vivo model of the expansion. A single dose of degrading ASO was 
intraventricularly administered to 3-month-old C9ORF72 bacterial artificial construct (BAC) 
transgenic mice. The authors reported a decrease of 40% in repeat-containing RNA in the 
cortex and the spinal cord. Administrations of the ASO also resulted in over 50% decrease of 
RNA foci and almost complete depletion of poly-GP and poly-GR DPRs. A different ASO 
targeting the repeat-exon boundary was shown to improve age dependent behavioural 
deficits when tested 6 months post administration (Jiang et al., 2016).  
We hypothesised that the use of transcript degrading antisense oligonucleotides may 
be detrimental if haploinsufficiency played an important role in the C9ORF72 patho-
mechanism. For this reason, we designed phosphorodiamidate morpholino oligomers 
(PMOs) directly targeted at the G4C2 expansion that would bind to, but do not degrade the 
target transcript.   
4.2 AIMS 
In this chapter, we aim to unravel the mechanism of action of PMOs targeting 
expanded G4C2 RNA transcripts and assess whether they are suitable for studying in iPSC 
models of the disease. To do so, we transfected HEK-293T cells with EGFP-38(G4C2) and 
EGFP-72(G4C2) expressing constructs and treated them with G4C2-targeting PPMOs (G4C2 
PPMOs).  We have shown the presence of intranuclear RNA foci, which sequester RNA 
binding proteins such as hnRNP-H when HEK-293T cells are transfected with these 
constructs. Moreover, we have detected the presence of the DPR poly-GP in these cells. We 
sought to assess the effect of PPMO treatment in the number cells containing RNA foci as 




All chemical reagents were purchased from Life Technologies unless otherwise stated. 
4.3.1 Protein-coupled PMO synthesis and sequence 
 Protein-coupled PMOs (PPMOs) and 5’ fluorescently labelled protein-coupled PMOs 
(5FL-PPMOs) where synthesized and by Sarepta Therapeutics (Cambridge, MA) and supplied 
as a lyophilised powder. PPMOs were resuspended in RNAse free water to form a stock 
concentration of 2mM as suggested by the company. PPMOs and 5FL-PPMOs were diluted 
to the required concentration in cell culture media. Further information is provided in the 
methods section. 
4.3.2 Cell culture and transfection  
Human embryonic kidney (HEK-239T) cells were maintained and plated as described 
in the methods section. 100,000 cells per well were plated in a 24-well plate, unless 
otherwise stated. Prior to transfection 300 ng of DNA with 1 μl of Lipofectctamine 
transfection reagent and 50 μl of Optimem per well for 30 minutes at room temperature. 
250 μl of cellular medium was removed and 50 μl of transfection mixture was added 
dropwise into the well (volumes were doubled for 12-well plates).  One day after plating, 
cells were transfected for 24 hours. The transfection mix was then removed and PPMOs were 
added at the appropriate concentration in 500 µl of growth media. 
4.3.3 Fluorescence in situ hybridisation and immunofluorescence 
Fluorescent in situ hybridisation and immunofluorescence was carried out was 
previously described in the methods section. Details of the FISH probes used can be found in 








Sequence Concentration Chemistry 
Sense-
Cy3 
48oC Over-night (C4G2)8 10 nM RNA 
Sense-
Cy5 






30 nM LNA 
Table 4.1: Details of FISH probes used 
4.3.4 Imaging and quantification of images 
Representative images were taken using a Leica laser scanning confocal microscope 
(TCS-SP5). For quantification of the number of RNA foci, 7-9 images were taken randomly 
per condition per biological replicate using a Leica CTR5000 microscope and 40X 
magnification by only looking at the DAPI counterstain using the same settings for all images. 
Image files were then renamed and the number of foci and foci-positive cells counted in a 
blinded manner. The number of total nuclei was quantified using MetaMorph Image System 
7.5 (v. 7.7, Molecular Devices). The percentage of foci per cell was then calculated. 
4.3.5 Western blotting  
 Western blotting analysis was carried out as previously described in the methods 
section. Poly-GP (own production by Eurogentech and validated in Lee et al. 2013) antibody 
was used at a 1:5000 dilution. GAPDH (Abcam, UK) antibody was used at a 1:2000 dilution. 
Membranes were detected using an Odyssey CLx system. Protein levels were calculated 
using Image J (version 1.45e, NIH, Bethesda, USA, http://rsb.info.nih.gov/ij/). Levels of poly-




 Statistical analysis was carried out using GraphPad Prism 7. Chosen statistical 
analysis is detailed in the figure legend for each experiment. Data is presented as mean ± 
SEM. Statistical significance was considered at p˂0.05 (*), p˂0.01 (**) and p˂0.001 (***).  
4.4 RESULTS 
4.4.1 Choice of experimental design for PPMO efficacy and mechanism testing 
In order to test the efficacy and mechanism of action of PPMOs targeting the G4C2 
expansion we used a previously validated ectopic expression model where EGFP-38(G4C2) 
and EGFP-72(G4C2) expressing constructs are transfected into HEK-293T cells. Cells 
transfected with the constructs have shown to reliably model some aspects of the disease 
pathology. Intranuclear RNA foci are present in a length-dependent manner and sequester 
pathologically relevant proteins such as hnRNP-H and the repeats can be translated through 
RAN translation yielding the dipeptide repeat protein poly-GP (Lee et al., 2013). Cells were 
transfected for 24 hours prior to incubation with PPMOs as it would be a more accurate 
model of the disease, whereby the RNA foci and the RAN translation products are present 
prior to treatment. A schematic representation of the experimental procedure is depicted in 
figure 4.1. Cells were incubated for three days with PPMOs following the advice given by 
Sarepta Therapeutics. Given that the G4C2-targeting PPMOs and the RNA detection probe 
have the same sequence, there was a high probability that any effect seen on the number of 
G4C2 RNA foci was due to a competition between the PMO and the detection probe when 
performing FISH. The EGFP sequence in the expression vector allowed us the possibility to 
test the efficacy of the PMOs with a non-competing fluorescent in situ hybridisation (FISH) 





Figure 4.1: Schematic representation of the experimental design. 
 
4.4.2 Uptake of 5FL-PPMOs by HEK-293T cells 
In order to show the PPMO cellular uptake 5’-Cy3 labelled protein-coupled PMOs 
(5FL-PPMOs) were synthesized, 100% of HEK-293T cells uptake similar levels of 5FL-PPMOs 
after 1-3 days of incubation (Figure 4.2). 
 
 
Figure 4.2: Uptake of PPMOs by HEK-293T cells 
 (A-C) Representative images of HEK-293T cells 1-3 days after incubation with increasing 
concentrations of 5’-Cy3 labelled peptide-coupled PMOs (5FL-PPMO). (D) Higher 
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magnification image of 3 day 5 μM incubation of 5-FL PPMO showing the subcellular 
distribution. Scale bar = 20 μm  
 
Additionally there are greater levels of 5FL-PPMOs with increasing concentrations 
and increasing duration of the incubation. Although there is some presence of the PMO in 
the nucleus, the cellular distribution is mostly cytoplasmic (Fig. 4.2 D). Previous studies have 
shown that once the PPMO is internalised, the cell penetrating peptide is cleaved off the 
PMO and diffuses homogenously throughout the nucleus and the cytoplasm (Lehto et al., 
2014). We therefore concluded that PPMOs are internalised by HEK-293T cells. 
4.4.3 Effect of PPMOs on the number of RNA foci detectable using a C4G2 FISH probe. 
HEK-293T cells were transfected with EGFP-72(G4C2) expressing constructs and 
treated with PPMOs for three days as explained in figure 4.1. Previous studies in our 
laboratory have shown the ability of this construct to model some aspects of the pathology 
as explained in the introduction. Fluorescent in situ hybridisation (FISH) was carried out using 
a (C4G2)8 probe.  The presence of large intranuclear RNA foci in EGFP-positive cells was 
observed (Fig 4.3 Avii). Upon treatment with increasing concentrations of G4C2 PPMO, the 
number of detectable foci was reduced in a concentration-dependent manner. A significant 
reduction in the percentage of foci-positive cells was observed in cells treated with 5µM and 
10µM G4C2 PPMO but not 1µM compared to untreated (UT) and control PPMO treatment 
in EGFP-72(G4C2) transfected cells. (Figure 4.3; UT = 22.7±1.5; control PPMO 1µM = 20.0% ± 
4.0; 5µM = 21.2% ± 3.9; 10µM = 20.3% ± 0.5; G4C2 PPMO 1µM = 16.2% ± 1.2; 5µM = 4.3% ± 
0.5 and 10µM = 1.9% ± 1.0. UT vs all control PPMO concentrations n.s., UT vs 1µM G4C2 
PPMO ns., UT vs 5µM and 10µM G4C2 PPMO p<0.001 ***; 5µM control vs 5µM C9ORF72 





Figure 4.3:  PPMO treatment reduces the percentage of foci-positive cells with G4C2 foci in 
a concentration-dependent manner. 
 (A i-vii) Representative images of fluorescent in situ hybridisation (C4G2 probe) of HEK-293T 
cells transfected with EGFP-72(G4C2) expressing constructs and treated with increasing 
concentrations of control and G4C2 PPMO. (B) Quantification of the effect of control and 
G4C2 PPMOs on the percentage of cells containing G4C2 RNA foci in EGFP-72(G4C2) 
transfected cells. Data represents mean ± SEM. Significance levels were determined by two-
way ANOVA with Bonferroni multiple comparisons, selected pairs. (*** p<0.001; >2100 cells 




This data not only shows that the G4C2 PPMO binds to the RNA foci and does so in 
a concentration-dependent manner, it is also able to bind to already existing RNA foci in live 
cells, thereby making it clinically relevant. Although we observed a significant reduction in 
the percentage of RNA foci per cell with 5µM G4C2 PPMO, 10µM concentration was selected 
for the following experiments as no cellular toxicity was observed.  
4.4.4 Validation of alternative FISH probe to study the effect of PPMOs on RNA foci. 
Given that the (C4G2)8 FISH detection probe and the G4C2 PPMO share the same 
target sequence, there was the possibility that the observed reduction was due to a masking 
of the foci and not a real reduction in the number of foci (Figure 4.4).  We designed a 
detection probe outside the G4C2 repeats, targeting the EGFP sequence of the constructs. 
This would allow us to study the effect of the PPMOs on the number of RNA foci with no 
interference. Furthermore, the new detection probe has a higher hybridisation temperature 
of 60°C that the (C4G2)8 probe. At this temperature, EGFP is denatured and partially loses its 
fluorescent ability. We exploited these two aspects to perform double fluorescent in situ 
hybridisation on EGFP-72(G4C2) transfected HEK-293T cells followed by 
immunofluorescence. An EGFP Cy3-labelled detection probe and a different C4G2-Cy5 
labelled detection probes were used showing that both detection probes colocalise with the 
pathologically relevant protein hnRNP-H (Fig 4.5 A). Quantification of percentage of foci-
positive cells using the EGFP-targeting probe in cells transfected with EGFP and EGFP-
72(G4C2) constructs showed that there is significantly more RNA foci when cells were 
transfected with EGFP-72(G4C2) (Fig 4.5 C; EGFP = 2.9% ± 1.7; Untreated = 18.1% ± 1.3. 
p<0.01 **). Additionally the number of foci hybridising with both EGFP and G4C2 probes was 




Figure 4.4: Schematic representation of competition of PPMO and C4G2 FISH detection 
probe 
This shows that the RNA foci resulting from the expressing vectors contain the EGFP 
sequence as well as the G4C2 sequence; they can be reliably detected with EGFP detection 
probe and have the ability to sequester pathologically relevant RNA-binding proteins such as 




Figure 4.5: Validation of an alternative EGFP targeting FISH probe 
(A) Representative image of double fluorescent in situ hybridisation followed by 
immunofluorescence showing that EGFP-targeting probe can detect G4C2 RNA foci, which 
sequester clinically relevant proteins. (B) Percentage of foci-positive cells detected with 
EGFP-targeting probe that colocalise with G4C2 foci in EGFP-72(G4C2) expressing cells. 
n=300 G4C2-detectable RNA foci from three independent experiments. (C) Percentage of 
foci-positive cells detected using an alternative EGFP-targeting probe. Data represents mean 
± SEM. Significance levels were determined by two-tailed t-test. (** p<0.01; >300 cells per 
condition from three independent replicates). Scale bar = 20 μm 
 
4.4.5 Effect of PPMOs on RNA foci using an EGFP-targeting detection probe 
Having shown the feasibility of using an EGFP-targeting detection probe to detect 
RNA foci, HEK-293T cells were transfected with EGFP-72(G4C2) expressing constructs and 
treated with 10 μM control and G4C2 PPMO for three days (Fig 4.1). Fluorescent in situ 
hybridisation was performed using an EGFP-targeting probe and the percentage of foci-
positive cells was quantified. We observed a significant reduction in the percentage of foci-
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positive cells detected with the EGFP-targeting probe upon treatment with G4C2 PPMO 
compared to Control PPMO (Fig 4.6; Untreated = 18.1% ± 1.3;  Control PPMO = 20.4% ± 3.2; 
G4C2 PPMO 8.0% ± 2.2. Control PPMO vs G4C2 PPMO p<0.05 *). 
Altogether, the data shows that the G4C2 PPMO significantly reduces the percentage 
of foci-positive cells in HEK-293T cells transfected with EGFP-72(G4C2), not only bind to 
them, and thereby possibly mitigate their toxicity. 
 
 
Figure 4.6: PPMO treatment reduced the percentage of foci-positive cells  
(A i-vi) Representative images of fluorescent in situ hybridisation probing with an alternative 
EGFP-targeting probe of cells transfected with EGFP-72(G4C2) for 24 hours. Cells were then 
treated with 10μM Control and G4C2 PPMO. (B) Quantification of the effect of Control and 
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G4C2 PPMOs on the percentage foci-positive cells detected with an EGFP-targeting probe. 
Cells transfected with EGFP-72(G4C2). Data represents mean ± SEM. Significance levels were 
determined by one-way ANOVA with Tukey’s multiple comparisons. (* p<0.05; >500 cells per 
condition from three independent replicates) 
 
4.4.6 Effect of PPMO on the levels of poly-GP 
The C9ORF72 expansion is translated into dipeptide repeat proteins in vivo (Mori et 
al., 2013c). Previous work carried out in our laboratory has shown that EGFP-38(G4C2) and 
EGFP-72(G4C2) expressing constructs undergo translation, yielding poly-GP protein. The 
effect of the G4C2 PPMO on the levels of poly-GP that are RAN translated from the two 
constructs was investigated. We carried out the same experimental procedure previously 
explained. Quantification of the levels of poly-GP/GAPDH showed a very slight but not 
significant decrease of the levels of poly-GP normalised to treatment with control PPMO in 
cells transfected with both EGFP-38(G4C2) and EGFP-72(G4C2) and treated with 10 µM G4C2 
PPMO (Fig 4.7; 0.88 A.U. ± 0.1 and 0.86 A.U. ± 0.1 respectively). This suggests that although 
the G4C2 PPMO may be interacting with the G4C2 RNA in the cytoplasm, it does not 




Figure 4.7: PPMO treatment does not reduce the levels of poly-GP. 
(A) Western blot showing the levels of poly-GP expressed in EGFP, EGFP-38(G4C2) and EGFP-
72(G4C2) transfected cells. Cells there treated for three days with 10 μM control and G4C2 
PPMO after 24-hour transfection. (B) Levels of poly-GP in EGFP-38(G4C2) transfected cells 
normalised to control PPMO. (C) Levels of poly-GP in EGFP-72(G4C2) transfected cells 
normalised to control PPMO. Data represents mean ± SEM. (Two-tailed t-test. n.s. = not 








In the present study, we have shown what the G4C2 PPMO significantly reduces the 
number of RNA foci, thereby reducing their ability to sequester RNA-binding proteins and 
potentially mitigate their toxicity. Additionally we have shown that although it may interact 
with G4C2 repeats in the cytoplasm it is not able to block the translation of the repeats into 
di-peptide repeat (DPR) proteins. However, we do not rule out the possibility that there is 
no detectable reduction of the levels of poly-GP because the expression of poly-GP takes 
place for 72 hours and the repeats are greatly overexpressed.  
Although we used an artificial ectopic expression system, there it served as an 
alternative to study the mechanism of action of “blocking” PMOs as it has been shown that 
the foci detected in iPSC-derived neurons are only formed by the G4C2 repeats and not any 
other flanking RNA region. Furthermore, this model presents obvious advantages; HEK-293T 
cells have high transfection efficiencies, there is no observable toxicity upon transfection of 
the EGFP-38(G4C2) and EGFP-72(G4C2) constructs and the presence of the EGFP sequence 
allows the study of the mechanism of the G4C2 PPMO effect by using a non-competing 
detection FISH probe. Additionally, this ectopic expression model recapitulates other aspects 
of the disease pathology such as the presence of di-peptide repeat proteins or the 
sequestration of hnRNP-H into RNA foci (Lee et al., 2013).  
Although the use of steric hindering antisense oligonucleotide have been previously 
reported in the literature, showing that their use reduces C9ORF72 iPSN increased glutamate 
toxicity, our study presents the first comprehensive insight into the mechanism of action of 
steric hindering ASOs in a G4C2-expressing model. As a unit this study does not constitute an 
important breakthrough in the field,  however, the unravelling of the mechanism of action is 
essential for the interpretation of the results that may arise from the testing of the G4C2 
PPMO in iPSC-derived neurons from C9ORF72 expansion carriers.  
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We therefore conclude that the G4C2 PPMOs interact with the G4C2 RNA repeats in 
the nucleus and are able to reduce the number of RNA foci that arise from the repeats. 
Furthermore, the G4C2 PPMOs do not reduce the levels of RAN translation in our ectopic 
expressing model. This may be due to the fact that the levels of RAN translation is too high 
to observe a decrease three days after transfection or that the PMOs are unable block the 


















5 TREATMENT OF C9ORF72 IPSN WITH G4C2 PPMOS 
5.1 BACKGROUND 
The use of iPSC-derived neurons (iPSN) has proven to be crucial in unravelling the 
mechanisms of toxicity for the C9ORF72 expansion mutation. All studies involving C9ORF72-
ALS iPSN report the presence of intranuclear RNA foci which can sequester RNA binding 
proteins such as hnRNP-H or ADARB2 (Donnelly et al., 2013; Sareen et al., 2013), but the 
detection of DPR is inconsistent (Almeida et al., 2013; Donnelly et al., 2013; Sareen et al., 
2013). Several additional changes have been reported including: elevated p62 levels and 
dysfunction of the proteasome system (Almeida et al., 2013), increased sensitivity to 
glutamate-induced stress (Donnelly et al., 2013), diminished capacity to fire continuous 
spikes upon depolarization (Sareen et al., 2013), hyper-methylation of the C9ORF72 
promoter (Esanov et al., 2016), decreased neurite (Burguete et al., 2015) and axonal 
outgrowth (Sivadasan et al., 2016), altered ER calcium homeostasis and increased cell death 
(Dafinca et al., 2016) mitochondrial stress and DNA damage (Lopez-Gonzalez et al., 2016), 
decreased levels of C9ORF72 transcript and protein levels (Aoki et al., 2017) and 
nucleocytoplasmic transport deficits (Zhang et al., 2015). Some of these deficits have been 
reversed with the in vivo and in vitro use of antisense oligonucleotides that facilitate the 
degradation of the target RNA (Aoki et al., 2017; Donnelly et al., 2013; Jiang et al., 2016; 
Sareen et al., 2013; Zhang et al., 2015). 
Neurons derived from iPSCs also present a suitable model in order to test potential 
therapies; iPSN derived from Alzheimer’s disease (AD) patients are resistant to 
therapeutically relevant concentrations of NSAID-Based GSMs that failed in clinical trials but 
had an effect on mouse models of the disease (Mertens et al., 2013). Moreover, iPSN from 
patients with bipolar disorder are responsive to therapeutically relevant lithium levels in the 
culture medium (Mertens et al., 2015b). The potential to test therapies has also been shown 
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in iPSN derived from ALS cases: mutant SOD1-IPSC derived motor neurons (iPSMN) show a 
loss of excitability and increased ER stress, deficits which were reversed following treatment 
with the FDA approved drug 4-aminopyridine (Naujock et al., 2016). Our group were the first 
to report that mutant TDP-43 iPSMNs develop detergent resistant, cytoplasmic TDP-43 
aggregates and reduced survival in long term culture (Bilican et al., 2012). Another study 
showed that some iPSMN phenotypes could be reversed with the histone acetyl transferase 
inhibitor anacardic acid (Egawa et al., 2012). 
5.2 AIM 
In the previous chapter we have shown that PPMOs directly targeting G4C2 repeats 
reduce the number of RNA foci in HEK-293T cells expressing EGFP-72(G4C2) constructs and 
prevent the sequestration of RNA binding proteins. In this study we generated iPSC from 
three healthy individuals and four C9ORF72-ALS cases and differentiated them into mature 
neurons in order to test the potential use of PPMOs as a therapeutic strategy. 
5.3 METHODS 
5.3.1 Fluorescent in situ hybridisation and immunofluorescence  
 Fluorescent in situ hybridisation and immunofluorescence was carried out 
was previously described in the methods section. Antibodies were used at the 







Antigen  Concentration Manufacturer 
MAP2 1:250 Abcam (ab5392) 
βIII tubulin 1:500 Abcam (ab78078) 
SMA 1:300 Abcam (ab5694) 
AFP 1:200 Santa Cruz (C-19) 
OCT4 1:200 Santa Cruz (SC-8628) 
NANOG 1:250 Abcam (ab80892) 
Table 5.1 List of antibodies 
5.3.2 Filter trap 
Filter trap assay was performed as described in the methods section. 20 µg of protein 
lysate was added to 100 µl of RIPA buffer and loaded into each well. 5 µg of HEK-293T cells 
transfected for 48 hours with ply-(GP)x125, poly-(GA)x125, poly-(GR)x125, poly-(PA)x125 
and poly-(PR)x125 overexpressing constructs was used as a positive control for the presence 
of dipeptide repeat proteins. 
5.3.3 Maintenance of iPSCs 
Induced pluripotent stem cells were maintained as described in the methods section. 
iPSCs were cultured in E8-Flex media and fed every other day. Colonies were split by washing 
aspirating the media and washing once with PBS.  1ml of Versene was then added for 3-5 
minutes. Versene was aspirated and 2ml of E8-Flex was added. Colonies were scraped and 
split 1:3 into geltrex coated 6-well plates.  
5.3.4 In vitro differentiation and maintenance of iPSC-derived neuronal progenitor cells 
iPSC lines from three healthy controls and four C9ORF72 expansion carriers were 
differentiated into neuronal progenitor cells (NPCs) as previously described. Neuronal 
progenitor cells were growth in T12.5 falcon flasks until 100% confluent and transferred into 
T25 flasks by dissociating with Accutase. Cells were passaged until 80%-90% of the cells 
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showed a neuronal progenitor-like morphology. NPCs were maintained as previously 
described in expansion medium containing FGF. 
5.3.5 In vitro differentiation of neuronal progenitor cells into mature neurons 
Neuronal progenitor cells were differentiated into mature neurons as described in 
the methods section. Cells were differentiated for 5 weeks to obtain mature neurons. Cells 
were differentiated in 24-well for FISH and ICC, in 12 well plates for western/dot blot analysis 
and 6 well plates for RNA extraction. All plates were coated with Matrigel at least one hour 
prior to plating and an appropriate number of cells were plated in for each experiment as 
described in the methods section 
5.3.6 RNA extraction  
Cells were manually scraped and collected into RNAse-free polypropylene tubes. 
Cells were centrifuged for 1 minute at 12 000 g and cell pellets were kept on ice and washed 
in PBS three times prior to RNA extraction. Total RNA was isolated from cultures of cell lines 
with the RNeasy kit (Qiagen) according to manufacturer’s instructions. RNA was quantified 
using a microvolume spectrophotometer (Nanodrop, Thermo Scientific). 
5.3.7 qRT-PCR 
Quantitative reverse transcriptase PCR was performed as described in the methods 
section. Primers were used at a concentration of 10pM. qRT-PCR was performed 
simultaneously for all samples and the same amount of DNA was used for each of the primer 
conditions. 
5.3.8 Gel electrophoresis 
Gel electrophoresis was performed as described in the methods section. RT PCR 
products were run in 2% agarose gels for 20 minutes and imaged using a UV transiluminator.  
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5.3.9 Alamar blue assay 
Control expansion carrier lines were differentiated in a 96-well plate for 5 weeks. 
Cells were incubated with appropriate concentrations of control and C9ORF72 targeting 
PPMOs for 7 days prior to carrying out the assay. Growth media was removed and an equal 
volume of medium containing Alamar blue reagent was added into each well following the 
manufacturer’s instructions. After 3 hours of incubation the media was collected and 
analysed using a microplate reader following the manufacturer’s indications. Results from 
the effect of PPMO incubation in each cell line were averaged. 
5.3.10 Neurite outgrowth Assay 
The Neurite outgrowth assay was performed as previously described in the methods 
section. The mean total neurite length per cell was measured for each cell line without PPMO 
treatment and by treating with 5μM of Control and G4C2 PPMO for 7 days in a blinded 
manner.  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑡𝑜𝑡𝑎𝑙 𝑛𝑒𝑢𝑟𝑖𝑡𝑒 𝑙𝑒𝑛𝑔𝑡ℎ =
𝑡𝑜𝑡𝑎𝑙 𝑛𝑒𝑢𝑟𝑖𝑡𝑒 𝑙𝑒𝑛𝑔𝑡ℎ 
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 
5.3.11 Fluorescently activated cell sorting (FACS) – Cell survival assay 
Cell survival of iPSC-derived neurons was measured with FACS soring using the cell 
death marker Annexin V and the mitochondrial depolarisation marker DICL.  iPSC-derived 
neurons were grown in 12-well plates. The culture media was collected. Cells were washed 
once with PBS, which was collected and added in the same tube. Cells were dissociated by 
incubating with 300µl of Accutase (Life Technologies) dissociation reagent for 7 minutes at 
37°C. Accutase was inactivated by adding 700µl of plain culture media and all the cells were 
collected into the corresponding falcon tube. The cells were pelleted by centrifugation at 
1000 rpm for 4 minutes. Cells were dissociated into a single cell suspension in PBS by 
pipetting gently with a P1000 pipette. Cells were then centrifuged and resuspended in 500µl 
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of warm PBS buffer containing DICL and Annexin V450 at 1:1000 and 1:500 concentrations 
respectively following the manufacturer’s instructions.  
5.4 RESULTS  
5.4.1 Characterisation of iPSCs 
 
Figure 5.1: Characterisation of iPSCs. 
(A) Representative images of iPSC colonies stained for the pluripotency markers NANOG and 
OCT4. All iPSC lines differentiate into (B) SMA positive cells (mesoderm) and (C) AFP positive 
cells (endoderm). (D) Representative Karyotyping of control and C9ORF72 #4. All cells 
maintained normal karyotype (E) qPCR analysis of SOX2 and OCT4 pluripotency markers for 
all iPSC lines normalised to human embryonic stem cell (hESC).  
 
In order to study the pathophysiology of the C9ORF72 expansion, we generated 
induced pluripotent stem cells (iPSCs) from unaffected individuals (controls #1-3) and four 
C9ORF72-ALS patients (C9ORF72 #1-4) from fibroblasts. Induced pluripotent stem cells were 
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derived by transduction of lentiviral vectors containing the four Yamanaka factors (OCT4, 
SOX2, KLF4 and cMYC) of human fibroblasts as described in (Bilican et al., 2012). All iPSCs 
expressed pluripotency makers and were differentiated into three germ layers (Fig 5.1B SMA 
- mesoderm, Fig 5.1C α-fetoprotein (AFP) - endoderm and Fig 5.3A- βIII-tubulin - ectoderm). 
All cells showed normal karyotyping (Fig. 5.1D). Silencing of the transduced SOX2 and OCT4 
transcription factors after reprogramming was confirmed by quantitative RT-PCR (qRT-PCR) 
by comparing to the levels observed in human embryonic stem cells (hESCs). 
5.4.2 C9ORF72 ALS patient information and confirmation of the presence of the 
expansion 
A) 




Diagnosis SALS/FALS  iPSC 
method 
C9ORF72 #1 male 59 32 ALS FALS retrovirus 
C9ORF72 #2 male 65 36 ALS FALS retrovirus 
C9ORF72 #3 female 39 31 ALS/FTD FALS retrovirus 
C9ORF72 #4 male 58 NA ALS SALS retrovirus 
 
Figure 5.2: ALS patient information and confirmation of the presence of the expansion  
(A) Clinical information of patients from which iPSCs where derived. (B) Electropherograms 
of repeat-prime PCR of control and C9ORF72 iPSC lines to confirm the presence of the G4C2 
expansion. Experiments were carried out Dr. Agnes Nishimura, Dr. Bradley Smith and Ms. 
Nada Alahmady. 
 
iPSCs were derived from human fibroblasts from four C9ORF72-ALS expansion 
carriers as described (Bilican et al., 2012). Clinical data from all C9ORF72 ALS cases is 
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summarised in figure 5.2A. Repeat primed PCR, carried out by Dr. Agnes Nishimura, Dr. 
Bradley Smith and Ms. Nada Alahmady as described in (Al-Sarraj et al., 2011), shows the 
presence of the expansion on iPSCs derived from the four C9ORF72-ALS cases and absent 
from iPSC control #1 (Fig 5.2 B).  
5.4.3 Neuronal differentiation of control and C9ORF72 iPSCs into mature neurons 
 
Figure 5.3: Neuronal differentiation of Control and C9ORF72 iPSCs 
(A) Representative images of 5-week old iPSN from Controls #1-3 and C9ORF72 #1-4 stained 
with βIII-tubulin (green) and DAPI (blue).  (B) Quantification of percentage of βIII-tubulin +ve 
cells of 5-week differentiation of Controls #1-3 and C9ORF72 #1-4 iPSN. n=3. Over 200 cells 




After characterisation, iPSCs were differentiated into neuronal progenitor cell (NPCs) 
lines from all seven iPSCs lines. Neuronal progenitor cells were differentiated for 5 weeks 
and stained for pan neuronal marker βIII-tubulin to assess the percentage of neurons in each 
differentiation batch (Fig 5.3 A-B). A high percentage of neurons was obtained (Fig 5.3 B; 
67%-81%) from all differentiated cell lines showing no significant difference between control 
and C9ORF72-positive cell lines (Control #1 = 67.5% ± 13.9; Control #2 = 72.6% ± 4.5; Control 
#3 = 77.5% ± 8.0; C9ORF72 #1 = 75.6% ± 11.3; C9ORF72 #2 = 72.9% ± 14.4; C9ORF72 #3 = 
81.8% ± 2.9 C9ORF72 #4 = 76.8% ± 5.1). We therefore concluded that we could reliably 
achieve a high percentage of mature neurons from all cell lines.  
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5.4.4 Effective internalisation of PPMOs into cells and lack of toxicity 
 
Figure 5.4: PPMO internalisation and toxicity. 
(A) All cells internalise 5’FL-PPMO after 7 day incubation. Representative images of Control 
#1 5week old iPSN were incubated with 0, 1 µM and 5 µM 5’FL-PPMO for 7 days in order to 
show the uptake of PPMOs by mature neurons. Cells were immunostained with βIII-tubulin 
(red) and DAPI (blue) and 5’FL-PPMO (green).  (B) 7 day PPMO treatment does not induce 
cell death in 5-week differentiated control #1-3 iPSN.  Cells were treated with 0, 1µM, 5µM 
and 10µM control (B i) and G4C2 PPMO (B ii) for 7 days. ALAMAR blue toxicity assay was 
carried out. n=3. 3 wells of a 96-well plate were averaged per iPSN line and normalised to 
PPMO treatment. Data is represented as mean ± SEM; no significant differences were 
observed. 
 






















Control PPMO toxicity 
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Mature neurons were incubated with 0, 1 and 5µM Control and G4C2-targeting 5FL-
PPMOs (previously described in chapter 2) for 7 days in order to show the efficiency of PPMO 
uptake. A 100% of PPMO internalisation was obtained upon incubation of neurons with 5 
µM control and G4C2 PPMOs (Fig 5.4). Unlike HEK-293T cells where the staining was 
concentrated, mature neurons showed a diffuse distribution. Furthermore, we observed a 
concentration-dependent increase in the amount of fluorescence in cells, showing clear 
concentration dependent uptake. Additionally, we observed that all cells internalised 
PPMOs, not only mature neurons (Fig 5.4A). 
The potential toxic effect of incubating mature neurons with PPMOs was assessed 
by Alamar blue assay. The assay exploits the ability of live cells to maintain a reducing 
environment. Cells are incubated with a compound that is able to cross the extracellular 
membrane. If cells are healthy, the compound will be reduced and a fluorescent by-product 
created. Cell health and viability can be therefore measured by measuring the fluorescence 
of such product. A decrease in the fluorescence detected is indicative of cell death due to 
the loss of reducing activity by unhealthy or dead cells.  
Control iPSC-derived neurons were incubated with 0, 1, 5 and 10 µM PPMO for 7 
days. Results were normalised to those of untreated cells. No significant levels of toxicity was 
observed upon incubation with any concentration of control PPMO (Fig 5.4 Bi; 1µM = 0.98 ± 
0.07; 5µM = 0.99 ± 0.07; 10µM = 0.93 ± 0.05) or C9ORF72 targeting PPMO (Fig 5.4Bii; 1µM = 
0.95 ± 0.05; 5µM = 0.91 ± 0.06; 10µM = 0.93 ± 0.02).  
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5.4.5 C9ORF72 neuronal progenitor cells show neurite outgrowth deficits 
 
Figure 5.5: C9ORF72 neuronal progenitor cells show reduced neurite outgrowth. 
(A) Representative images of 7 day neurite outgrowth deficits in NPCs derived from control 
#1 and C9ORF72 #3. MAP2 (green) and DAPI (blue). Scale bar = 40 µm (B) NPCs derived from 
C9ORF72 expansion carriers show reduced 7 day neurite outgrowth compared to control 
NPCs. Each point represents the mean neurite length per cell of each line.  Results are 
represented as mean ± SEM. n=3 two-tailed t-test (p<0.05 *) (C) Average 7 day neurite 
outgrowth of individual control and C9ORF72 NPC lines. Data is represented as mean ± SEM. 
n=3. One-way ANOVA with Tukey’s multiple comparisons (p<0.05 *, p<0.01**). 
 
We investigated the ability of control and C9ORF72 NPC lines to grow neurites upon 
the removal of FGF from the growth media. Cells were plated at a low confluency and neurite 
projection was allowed for 7 days after the removal of FGF. Cells were then fixed and stained 
for MAP2. Images from all conditions were taken in a blinded manner and 30-60 cells were 
analysed per condition. Three individual replicates were carried out and averaged. The total 
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length of all neurites was added and divided by the number of cells in order to calculate the 
average neurite length per cells. 
Dendritic and synaptic loss and distal axonal degeneration are early and consistent 
features of all neurodegenerative disorders, affecting predominantly, but not exclusively, the 
motor neurons in ALS. Our results show that the average neurite length of C9ORF72 neurons 
was ~25% shorter than controls (Fig 5.5 A-B; C9ORF72 #1-4 = 141.1µm ± 20.2 and Control 
#1-3 = 204.2µm ± 4.2; C9ORF72 #1-4 vs. Controls #1-3 p˂0.05 *. Two-tail t-test). Further 
analysis shows that only three out of the four C9ORF72 neuronal progenitor cell lines showed 
neurite outgrowth deficits (Fig 5.5 C; Control #1 = 200 .5µm ± 15.6; Control #2 = 212.5µm ± 
16.4; Control #3 = 199.2 µm ± 12.3; C9ORF72 #1 = 180.1µm ± 16.9; C9ORF72 #2 = 131.2µm 
± 10.6; C9ORF72 #3 = 112.2µm ± 12.2; C9ORF72 #4 = 101.8µm ± 3.2; All Controls vs. C9ORF72 
#1 p>0.05 ns; All Controls vs. C9ORF72 #2 p<0.05 *, All Controls vs. C9ORF72 #3 p<0.05 * All 











5.4.6 C9ORF72 iPSN have intranuclear RNA foci but no DPR proteins 
 
Figure 5.6: C9ORF72 iPSN contain intranuclear RNA foci and increased cell death but we are 
unable to detect DPR proteins. 
(A) Representative images of G4C2 intranuclear RNA foci detected in C9ORF72 iPSN but not 
in controls. βIII-tubulin (green), G4C2 (red) and DAPI (blue). Scale bars = 20 µm (B) 
Intranuclear G4C2 RNA foci are detected in C9ORF72 iPSN. Results are represented as mean 
± SEM. n=3 One-way ANOVA with Tukey’s multiple comparisons (p<0.05 *, p<0.01**, 
p<0.001 ***) (C) DPRs are not detected in C9ORF72 or Control iPSN through slot blot analysis. 
HEK-293T expressing DPRs are used as a positive control. (i) poly-GP (ii) poly-GA (iii) poly-PR 
(iv) poly-PA and (v) poly-PR. (D) iPSN neurons derived from C9ORF72 expansion carriers show 
decreased survival. Results are represented as mean ± SEM. one-way ANOVA, with Tukey’s 




We next generated neurons from the seven iPSC (iPSN) lines and performed 
fluorescent in situ hybridisation for G4C2 repeat RNA. All quantification was carried out in a 
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blinded manner. We detected intranuclear sense RNA foci in ~30% to ~60% of neurons 
generated from C9ORF72-ALS patients (Fig 5.6 A-B; Control #1 = 3.5% ± 1.1; Control #2 = 
2.0% ± 0.7; Control #3 = 2.4% ± 0.6; C9ORF72 #1 = 30.7 ± 3.4; C9ORF72 #2 = 38.1% ± 9.4; 
C9orf72 #3 = 55.8% ± 8.8; C9orf72 #4 = 49.5% ± 10.9, Controls #1-3 vs C9ORF72 #1 p˂0.05 *, 
Controls #1-3 vs C9ORF72 #2 p˂0.01 ** Controls #1-3 vs C9ORF72 #3-4 p˂0.001 ***. No 
significance observed within controls #1-3 or C9ORF72 #1-4 lines). Intranuclear RNA foci have 
been extensively reported in iPSN and are known to recruit several RNA binding proteins 
such as ADARB2 or hnRNP-H and are one of the pathological hallmarks of C9ORF72-linked 
ALS/FTD (Cooper-Knock et al., 2014a; Lee et al., 2013; Mizielinska et al., 2013; Prudencio et 
al., 2015).  
The presence of DPR proteins generated through RAN translation from the G4C2 
repeats was assessed by performing filter trap assay in neurons differentiated for 75 days. 
We used lysates from cells HEK-293T cells transfected with constructs capable of generating 
all five DPR proteins as a positive control. Using this methodology, none of the five DPR 
proteins were detected in mature iPSN (Fig 5.6 C).  
The death of neurons is a defining feature of ALS and FTD pathology. In order to 
assess the neuronal survival we performed fluorescent activated cell sorting (FACS) of iPSN 
from control and C9ORF72 lines. The iPSN from C9ORF72-ALS cases (#1 and #2) showed a 
significant increase of cell death (Fig 5.6 D, Results generated by Dr. Agnes Nishimura with 
the help of Dr. Han-Jou Chen). We therefore chose assays of neurite outgrowth and cell death 
as two robust parameters to test the efficacy of PPMOs as a potential therapeutic strategy 
for C9ORF72-ALS.  
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5.4.7 PPMOs treatment reduces RNA foci but does not reduce the level of C9orf72 
transcripts 
 
Figure 5.7: Treatment with G4C2 PPMO significantly reduces the number of RNA foci in iPSN 
but does not reduce the total levels of C9ORF72 transcripts. 
(A) Representative images of iPSN derived from C9ORF72 expansion carriers treated with 
control and G4C2 PPMO. βIII-tubulin (green), G4C2 (red) and DAPI (blue). Scale bar = 20 µm 
(B) Treatment of iPSN with G4C2 PPMO significantly reduces the number of detectable G4C2 
RNA foci in C9ORF72 iPSN. Results are represented as mean ± SEM. Two-way ANOVA with 
Tukey’s multiple comparisons, selected pairs (p<0.05 *, p<0.01**) (C) G4C2 PPMO treatment 
does not alter the levels of total C9ORF72 transcript. Representative RT-PCR results. GAPDH 
was used as a loading control. (D) Quantification of the effect of PPMO treatment on the 
levels of total C9ORF72 transcripts compared to control PPMO treatment. Results are 
represented as mean ± SEM. Two-way ANOVA with Tukey’s multiple comparisons, selected 






In order to test the efficacy of using PPMOs as a therapeutic strategy we treated iPSN 
derived from control and C9ORF72 expansion carriers for 7 days with control and G4C2 
PPMOs. The effect of G4C2 PPMO treatment on the number of detectable RNA foci was 
assessed, showing a significant decrease in all four C9ORF72 iPSN lines when compared to 
control PPMO (Fig 5.7 A-B; Control #1: Control PPMO = 4.1% ± 0.5, G4C2 PPMO = 5.4% ± 1.0; 
C9ORF72 #1: Control PPMO = 32.2% ± 5.6, G4C2 PPMO = 7.0 % ± 1.9; C9ORF72 #2: Control 
PPMO = 37.8% ± 4.9, G4C2 PPMO = 11.1 % ± 1.3; C9ORF72 #3: Control PPMO = 52.3% ± 10.0, 
G4C2 PPMO = 13.3 % ± 2.0; C9ORF72 #4: Control PPMO = 41.4% ± 3.3, G4C2 PPMO = 8.5% ± 
1.6; C9ORF72 #1: Control PPMO vs G4C2 PPMO p<0.05 *; C9ORF72 #2: Control PPMO vs 
G4C2 PPMO p<0.05 *; C9ORF72 #3: Control PPMO vs G4C2 PPMO p<0.01 **; C9ORF72 #4: 
Control PPMO vs G4C2 PPMO p<0.01 ** Two way ANOVA with Tukey’s multiple 
comparisons). This result shows that PPMOs are internalised into mature iPSN, bind G4C2 
expanded transcripts and reduce the number of RNA foci.  
The effect of PPMO treatment on the total levels of C9ORF72 transcript levels was 
assessed by qRT-PCR. As expected, treatment of control and C9ORF72 iPSN with lines with 
control and G4C2 PPMO resulted in no significant change in the levels of total C9ORF72 










5.4.8 PPMO treatment rescues C9ORF72 NPC neurite outgrowth deficits 
 
 




(A) Representative images of PPMO treatment on 7 day neurite outgrowth NPCs derived 
from control #1 and C9ORF72 #3. MAP2 (green) and DAPI (blue). Scale bar = 40 µm (B) PPMO 
treatment does not affect 7 day neurite outgrowth in control NPCs. Cells were treated with 
5µM control and G4C2 PPMO, or untreated. Each point represents the average neurite 
length of each control line. n=3. 30-60 NPCs were analysed per condition. No significant 
differences were observed. (C) Treatment of iPSN with G4C2 PPMO reverses neurite 
outgrowth deficits in C9ORF72 NPCs. Results are represented as mean ± SEM. Each point 
represents the mean neurite length per cell of each line. Results are represented as mean ± 
SEM. n=3 two-tailed t-test (p<0.05 *) (D) PPMO treatment increases cell survival of C9ORF72 
iPSN. Results are represented as mean ± SEM. Two-way ANOVA with Tukey’s multiple 
comparisons, selected pairs (p<0.05 *). 
 
Prior to investigating the effect of PPMO treatment on the average neurite length in 
C9ORF72 NPCs, we tested them in all three control lines. Control cell lines of the same 
passage were incubated for 7 days with 5µM control and G4C2 PPMO at the same time as 
FGF was removed from the culture media. Control cell lines showed no significant difference 
in the average neurite outgrowth upon incubation with G4C2 PPMO and control PPMO 
compared to no PPMO control. Three individual replicates were carried out for cell line 
(Figure 5.8 A and B; No PPMO = 201.9 µm ± 5.7; Control PPMO = 199.8 µm ± 5.5; G4C2 PPMO 
= 209.4 µm ± 4.8). We therefore concluded that PPMO treatment has no effect on the ability 
of NPC lines to grow neurites and that any effect observed in C9ORF72 NPC lines may be due 
to the effect of the PPMO and not the cell penetrating peptide. 
5.4.9 PPMOs rescue neurite outgrowth deficits in C9ORF72 neuronal progenitor lines 
Having established that PPMOs are internalised by iPSN and bind expanded G4C2 
repeats we tested the effect of treating NPCs and iPSNs derived from C9ORF72-ALS patients 
with PPMOs and assess the impact on the neurite outgrowth and decreased cell survival. 
Control and C9ORF72 NPCs were treated with 5µM PPMO for the duration of the 
differentiation protocol. Treatment of C9ORF72 lines with G4C2 PPMO resulted in a rescue 
event on the neurite length by ~33% compared to control treatment (Fig 5.8 C). Moreover, 
treatment of control NPCs with control and G4C2 PPMO had no effect on the average neurite 
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length (Fig 5.8 B), showing that the PPMO binding expanded RNA transcripts is responsible 
for the phenotypic recovery. 
5.4.10 Treatment with PPMO improves survival of C9ORF72 ALS iPSC-derived neurons 
The ultimate aim of antisense oligonucleotides is to mitigate the toxic effect of the 
expanded G4C2 transcripts and increase cell survival. We treated mature iPSN with control 
and G4C2 PPMOs and performed FACS analysis. There was no significant difference in cell 
survival upon treatment of control iPSN with control and G4C2 PPMOs (Fig 5.8 D), confirming 
what was observed by ALAMAR blue assay (Fig 5.4 B). Treatment of mature iPSN with G4C2 
PPMO resulted in a significant decrease in cell death in two out of the four C9ORF72 iPSN 
studied (C9ORF72 #1 and #2) (Fig 5.8 D). Although we observed a slight decrease in cell death 
in the other two C9ORF72 iPSN lines (#3 and #4) the effect was not enough to reach statistical 
significance. Although the results were variable, reflecting the heterogeneity of human 
patient-derived cells they demonstrate the potential therapeutic use of PPMOs to mitigate 
the toxic effect of the C9ORF72 expansion. 
5.5 DISCUSSION  
In the present study we analysed iPSC-derived neurons from three health controls and 
four C9ORF72-ALS expansion mutation carriers. We have shown that C9ORF72 ALS iPSN 
contain intranuclear G4C2 RNA foci but we were unable to detect any DPRs by filter trap 
assay. C9ORF72 ALS neuronal progenitor cells showed impaired neurite outgrowth 
compared to control lines and reduced cell survival by FACS analysis. We demonstrated that 
treatment with G4C2-targeting PPMOs reversed the neurite outgrowth deficits in C9ORF72 
neuronal progenitor cell lines and improved cell survival in mature iPSNs.  
Several studies investigating iPSCs from C9ORF72 ALS patients report a variety of 
pathological phenotypes including impaired ubiquitin proteosome system function (Almeida 
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et al., 2013), increased sensitivity to glutamate toxicity (Donnelly et al., 2013), reduced 
neurite outgrowth (Burguete et al., 2015), impaired nucleocytoplasmic transport (Zhang et 
al., 2015) and increased cell death (Dafinca et al., 2016). We confirmed reduced neurite 
outgrowth in neuronal progenitor cells. We chose to analyse immature neurons due to the 
complexity of the neurite arbour of more mature neurons and because they can be rapidly 
analysed after a short period of culture.  Post mortem studies of C9ORF72 ALS cases reveal 
dystrophic neurites in C9ORF72 spinal motor neurons (Simon-Sanchez et al., 2012), indicating 
that this phenotype in neuronal progenitor cells may be relevant to disease pathology. 
However, the fact NPCs may not be entirely relevant as ALS is a late onset disease and not a 
developmental disorder. The use of these cells may provide a fast drug discovery assay which 
is should be explored in the future with the use of high throughput assays. This will be 
discussed in greater detail in the discussion section. We have also shown that 2/4 iPSN lines 
derived from C9ORF72 expansion carriers show a significant reduced cell survival by FACS 
analysis, which is consistent with previously published studies (Dafinca et al., 2016; Donnelly 
et al., 2013). We were unable to detect the presence of any DPR in neurons cultured for 75 
days, suggesting that any phenotype observed in iPSN is due to an RNA gain-of-function 
toxicity. We are aware of the limitations of this assay and we acknowledge that the use of a 
Meso Scale Discovery-based poly-GP immuno-assay (Gendron et al., 2017) could be used to 
detect the presence of poly-GP in a more accurate manner. In the absence of detectable 
DPRs we hypothesize that toxicity in iPSN is due to the presence of expanded G4C2 RNA 
transcripts that recruit RNA binding proteins and may disturb many steps in the processing 
of RNA from splicing, transport and translation. 
Previous studies exploring the use of antisense oligonucleotides to mitigate the 
C9ORF72 expansion toxicity have yielded promising results, reversing C9ORF72-specific 
increased glutamate sensitivity and splicing dysregulation (Donnelly et al., 2013; Sareen et 
al., 2013) and C9ORF72BAC transgenic mice (Jiang et al., 2016). It must be noted that 
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Donnelly et al. 2013 reverses C9ORF72-specific phenotypes in iPSN using degrading ASOs but 
does not report a decrease in the total levels of C9ORF72 transcripts. However, the ASOs 
used by Jiang et al. 2015 that reverse C9ORF72-specific phenotypes in C9ORF72 BAC mice 
achieve ~50% reduction in the total levels of C9ORF72 transcript levels.  Degrading the target 
mRNA may not be a suitable therapeutic strategy if haploinsufficiency of C9ORF72 plays a 
pathogenic role in C9ORF72 ALS neurodegeneration. Using of non-degrading PPMOs that 
target the G4C2 expansion we were able to reverse neurite outgrowth deficits in C9ORF72 
ALS neuronal progenitors (Fig 5.8 A and C) and significantly improve the survival of mature 
C9ORF72 ALS neurons (Fig 5.8 D). 
It must be mentioned that the use of iPSN is used to model a late-onset 
neurodegenerative disorder. Clearly, the few months of cell culture do not compare to years 
of aging in the adult nervous system. Moreover, recent studies have suggested that iPSN are 
transcriptionally closer to fetal human neurons than to mature human neurons (Mertens et 
al., 2015a). Additionally, the timescale of the differentiation protocol is likely to be a critical 
parameter. Some studies have used neurons differentiated for up to 365 days in an attempt 
to model MAPT-linked FTD (Sposito et al., 2015). The potential of iPSN to model late--onset 
conditions will be explored in greater detail in the general discussion.  
Our results strengthen the hypothesis that expanded G4C2 RNA transcripts are the 
main contributor to toxicity in C9ORF72 ALS and that PPMOs targeting G4C2 repeats  can 
reverse pathogenic phenotypes. The lack of detectable DPRs in C9ORF72 ALS iPSC-derived 
neurons in culture and their virtual absence in C9ORF72 ALS spinal motor neurons at post 
mortem tissues challenges a major role in disease pathogenesis.   
Finally, we have shown the promising therapeutic potential of non-degrading PMOs 
to mitigate G4C2 toxicity in cell culture setting. We have shown that PMO treatment is able 
to rescue specific phenotypes linked to C9ORF72 by blocking and not degrading the G4C2 
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expanded RNA. This opens a new and exciting therapeutic avenue that must be tested 





















6 GENERAL DISCUSSION 
6.1 DPR INCLUSIONS ARE EXTREMELY RARE IN C9ORF72-ALS SPINAL MOTOR 
NEURONS 
The presence of aggregated protein inclusions is a feature common to all 
neurodegenerative conditions. In Alzheimer’s disease the presence of extracellular 
aggregates of amyloid-β peptides, intracellular inclusions of microtubule-associated protein 
tau forming neurofibrillary tangles and neuritic plaques are pathological hallmarks of the 
disease (Canter et al., 2016). α-synuclein aggregates form in dopaminergic neurons in the 
substantia nigra in Parkinson’s disease (Spillantini et al., 1997) and are more widely 
distributed in Dementia with Lewy bodies (Baba et al., 1998).  Similarly, cytoplasmic TDP-43 
inclusions are the pathological hallmark of ALS and tau-negative FTD (Neumann et al., 2006). 
The presence of cytoplasmic, poly-ubiquitinated, hyper-phosphorylated TDP-43 aggregates 
correlates closely with the site of symptomatic neurodegeneration in ALS and FTD (Davidson 
et al., 2016). For C9ORF72 ALS however another set of inclusions are present, due to repeat 
associated non-ATG translation of G4C2 transcripts to generate DPRs of poly GA, GP, GR from 
the sense strand and PA and PR from antisense. Cytoplasmic and intra-nuclear DPR inclusions 
are abundant in the cerebellum, frontal and temporal lobes and have been shown to be toxic 
in a range of cellular and in vivo studies. This has implicated them in driving the 
neurodegeneration seen in C9ORF72 ALS and FTD. 
In this study we sought to quantify the number of inclusions present in the spinal cord 
of C9ORF72 ALS cases. We used highly specific DPR antibodies that had been previously 
extensively validated by others in FTD cases (Chew et al., 2015b; Gendron et al., 2013). Using 
a previously published semi-quantitative scale (Mackenzie et al., 2013b) to estimate the 
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relative abundance of TDP-43 inclusions in the spinal cord we observed no difference in the 
scores for TDP-43 aggregation between C9+ve ALS and C9-ve ALS cases, confirming previous 
reports (Murray et al., 2011). Having confirmed that our anti-DPR antibodies were sensitive 
in detecting DPR inclusions in the cortex and cerebellum in C9ORF72-FTD we analysed the 
spinal cord of ten C9+ve ALS and 5 C9-ve ALS cases. The number of DPR aggregates was highly 
consistent within cases and all DPRs were scored as either rare, very rare or absent and no 
more than twelve inclusions of any DPR was observed in any of the cases analysed. DPRs 
translated from the sense strand (poly-GP, GA and GR) were more abundant than those 
translated solely from the antisense strand (poly-PR, PA). In contrast TDP-43 inclusions were 
detected in 38% of surviving motor neurons. It is impossible to exclude the possibility that 
neurons with toxic DPRs had died and been removed or that toxic DPR species are too small 
to be detected by confocal microscopy but this would be at variance with all other 
neurodegenerative disorders where the neurotoxic proteins are readily detected. Our study 
provides strong circumstantial evidence that it is TDP-43 aggregation or mislocalisation, and 
not DPRs, that plays a dominant mechanistic role in motor neuron degeneration in C9ORF72 
ALS.  Others have suggested that the presence DPRs may gradually trigger TDP-43 pathology 
and subsequent region-specific neurodegeneration in a cascade similar to amyloid-β peptide 
in Alzheimer's disease (Edbauer et al., 2016). In order to test this hypothesis, mouse models 
of each DPR may provide useful to understand the distribution of DPRs throughout the 
disease process. Furthermore it is possible that neurons containing DPR aggregates have 
died. 
Our study was the first to quantify all five DPRs in the spinal cord of ALS cases, which 
is the main site of neurodegeneration in ALS (Gomez-Deza et al., 2015). Since that 
publication, other studies have confirmed our findings (Davidson et al., 2016; Mackenzie et 
al., 2015). Additional evidence comes from a separate study showing that the levels of all 
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soluble DPRs are very low in the spinal cord of C9+ve ALS cases, casting doubt on their role 
in causing neurodegeneration (Mackenzie et al., 2015). 
Models of the DPR toxicity have not always provided consistent results. Most in vitro 
and in vivo studies have reported that poly-GP and poly-PA are not toxic and that the 
arginine-rich poly-GR and poly-PR DPR proteins are the main source of toxicity (Mizielinska 
et al., 2014; Wen et al., 2014) although others suggest that poly-GA is the main driver of cell 
death (Schludi et al., 2017; Zhang et al., 2016b). Additionally only cellular models expressing 
poly-GA reproduce the typical p62 positive, neuronal cytoplasmic aggregates observed in 
human post-mortem tissue (Schludi et al., 2015). Perhaps unsurprisingly, adding arginine rich 
poly-GR and poly-PR to the cell culture medium results in these DPRs being internalised by 
cells going to the nucleolus (Kwon et al., 2014) since arginine rich peptides have been 
exploited commercially as cell-penetrating peptides to facilitate the internalisation of a wide 
range of cargos into cells (Guidotti et al., 2017). 
The modelling of DPR protein toxicity has been carried out using DPRs of varying 
lengths which show different subcellular localisations (Bennion Callister et al., 2016). 
Therefore elucidating the length of the DPRs present in post mortem tissue may help develop 
better models of the DPR toxicity. Additionally, the lack of TDP-43 pathology in most of these 
in vitro and in vivo models suggests that the toxicity observed is due to the high level of DPR 
expression of these proteins and do not fully model the disease pathology. Finally, two 
studies have reported the necessity for poly-GA (Zhang et al., 2016b) and poly-PR (Wen et 
al., 2014) to aggregate in order induce toxicity, strengthening our observation that DPR 
protein inclusions are not the main source of toxicity in C9ORF72 ALS.  
Whilst we cannot entirely exclude the possibility that DPR aggregation and toxicity 
occurs at the sub-microscopic level, or that all motor neurons containing DPR inclusions were 
lost, this explanation seems unlikely as neurotoxic protein aggregates are detected in the 
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affected neurons for all other neurodegenerative diseases. As the number of TDP-43 
inclusions in ALS cases, with and without the C9ORF72 mutation are nearly identical we can 
find no evidence that dipeptide repeat proteins are playing a strong pathogenic role in 
C9ORF72 ALS. 
6.2 SENSE AND ANTISENSE RNA FOCI ARE ABUNDANT IN THE SPINAL CORD OF ALS 
CASES 
We have shown that both sense and antisense RNA foci are common in C9+ve-ALS 
spinal cords, with sense RNA foci being significantly more common than antisense foci. Most 
of the studies quantifying the number of sense and antisense RNA foci in C9ORF72 ALS and 
FTD have focussed on the frontal cortex (DeJesus-Hernandez et al., 2017; Gendron et al., 
2013; Mizielinska et al., 2013) and the hippocampus (Cooper-Knock et al., 2014a). These 
studies have provided valuable information showing that sense and antisense RNA foci are 
present in the central nervous system of C9ORF72-FTD cases and are primarily located in the 
nucleus of neurons (DeJesus-Hernandez et al., 2017; Mizielinska et al., 2013). 
Only two studies by the same group (Cooper-Knock et al., 2015; Cooper-Knock et al., 
2014a) have attempted to quantify sense and antisense foci in the spinal cord motor neurons 
in C9+ve-ALS. These publications however report on a small number of patients (n=7) and a 
small number of motor neurons (n=54). Cooper-Knock et al. (2014) compared the presence 
of foci-positive neurons in the granule neurons with spinal motor neurons in only one 
C9ORF72-ALS/FTD and three C9ORF72-ALS cases. They concluded that there were a 
significantly greater number of sense foci-positive motor neurons than granule neurons. 
Subsequently they reported that the number of antisense and not sense RNA foci, or poly-
GA aggregates that correlated with TDP-43 nuclear depletion (Cooper-Knock et al. 2015) but 
they analysed only 54 spinal motor neurons in seven C9+ve-ALS cases. We therefore sought 
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to replicate and validate their findings in a larger sample size by analysing almost 300 spinal 
motor neurons in 10 C9+ve-ALS cases. We observed that both sense and antisense RNA foci 
were commonly detected in spinal cord motor neurons but sense foci were more common 
than antisense foci. We did not observe a significant correlation between the presence of 
sense or antisense RNA foci and TDP-43 nuclear depletion. We attribute the differences in 
our results from the earlier studies to case to case variation and stand by our results which 
analysed a much larger number of neurons and cases reducing the influence of case to case 
variation commonly seen in post mortem studies. 
In summary, we showed that sense RNA foci are the most common pathological 
feature in the spinal cord and motor neurons of C9ORF72-ALS cases, followed by antisense 
RNA foci and DPR protein inclusions. Based on circumstantial evidence we suggest that the 
presence of sense RNA foci are more likely to contribute to pathogenesis of C9+ve-ALS driven 
principally by TDP-43 aggregation or nuclear depletion. However the strong cellular animal 
evidence showing DPR toxicity suggests that DPR toxicity may be also be an important 
contributing factor to neurodegeneration. 
6.3 ANTISENSE OLIGONUCLEOTIDES TARGETING G4C2 REDUCE RNA FOCI BUT NOT 
DPRS 
We next investigated the potential of using non-degrading PMOs to bind and block 
G4C2 repeats without inducing the degradation of the target transcript. Several groups have 
reported that the use of ASOs which degrade the C9ORF72 transcript and reduce the levels 
of DPRs and RNA foci in vitro (Donnelly et al., 2013; Lagier-Tourenne et al., 2013; Sareen et 
al., 2013) reversing C9ORF72-specific phenotypes such as increased glutamate toxicity, and 
in vivo reducing anxiety-like behaviour of transgenic mice expressing the full C9ORF72 gene 
with 450 repeats (Jiang et al., 2016). The ASOs used in these studies however also reduce the 
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level of total C9ORF72 transcripts. Decreasing the C9ORF72 protein levels may be 
counterproductive as it has been shown to play in important role in the immune system 
(Atanasio et al., 2016; O'Rourke et al., 2016) and one of the proposed toxic mechanisms of 
C9ORF72-ALS/FTD is haploinsufficiency (DeJesus-Hernandez et al., 2011). 
We have previously reported that G4C2 repeats are neurotoxic in a length-dependent 
manner (Lee et al., 2013). Cells expressing EGFP-G4C2 repeats contain intranuclear G4C2 foci 
which sequester proteins such as hnRNP-H and undergo RAN translation yielding DPR 
proteins such as poly-GP. Here I have shown that G4C2-targeting PPMOs reduce the number 
of RNA foci in a concentration-dependent manner in cells expressing 38X and 72X repeats. 
In order to exclude the possibility that PPMOs were merely masking the detection of RNA 
foci we designed an alternative, non-competing FISH probe targeting the EGFP sequence in 
the EGFP-G4C2 transcript, a strategy previously applied in other repeat expansion disorders 
(Wheeler et al., 2009). Using this probe, we showed that G4C2-targetted PMOs also reduce 
the number of EGFP foci confirming their clearance from the nucleus although the 
mechanism by which this occurs is uncertain. Given that cells are transfected for 24 hours 
prior to PMO treatment, we hypothesize that PMOs dissociate the RNA foci, however it is 
possible that the PMOs also prevents the formation of RNA foci.  
Although RNA foci were reduced we did not observe a significant decrease in the total 
levels of poly-GP following PPMO treatment. PMOs are known to efficiently block translation 
(DeVos and Miller, 2013) so we hypothesize that this may be due to the fact that cells were 
transfected with G4C2 constructs one day prior to the PPMO treatment and that PPMOs are 
slowly internalised over 24 hours (DeVos and Miller, 2013) so that DPR synthesis may have 
already taken place. Moreover, it is also possible that binding of PMO does not affect the 
structural motifs required to initiate RAN translation. It would be of interest to investigate 
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whether PMOs have the ability of preventing the formation of secondary RNA structures 
such as G-quadruplexes. 
We concluded that the use of non-degrading PPMOs targeted at the G4C2 repeats 
reduce the number of G4C2 RNA foci and that their potential therapeutic use should be 
tested in a physiologically relevant model of the disease such as iPSC-derived neurons (iPSN) 
from C9ORF72 expansion carriers.  
6.4 C9ORF72-ALS IPSC NEURONS HAVE INTRANUCLEAR RNA FOCI, DECREASED 
NEURITE OUTGROWTH AND SURVIVAL 
We generated iPSCs from C9ORF72 ALS cases and controls and have shown that iPS-
derived neurons carrying the G4C2 expansion have an abnormal phenotype. All studies that 
have generated C9ORF72-iPSN have reported the presence of RNA foci which are able to 
recruit RNA binding proteins such as hnRNP-H (Sareen et al., 2013) and ADARB2 (Donnelly et 
al., 2013). The presence of insoluble DPRs in C9ORF72 iPSNs has not been consistently 
reported; Almeida et al. (2013) detected DPRs in 28 day old cortical neurons by filter trap 
analysis, Donnelly et al. (2013) identified poly-GP by immunofluorescence but Sareen et al. 
(2013) was unable to detect them by dot blot analysis or immunofluorescence. We were also 
unable to detect any of the five DPR proteins by filter trap assay in cortical neurons cultured 
over 75 days or immunocytochemistry. This discrepancy may be due differences in the 
C9ORF72 ALS cell lines, differentiation protocols and time in culture. 
The use of iPSN has been instrumental in the study of the C9ORF72 expansion. A 
variety of important phenotypes have been observed in C9ORF72 iPSN including; impaired 
UPS function (Almeida et al., 2013), neurite outgrowth (Burguete et al., 2015) and 
nucleocytoplasmic transport (Zhang et al., 2015), as well as increased sensitivity to glutamate 
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toxicity (Donnelly et al., 2013) and cell death (Dafinca et al., 2016). Here we have shown that 
the average total neurite length of C9ORF72 neuronal progenitor cells (NPCs) is ~33% shorter 
than control NPCs. We chose to analyse neurites from immature neurons due to the complex 
structure of more mature neurons and the short time taken to grow NPCs is suitable for high-
throughput drug discovery assays. 
Dendritic and synaptic loss and distal axonal degeneration are early and consistent features 
of all neurodegenerative disorders, affecting predominantly, but not exclusively, the motor 
neurons in ALS. Neurite outgrowth deficits have been previously reported in FUS (Kabashi et 
al., 2011), TDP-43 (Egawa et al., 2012) and C9ORF72 (Burguete et al., 2015) in vitro and in 
vivo models of ALS. Neurite outgrowth depends on a complex interplay between 
extracellular guiding cues and intracellular signaling pathways. Extracellular cues are 
detected by molecules expressed on the surface of neurons, and transduced to activate cell 
signaling and gene transcription inside the cell (Hansen et al., 2008). 
Precisely how G4C2 transcripts affect the behaviour and survival of neurons is 
unknown and it is important to acknowledge that iPSNs are immature cells grown for short 
time intervals in a non-physiological environment and to avoid making direct correlations to 
the human pathology which occurs over many years in an aging and complex nervous system. 
Given that several groups have demonstrated a reversal of the abnormal phenotype using 
G4C2 targeted ASOs these cellular events are likely to genuinely reflect G4C2-driven 
neuronal dysfunction. It is possible that RNA foci leads to the sequestration of RNA binding 
proteins and aberrant RNA processing affecting a wide range of  cellular functions. 
Transcripts containing G4C2 repeats have been detected in the neurites of C9ORF72 iPSN 
(Burguete et al., 2015) and it is therefore possible that they may bind RNA binding proteins 
and alter axonal transport and peripheral translation of mRNA including TDP-43 itself. The 
G4C2 repeats form G-quadruplexes in vitro (Fratta et al., 2012) and in vivo (Conlon et al., 
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2016a). Moreover TDP-43 binds to G-quadruplexes in neurites of iPSC-derived neurons 
(Ishiguro et al., 2016) and IPSN derived from patients carrying TARDBP mutations show 
impaired axonal transport (Alami et al., 2014). Regardless of the mechanism, motor neurons 
are the most polarised cell in the body with axons reaching a meter in length, abnormal 
neurite outgrowth and cargo transport might be especially relevant in predisposing these 
cells to degeneration as is seen in ALS. 
The dysfunction and death of neurons is fundamental to the irreversible progression 
of ALS and FTD. We have shown that 2/4 C9ORF72 iPSN lines investigated show significant 
reduced cell survival. Our results are consistent with other published studies (Dafinca et al., 
2016; Donnelly et al., 2013). The loss of neurons has been widely reported in animal models 
of TDP-43 (Mitchell et al., 2015), FUS (Mitchell et al., 2013) and C9ORF72 (Chew et al., 2015b; 
Liu et al., 2016). Dafinca et al. (2016) reported that C9ORF72 iPSN decreased survival is 
correlates with disrupted calcium homeostasis and ER dysfunction. We observed a similar 
rate of neuronal cell death in our C9ORF72 iPSNs as reported by Dafinca et al. (2016). The 
fact that RNA foci are abundant and DPRs are absent in our C9ORF72 IPSNs and suggests that 
the increased cell death observed is likely to be driven by expanded G4C2 RNA transcripts 
and not DPRs.  
Because C9ORF72 NPCs and iPSN replicate some aspects of human pathology, such as 
the presence of intranuclear RNA foci (DeJesus-Hernandez et al., 2011; Mizielinska et al., 
2013), neurite outgrowth deficits (Simon-Sanchez et al., 2012) and neuronal death we 




6.5 G4C2 PPMOS DECREASE THE NUMBER OF RNA FOCI BUT NOT THE LEVELS OF 
C9ORF72 TRANSCRIPTS 
We have shown that G4C2 PPMOs are internalised into mature iPSN and that upon 
doing so they reduce the number of detectable RNA foci without decreasing the total 
C9ORF72 transcripts levels. This result demonstrates that G4C2 PMOs bind to G4C2 RNA in 
iPSN. RNA foci in C9ORF72 iPSNs have been reported to solely comprise G4C2 repeats edited 
out from the C9ORF72 transcript (Donnelly et al., 2013). Although we did not confirm this 
with probes for neighbouring intronic or exonic sequence the results from our EGFP-G4C2 
transfection studies strongly suggest that the PMOs are reducing the number of G4C2 foci 
and not just masking them, which would not be predicted to reverse the abnormal cellular 
phenotypes we and others have observed. 
Previous studies exploring the use of antisense oligonucleotides to mitigate the 
C9ORF72 expansion have yielded promising results, reversing C9ORF72 specific phenotypes 
in iPSN (Donnelly et al., 2013; Sareen et al., 2013) and C9ORF72 mouse model (Jiang et al., 
2016). These ASOs however degrade the target mRNA, which may not be a suitable 
therapeutic strategy if haploinsufficiency plays a role in the pathogenic mechanism of 
C9ORF72-ALS. More broadly they can have important side effects as the knockdown of 
C9ORF72 has shown to cause important immunological deficits in mice (Atanasio et al., 2016; 
O'Rourke et al., 2016). In these experiments we have shown that the number of RNA foci can 
be decreased without reducing the total levels of C9ORF72. The lack of C9ORF72 knockdown 
may therefore reduce possible side effects then administering the PMO. 
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6.6 G4C2 PMOS REVERSE DISEASE-SPECIFIC PHENOTYPES 
We have shown that the neurite outgrowth deficits observed in C9ORF72 ALS NPCs is 
reversed by treatment with G4C2 targeting PPMOs. Moreover, we have shown that PMO 
treatment significantly reduces cytotoxicity in mature C9ORF72 iPSN. From a mechanistic 
point of view, the absence of detectable DPRs and the presence of intranuclear RNA foci 
suggests that C9ORF72 ALS toxicity is due to a gain-of-function arising from the RNA 
transcripts and possibly the foci themselves. We and others have shown that G4C2 repeats 
are neurotoxic (Lee et al., 2013; Stopford et al., 2017) and that they sequester numerous 
RNA binding proteins (Cooper-Knock et al., 2014a; Lee et al., 2013). Moreover the presence 
of G4C2 RNA transcripts in neurites suggests that toxicity may also be driven by expanded 
transcripts in the cytoplasm (Burguete et al., 2015). Our results show that PMOs bind G4C2 
repeats and disrupt RNA foci; however we have also shown that after internalisation, PMOs 
uniformly distribute in the nucleus and the cytoplasm. It is therefore possible that the binding 
of PMOs to expanded G4C2 transcripts in the cytoplasm at very low levels, as well as the 
disruption of RNA foci, may contribute to the improvement in neurite outgrowth and 
decreased cell death observed. For this reason it would interesting to investigate the effect 
G4C2 repeat RNA that localise in the cytoplasm and neurites of neurons and their binding 
partners. Although we did observe occasional RNA foci in the cytoplasm of C9ORF72 iPSN, it 
was technically challenge to detect RNA foci in the neurites given that iPSN grow in dense 
networks making it difficult to identify the neurites arising from an individual neuron. It is 
also possible that expanded G4C2 repeats present in the cytoplasm of neurites and able to 
exert a toxic effect even though they do not form classical quadruplex structures and visible 
RNA foci. 
It must be noted that Donnelly et al. (2013) explored the effect of treating C9ORF72 iPSN 
with a blocking ASO of a different backbone chemical modification to ours. They show that 
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this MOE ASO does significantly reduce the sensitivity of C9ORF72 iPSN to glutamate 
excitotoxicity, but less effectively than the other degrading ASOs tested. This may be due to 
poor uptake of iPSN due to the MOE ASO but no data on this was reported. However, their 
results confirm that non-degrading ASOs can reverse C9ORF72-specific phenotypes in other 
laboratories and further validates our results. 
From a therapeutic and drug discovery perspective, our results highlight a novel therapeutic 
approach which consists in blocking the G4C2 expanded RNA transcripts but not degrading 
them. This may be important given that haploinsufficiency of C9ORF72 protein may also be 
a component of the C9ORF72 ALS pathogenic mechanism. Our study also highlights the 
potential of iPSC-derived neurons for drug testing, which has been previously described for 
ALS (Egawa et al., 2012). 
It would be of great interest to assess the efficacy of G4C2 PPMOs in a mouse model 
of the disease. Several C9ORF72 transgenic mouse models have been developed with 
inconsistent results. Two studies that generated C9ORF72 mouse models expressing the full 
C9ORF72 human gene reported the presence of DPRs and sense and antisense RNA foci but 
observed no neuronal loss or phenotypic deficits (O'Rourke et al., 2015; Peters et al., 2015). 
Another group has reported that C9ORF72 transgenic mice have sense and antisense RNA 
foci, DPR proteins aggregates as well as TDP-43 aggregates in the main sites of 
neurodegeneration (Liu et al., 2016). These mice show strong dose and gender-dependent 
phenotypic differences. Jiang et al. (2016) showed that the neuronal loss and FTD-like anxiety 
phenotypes observed in C9ORF72 transgenic mice can be recovered with a single dose of 
G4C2-targeting ASO. These mice however did not show any TDP-43 pathology which may be 
due to difference in the length of repeats expressed of background mouse strains. Finally, 
Chew at al. (2015) showed that 66X G4C2 repeats expressed in the central nervous system 
of mice, lead to nuclear RNA foci, DPR inclusions and TDP-43 pathology in the cortex and 
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hippocampus of mice, suggesting that the repeat itself, possibly through foci formation, RAN 
translation or another mechanisms entirely, caused aberrant TDP-43 deposition (Chew et al., 
2015b). This would be a suitable model to test the potential therapeutic use of G4C2 PPMOs 
as it consistently replicates the pathological features observed in C9ORF72-linked ALS and 
FTD.  
6.7 LIMITATIONS OF OUR PATHOLOGICAL STUDY 
The current pathological study assessing the abundance of DPR protein inclusions in 
the spinal cord of C9ORF72 cases was limited by the availability of commercial antibodies 
that detect DPR proteins. At the time the study was conducted there were no commercially 
available DPR antibodies but we were fortunate to receive a panel of extensively validated 
antibodies from Dr. Leonard Petrucelli. The small quantities of antibody we received 
however meant that we had to focus on assessing the presence of DPR protein inclusion in 
only the spinal cord and we could not run western blots to quantify soluble DPRs. Moreover, 
our results would be more robust if several different antibodies that recognised the same 
DPR had been used to quantify the number of DPR protein aggregates. Nevertheless, the 
antibodies used have been validated (Chew et al., 2015b; Gendron et al., 2013) and a section 
of the frontal cortex of ALS and FTD cases. Our results have since been replicated by two 
independent studies (Davidson et al., 2016; Mackenzie et al., 2015) which increases our 
confidence that this data is correct. 
The DAB IHC protocol used by some groups may be more sensitive in detecting specific 
DPR protein aggregates but we performed double immunofluorescent histochemistry in 
order to assess the co-aggregation and co-occurrence of DPR and TDP-43 pathology. Because 
we have extensive experience in ALS pathology and can reliably identify motor neurons by 
their large pale nucleus, it would however have been desirable to use a motor neuron specific 
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antigen (such as CHAT) to determine more precisely  which cells contained DPR inclusions as 
well as sense and antisense RNA foci. Finally, although we were able to detect cells with large 
numbers of sense and antisense RNA foci, and therefore validating our FISH protocol, it 
would have been of interest to obtain tissue from the cases published by Cooper-Knock et 
al. 2015 showing large numbers of antisense foci as a positive control in our FISH protocol. 
6.8 LIMITATIONS OF IN VITRO DISEASE MODELLING AND PPMO TESTING 
It must be mentioned that the use of iPSN is used to model a late-onset 
neurodegenerative disorder. Clearly, the few months of cell culture do not compare to years 
of aging in the adult nervous system. A potential strategy to address this limitation is to 
promote premature aging in cell culture. Hutchinson-Gilford progeria syndrome (HGPS) is a 
human premature ageing disease that is caused by a single point mutation in the lamin A 
gene (LMNA) (Eriksson et al., 2003). Mutations in LMNA result in the production of a shorter 
transcript known as progerin. Miller et al. 2013 showed that overexpression of progerin 
induces multiple aging-related processes and characteristics in iPSC-derived neurons. 
Furthermore, this study reported multiple progerin-induced neurodegenerative phenotypes 
in Parkinson’s disease patient iPSC-derived neurons that were not observed otherwise 
(Miller et al., 2013a).  
Another limitation of this project is phenotypic variability arising from in vitro 
differentiation of iPSNs. We and others working in the field consistently observe 
heterogeneity of cell lines through all stages of differentiation. It is possible that subtle 
differences in the percentage of cells at different stages of maturation could result in non-
cell autonomous effects that are not accounted for. In our study 2/4 C9ORF72 iPSN showed 
significant increased cell death and 1/4 of the C9ORF72 NPCs did not show any neurite 
outgrowth deficits. Although this may be representative of the heterogeneity observed in 
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human populations, the way to overcome this problem is by increasing the number of iPSC 
lines from C9ORF72 ALS cases and controls. Another possible solution is to generate isogenic 
lines and introducing point mutations or removing the G4C2 repeats using CRISPR-Cas9 
technology (Cong et al., 2013), although this might be more challenging that it is initially 
thought as PAM sequences requited for CRISPR cleavage are not always present adjacent to 
the mutation insertion site or the CRISPR cleavage is not efficient, meaning many rounds of 
selection are likely to be necessary. 
Another aspect to consider is to what extent are iPSC-derived neurons are 
representative of human adult neurons. Recent studies have suggested that iPSN are 
transcriptionally closer to fetal human neurons than to mature human neurons (Mertens et 
al., 2015a) and that iNeurons generated by direct reprogramming of fibroblasts by the 
knockdown of PTB reproduce aging phenotypes better than iPSN. iNeurons differentiated in 
this way also preserved epigenetic information while iPSN do not. Additionally, the timescale 
of the differentiation protocol is likely to be a critical parameter. Some studies have used 
neurons differentiated for up to 365 days in an attempt to model MAPT-linked FTD (Sposito 
et al., 2015). Although it may be seen as a limitation, iPSN can be used as a disease 
progression model. The same line of neurons differentiated for different lengths of time 
could be compared in order to assess the burden of a mutation as the neuron matures. 
Moreover a study has showed that neurons differentiated for 150 days show detectable 
levels of insoluble DPRs (Lopez-Gonzalez et al., 2016). We differentiated neurons for 75 days 
and were unable to detect any DPR by filter trap assay. Recent studies have reported the 
used of Meso Scale Discovery-based immunoassay to detect low levels of DPR protein (e.g. 
poly-GP) in the CSF pre-symptomatic and symptomatic C9ORF72 expansion carriers 
(Gendron et al., 2017; Lehmer et al., 2017). It would be of great interest to use this system 
to assess the presence of poly-GP in our C9ORF72-iPSN and to assess the effect of PPMO 
treatment in the levels of DPRs, if detected. However it must be noted that this assay 
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measures the abundance of poly-GP that has not shown to be toxic in any in vitro or in vivo 
study. 
6.9 FUTURE DIRECTIONS 
Our pathological study analysed one of the largest samples of C9ORF72 ALS spinal 
cords published to date which allowed us to reduce the influence of case-to-case variability. 
In the future, it would be of great interest to analyse the specific cell type in which DPRs and 
foci are present with the use of neuronal sub-type specific markers. Although sense and 
antisense RNA foci are mostly present in neuronal cells in the frontal cortex of FTD patients 
(DeJesus-Hernandez et al., 2017; Mizielinska et al., 2013) it would be interesting to discover 
whether this is also true in the spinal cord of C9ORF72 ALS cases. 
Furthermore, with the improvement in imaging methods, it would be interesting to 
analyse in greater subcellular detail cells containing DPRs or foci and other phenotypes that 
have been reported in C9ORF72 iPSN. In a recently published study, Mizielinsta et al. (2017) 
shows that neurons containing arginine-rich DPR aggregates and sense RNA foci in the frontal 
cortex of C9ORF72-FTD cases have enlarged nucleoli (Mizielinska et al., 2017). Laser-capture 
of these cells, followed by transcriptomic analysis could be carried out to elucidate the 
cellular response to DPR aggregates of RNA foci or to reveal cell-specific differences to 
explain why is it that, although many cells contain foci or DPR aggregates, it is the motor 
neurons that mostly degenerate in ALS.  
We have shown that C9ORF72 NPCs exhibit reduced neurite outgrowth compared to 
control cells and that these deficits can be reversed by treatment with G4C2 PPMO. This 
paradigm could be modified in order to develop a high throughput assay for drug discovery 
purposes. Control NPCs and G4C2 PPMO treated NPCs could be used as a positive control as 
it has already been tested (Yeyeodu et al., 2010). Candidate compounds could then be 
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validated in more complex models of the disease such as Drosophila (Xu et al., 2013) or mice 
(Chew et al., 2015b). The generation of a high sensitivity high throughput protocol would 
allow for more subtle and relevant phenotypes, such as neurite branching or neurite area to 
be studied. 
We generated neurons from iPSCs following a published protocol (Devlin et al., 2015). 
The majority of neurons generated with this protocol are cortical neurons.  We consider that 
this is suitable to study the impact of the C9ORF72 expansion as it affects ALS and FTD 
patients. However, recent protocols have shown that the generation of motor neurons from 
iPSCs can be achieved rapidly, yielding a high percentage of CHAT positive cells (Du et al., 
2015). Generating motor neurons using such a protocol and assess cell-specific differences 
may provide valuable information about the disease mechanism. The decrease in cost of 
transcriptomic analysis techniques has made it possible to perform this analysis in a much 
larger number of neurons. Performing transcriptomic analysis on neurons treated with 
control and G4C2 PPMOs could provide an answer about the cellular mechanism responsible 
for the phenotypic recoveries that we report.  
Finally, given that we have shown that G4C2 PPMOs reduce the number of RNA foci 
and reverse C9ORF72-specific phenotypes in human NPCs and iPSN, the potential 
therapeutic use of these PMOs should be tested in G4C2 mouse models of the disease. 
Mouse models expressing the C9ORF72 full gene do not fully replicate all aspects of the 
disease (Jiang et al., 2016). It would be of interest to test the PMOs in the mouse model 
developed by Chew et al. (2015) as these mice replicate most aspects of the human 





Collectively, our results implicate expanded G4C2 RNA transcripts foci and TDP-43 
aggregation, rather than DPRs, as being the main contributor to neurotoxicity in C9ORF72 
ALS. We have shown that sense RNA foci are the most common species in spinal cord motor 
neurons in C9ORF72 ALS cases and C9ORF72 iPSC neurons in culture but DPRs are extremely 
rare in spinal motor neurons and undetectable in C9ORF72 iPSC neurons. The limitations of 
post mortem and cell culture studies are acknowledged and our results do not exclude a 
contribution from haploinsufficiency and DPR toxicity in C9ORF72 linked ALS and FTD. Our 
evidence that PMOs targeting G4C2 repeats are able to dramatically decrease the number of 
RNA foci and reverse deficits in neurite outgrowth and improve neuronal survival in iPSNs 
implies that RNA foci may directly contribute to G4C2-mediated toxicity. Therefore, PPMOs 
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